Clinical trial NCT03928327
Conditions: Healthy Volunteers
Keywords: Drug Therapy
Sponsor: Millennium Pharmaceuticals, Inc.
Start date: 2019-05-02; Completion date: 2019-08-16
Enrollment: 24 participants; Allocation: NON_RANDOMIZED; Intervention model: SEQUENTIAL

Brief summary:
The purpose of this study is to characterize the effect of itraconazole (Part 1) and rifampin (Part 2) on the single-dose pharmacokinetics (PK) of TAK-788 and its active metabolites (AP32960 and AP32914) in healthy adult participants.

Detailed description:
The drug being tested in this study is called TAK-788 (Mobocertinib). The study assessed the drug-drug interaction of TAK-788 with either a strong cytochrome P-450 (CYP)3A inhibitor, itraconazole (Part 1) or with a strong CYP3A inducer, rifampin (Part 2) in healthy adult participants.

The study enrolled 24 healthy participants. The study was designed to consist of 2 parts: Part 1- TAK-788 assessment with itraconazole Part 2- TAK-788 assessment with rifampin. Part 1 had 2 cohorts:

Part 1: Participants (n = 12) received a single oral dose of 20 mg capsule of TAK-788 on Day 1 of Period 1 followed by 200 mg itraconazole oral solution once daily (QD) in Period 2 on Days 1 to Day 14 and a single oral dose of TAK-788 20 mg capsule were coadmistered on Day 5 of Period 2.

In Part 2 participants (n = 12) received a single oral 160 mg dose of TAK-788 capsules in Period 1 of Day 1 followed by 600 mg capsules of rifampin QD in Period 2 Days 1 to Day 13 and a single dose of 160 mg TAK-788 capsules was coadministered on Day 7 of Period 1. There was a washout period of 7 days between the dose of TAK-788 on Period 1 and the first dose of rifampin in Period 2.

This single-center trial was conducted in the United States. The overall time to participate in this study was approximately 120 days (including screening period). Participants were contacted by telephone 30 days after the last dose of study drug for a follow-up assessment.

Arms: arm 1: TAK-788 20 mg, capsule, at Hour 0 on Day 1 followed by an overnight fast (Treatment A). Following Treatment A, participants received itraconazole 200 mg solution, orally, once daily (QD) on Days 1 to Day 14 and a single oral dose of TAK-788 20 mg capsule was coadministered on Day 5 (Treatment B). There was a washout period of 7 days between the two treatments. arm 2: TAK-788 160 mg, orally, at Hour 0 on Day 1 following an overnight fast (Treatment C). Following Treatment C, participants received rifampin 600 mg as capsules, orally, once daily (QD) on Days 1 to 13 and TAK-788 160 mg as capsules, orally was coadministered on Day 7 (Treatment D). There was a washout period of 7 days between the two treatments.
Interventions: intervention 1: TAK-788 intervention 2: Itraconazole intervention 3: Rifampin
Intervention descriptions: intervention 1: TAK-788 Capsules intervention 2: Itraconazole Oral solution intervention 3: Rifampin Capsules

Protocol documents:
Prot_000.pdf: 



Title: A Phase 1 Study of Oral TAK-788 to Evaluate the Drug-Drug Interaction with Itraconazole 
and Rifampin in Healthy Adult Subjects
NCT Number: NCT03928327
Protocol Approve Date: 16 April 2019
Certain information within this protocol has been redacted (ie, specific content is masked irreversibly from 
view with a black/blue bar) to protect either personally identifiable information (PPD) or company 
confidential information (CCI). 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential 
information under prior agreements with license holder.
Other information as needed to protect confidentiality of Takeda or partners, personal information, or 
to otherwise protect the integrity of the clinical study.


TITLE PAGE
TAKEDA PHARMACEUTICALS
PROTOCOL
A Phase 1 Study of Oral TAK-788 to Evaluate the Drug-Drug Interaction with Itraconazole 
and Rifampin in Healthy Adult Subjects
Study Identifier:
TAK-788-1006
Compound:
TAK-788
Date:
16 April 2019
Version/Amendment 
Number:
Final
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 2 of 85
Protocol Final
16 April 2019
TABLE OF CONTENTS
1.0
STUDY SUMMARY ......................................................................................................6
2.0
STUDY SCHEMATIC..................................................................................................13
3.0
SCHEDULE OF STUDY PROCEDURES ....................................................................15
4.0
INTRODUCTION.........................................................................................................23
4.1
Background .............................................................................................................23
4.1.1
TAK-788 ...........................................................................................................23
4.1.2
Itraconazole .......................................................................................................24
4.1.3
Rifampin............................................................................................................25
4.2
Rationale for the Proposed Study.............................................................................26
4.3
Benefit/Risk Profile .................................................................................................27
5.0
STUDY OBJECTIVES AND ENDPOINTS..................................................................28
5.1
Hypothesis...............................................................................................................28
5.2
Study Objectives......................................................................................................28
5.2.1
Study Primary Objective ....................................................................................28
5.2.2
Study Exploratory Objective ..............................................................................28
5.3
Endpoints.................................................................................................................28
5.3.1
Primary Endpoint...............................................................................................28
5.3.2
Exploratory Endpoints .......................................................................................28
6.0
STUDY DESIGN AND DESCRIPTION.......................................................................29
6.1
Study Design ...........................................................................................................29
6.2
Dose Escalation .......................................................................................................32
6.3
Rationale for Study Design, Dose, and Endpoints ....................................................33
6.3.1
Rationale of Study Design and Dose ..................................................................33
6.3.2
Rationale for Endpoints......................................................................................34
6.3.3
Future Biomedical Research...............................................................................34
6.3.4
Critical Procedures Based on Study Objectives: Timing of Procedures...............34
6.4
Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters...............................................................................................................35
6.5
Study Beginning and End/Completion .....................................................................35
6.5.1
Definition of Beginning of the Study..................................................................35
6.5.2
Definition of End of the Study ...........................................................................35
6.5.3
Definition of Study Completion .........................................................................35
6.5.4
Definition of Study Discontinuation...................................................................35
6.5.5
Criteria for Premature Termination or Suspension of the Study..........................35
6.5.6
Criteria for Premature Termination or Suspension of a Site................................35
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 3 of 85
Protocol Final
16 April 2019
7.0
SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS..............36
7.1
Excluded Medications, Supplements, Dietary Products............................................36
7.2
Diet, Fluid, Activity.................................................................................................36
7.2.1
Diet and Fluid ....................................................................................................36
7.2.2
Activity..............................................................................................................37
7.3
Criteria for Discontinuation or Withdrawal of a Subject...........................................37
7.4
Procedures for Discontinuation or Withdrawal of a Subject......................................37
7.5
Subject Replacement................................................................................................38
8.0
CLINICAL STUDY MATERIAL MANAGEMENT.....................................................39
8.1
Clinical Study Drug .................................................................................................39
8.1.1
TAK-788 Capsules.............................................................................................39
8.1.2
Itraconazole Solution .........................................................................................40
8.1.3
Rifampin Capsules.............................................................................................40
8.1.4
Clinical Study Drug Labeling.............................................................................40
8.1.5
Clinical Study Drug Inventory and Storage ........................................................41
8.1.6
Clinical Study Drug Blinding.............................................................................41
8.1.7
Randomization Code Creation and Storage ........................................................41
8.1.8
Clinical Study Blind Maintenance/Unblinding Procedure...................................41
8.1.9
Accountability and Destruction of Sponsor-Supplied Drugs...............................41
9.0
STUDY PROCEDURES...............................................................................................42
9.1
Administrative Procedures.......................................................................................42
9.1.1
Informed Consent Procedure..............................................................................42
9.1.2
Inclusion and Exclusion .....................................................................................42
9.1.3
Medical History/Demography ............................................................................45
9.1.4
Concomitant Medications...................................................................................45
9.2
Clinical Procedures and Assessments.......................................................................45
9.2.1
Full Physical Exam ............................................................................................45
9.2.2
Height and Weight .............................................................................................45
9.2.3
BMI ...................................................................................................................46
9.2.4
Vital Signs .........................................................................................................46
9.2.5
12-Lead ECG.....................................................................................................46
9.2.6
Pulmonary Function Test ...................................................................................46
9.2.7
Study Drug Administration ................................................................................47
9.2.8
AE Monitoring...................................................................................................48
9.2.9
Laboratory Procedures and Assessments ............................................................48
9.3
Pharmacokinetic Samples ........................................................................................49
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 4 of 85
Protocol Final
16 April 2019
9.3.1
PK Measurements..............................................................................................50
9.3.2
Biomarker Measurements...................................................................................51
9.3.3
PGx Measurements ............................................................................................51
9.3.4
Confinement ......................................................................................................51
10.0
ADVERSE EVENTS ....................................................................................................52
10.1
Definitions and Elements of AEs .............................................................................52
10.1.1 SAEs..................................................................................................................54
10.1.2 Special Interest AEs...........................................................................................55
10.2
AE Procedures.........................................................................................................55
10.2.1 Assigning Severity/Intensity of AEs...................................................................55
10.2.2 Assigning Causality of AEs................................................................................56
10.2.3 Start Date...........................................................................................................56
10.2.4 End Date............................................................................................................56
10.2.5 Action Taken With Study Treatment..................................................................56
10.2.6 Outcome ............................................................................................................56
10.2.7 Collection and Reporting of AEs, SAEs, Special Interest AEs, and Abnormal 
LFTs ..................................................................................................................57
10.2.8 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities.....59
10.2.9 Procedures for Reporting Product Complaints or Medication Errors (Including 
Overdose) ..........................................................................................................59
11.0
STATISTICAL METHODS..........................................................................................61
11.1
Statistical and Analytical Plans ................................................................................61
11.1.1 Analysis Sets......................................................................................................61
11.1.2 Analysis of Demography and Other Baseline Characteristics .............................61
11.1.3 PK Analysis.......................................................................................................61
11.1.4 Pharmacodynamic Analysis ...............................................................................62
11.1.5 Safety Analysis ..................................................................................................62
11.2
Interim Analysis and Criteria for Early Termination ................................................63
11.3
Determination of Sample Size..................................................................................63
12.0
QUALITY CONTROL AND QUALITY ASSURANCE...............................................64
12.1
Study-Site Monitoring Visits ...................................................................................64
12.2
Protocol Deviations..................................................................................................64
12.3
Quality Assurance Audits and Regulatory Agency Inspections ................................64
13.0
ETHICAL ASPECTS OF THE STUDY........................................................................65
13.1
IRB and/or IEC Approval ........................................................................................65
13.2
Subject Information, Informed Consent, and Subject Authorization .........................66
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 5 of 85
Protocol Final
16 April 2019
13.3
Subject Confidentiality ............................................................................................67
13.4
Publication, Disclosure, and Clinical Study Registration Policy ...............................67
13.4.1 Publication and Disclosure.................................................................................67
13.4.2 Clinical Study Registration.................................................................................68
13.4.3 Clinical Study Results Disclosure.......................................................................68
13.5
Insurance and Compensation for Injury....................................................................68
14.0
ADMINISTRATIVE AND REFERENCE INFORMATION.........................................69
14.1
Administrative Information......................................................................................69
14.1.1 Study Contact Information .................................................................................69
14.1.2 INVESTIGATOR AGREEMENT......................................................................70
14.1.3 Study-Related Responsibilities...........................................................................71
14.1.4 List of Abbreviations .........................................................................................71
15.0
DATA HANDLING AND RECORDKEEPING............................................................73
15.1
CRFs .......................................................................................................................73
15.2
Record Retention .....................................................................................................73
16.0
REFERENCES..............................................................................................................75
17.0
APPENDICES...............................................................................................................77
LIST OF IN-TEXT TABLES
Table 3.a
Pharmacokinetic Plasma Concentration Sampling Schedule (Part 1) ..................21
Table 3.b
Pharmacokinetic Plasma Concentration Sampling Schedule (Part 2) ..................22
Table 6.a
Part 1 TAK-788 assessment with Itraconazole....................................................29
Table 6.b
Part 2 TAK-788 assessment with Rifampin ........................................................30
Table 6.c
Planned Doses of TAK-788, Itraconazole (Part 1), and Rifampin (Part 2) ..........32
Table 7.a
Excluded Medications, Supplements, and Dietary Products................................36
Table 9.a
Primary Specimen Collections ...........................................................................49
Table 10.a
Takeda Medically Significant AE List................................................................55
LIST OF APPENDICES
Appendix A
Responsibilities of the Investigator.....................................................................77
Appendix B
Elements of the Subject Informed Consent.........................................................79
Appendix C
Investigator Consent to the Use of Personal Information ....................................82
Appendix D
Pregnancy and Contraception.............................................................................83
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 6 of 85
Protocol Final
16 April 2019
1.0
STUDY SUMMARY
Name of Sponsor:
Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of 
Takeda Pharmaceutical Company, Ltd
40 Landsdowne Street
Cambridge, Massachusetts USA 02139
Telephone: +1 (617) 679-7000
Compound:
TAK-788
Study Identifier: TAK-788-1006 (CA24219)
Phase: 1
Protocol Title: A Phase 1 Study of Oral TAK-788 to Evaluate the Drug-Drug Interaction with Itraconazole and 
Rifampin in Healthy Adult Subjects
Study Design:
This is a 2-part study. Each part will be conducted as an open-label, 2-period, fixed sequence study with TAK-788 
designed to characterize TAK-788 drug-drug interaction with either a strong cytochrome P-450 (CYP)3A inhibitor, 
itraconazole (Part 1) or with a strong CYP3A inducer, rifampin (Part 2) in healthy adult subjects. Subjects 
participating in Part 1 will be different from those participating in Part 2. Additionally, Part 1 will be a sequential study
design; Part 1 Cohort 2 will not start until pharmacokinetic (PK) data from Part 1 Cohort 1 (up to Period 2 Day 15) has 
been evaluated. The study parts may be conducted concurrently.
Part 1: TAK-788 assessment with Itraconazole
Part 1 will be conducted in 2 cohorts: Cohort 1 will enroll 4 subjects and will assess whether the 20 mg dose of 
TAK-788 is an appropriate dose for the TAK-788/itraconazole drug-drug interaction study; depending on the PK 
results, Cohort 2 will either continue to enroll 8 more subjects at this same dose level or enroll 12 more subjects at a 
revised TAK-788 dose level. Other than the dose of TAK-788, the study design will be exactly the same for each 
cohort. 
This study part will comprise of a screening period, 2 treatment periods and a follow-up phone call in up to 16 healthy 
subjects. Dose administration and PK collection scheme for the treatment period is outlined in the table below.
Treatment Period 1
Treatment Period 2
Study Day
-1
1
2
3
4
5
6
8*
1*
2
3
4
5
6
7
8
9
10
11
12
13
14
15
TAK-788 PO 
X
X
Itraconazole 
200 mg QD 
PO
X
X
X
X
X
X
X
X
X
X
X
X
X
X
PK Blood 
Samples 
X
X
X
X
X
X
X*
X*
X
X
X
X
X
X
X
X
X
Overnight in 
Clinics
X
X
X
X
X
X
X
X
*Since the washout period is 7 days the timing of the last PK blood draw of Period 1 will occur within 60 minutes prior to the first dose of itraconazole 
on Period 2 Day 1; only one PK sample will be taken.
Abbreviation: PK=Pharmacokinetics; PO=per oral; QD=once daily
On Period 1 Day 1, subjects will receive a single 20 mg oral dose of TAK-788 or a TAK-788 oral dose to be 
determined (TBD) (Cohort 2) as capsules (fasting). A standardized meal will be provided at least 4 hours postdose. 
Subjects will remain in the clinic research unit (CRU) until the morning of Day 4 after the 72-hour PK sample is 
collected. Additional PK samples will be taken as an outpatient up to 168 hours postdose (Period 1 Day 8, which is the 
same as Period 2 Day 1). 
In Period 2, subjects will receive 200 mg itraconazole once daily (QD) alone as an oral solution on an empty stomach 
(no food from at least 1 hour prior until at least 2 hours after dosing). Subjects will be admitted to the CRU in Period 2 
Day 4. In the morning of Period 2 Day 5, subjects will receive 200 mg itraconazole together with 20 mg oral TAK-788 
or TBD oral dose of TAK-788 (fasting). A standardized meal will be provided at least 4 hours postdose. Subjects will 
be furloughed from the CRU after the 72-hour PK sample is collected in the morning of Period 2 Day 8. There will be 
outpatient visits to the CRU for dosing itraconazole and/or PK sampling from Day 1 to Day 3 and Day 9 to Day 14. A 
final post-treatment follow-up and last PK sampling (Table 3.a) will occur at 240 hours post-Day 5 TAK-788 dose 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 7 of 85
Protocol Final
16 April 2019
(Period 2 Day 15). 
All PK data (TAK-788 and its 2 active metabolites, AP32960 and AP32914) collected in Cohort 1 (up to Day 15) will 
be evaluated to determine the dose of TAK-788 administered to subjects in Cohort 2 of the study. The TAK-788 dose 
in Cohort 2 may remain at 20 mg or may be modified to an appropriate level to approximate a similar exposure 
compared to the geometric mean of single-dose exposure previously observed at 160 mg single dose TAK-788 alone 
in healthy subjects. 
Part 2: TAK-788 assessment with Rifampin
Part 2 will comprise of a screening period, 2 treatment periods, and a follow-up phone call in 12 subjects. Dose 
administration and PK collection scheme for the treatment periods are outlined in the table below. 
Treatment Period 1
Treatment Period 2
Study Day
-1
1
2
3
4
5
6
8*
1*
2
3
4
5
6
7
8
9
10
11
12
13
14
TAK-788 160 mg 
PO 
X
X
Rifampin 
600 mg QD PO
X
X
X
X
X
X
X
X
X
X
X
X
X
PK Blood 
Samples 
X
X
X
X
X
X
X*
X*
X
X
X
X
X
X
X
Overnight in 
Clinics
X
X
X
X
X
X
X
X
*Since the washout period is 7 days the timing of the last PK blood draw of Period 1 will occur within 60 minutes prior to the first dose of rifampin on 
Period 2 Day 1; only one PK sample will be taken.
Abbreviation: PK=Pharmacokinetics; PO=per oral; QD=once daily
On Period 1 Day 1, a different group of subjects from Part 1 will receive a single 160 mg oral dose of TAK-788 as 
capsules (fasting). A standardized meal will be provided at least 4 hours postdose. Subjects will remain in the CRU 
until the morning of Day 4 after the 72-hour PK sample is collected. Additional PK samples (Table 3.b) will be taken 
as an outpatient up to 168 hours postdose (Period 1 Day 8, which is the same as Period 2 Day 1). 
In Period 2, subjects will receive 600 mg rifampin QD alone as capsules (fasting). Subjects will be admitted to the 
CRU on Day 6. In the morning of Day 7, subjects will receive 160 mg oral TAK-788 together with 600 mg rifampin 
(fasting). A standardized meal will be provided at least 4 hours postdose. Subjects will be furloughed from the CRU 
after the 72-hour PK sample is collected in the morning of Day 10. There will be outpatient visits to the CRU for 
dosing rifampin and/or PK sampling from Day 1 to Day 5 and Day 11 to Day 13. A final post-treatment follow-up and 
last PK sampling will occur at 168 hours post Day 7 dose (Day 14). 
Part 1 and Part 2: 
TAK-788 and rifampin will be orally administered with approximately 240 mL of water. For itraconazole dosing, a 
total aqueous volume of approximately 240 mL will be administered; this will include the dose of itraconazole oral 
solution and two rinses of the full dose unit container with water followed by ingestion of the remaining dosing water. 
All doses of TAK-788, itraconazole, and rifampin will be administered at the CRU during this study, either during 
confinement or on an outpatient basis.
Spirometry as the pulmonary function test (PFT) is required to be performed and be assessed as normal at screening. 
Post-dose spirometry will be performed only if indicated on the basis of pulmonary symptoms, at the discretion of the 
Investigator or designee. 
A final safety follow-up phone call will occur 30 ± 2 days after the last TAK-788 dose to determine if any adverse 
events (AEs) have occurred since the last study visit.
Any subject who experiences emesis within 8 hours post dosing with TAK-788 will be excluded in the final data 
analysis. Replacement of discontinued or withdrawn subjects due to any reason will be assessed on a case by case 
basis by the Sponsor and Investigator to ensure a minimum of 10 PK-evaluable subjects complete in each part of 
study.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 8 of 85
Protocol Final
16 April 2019
Study Primary Objective:
Part 1: To characterize the effect of itraconazole, a strong CYP3A inhibitor, on the single-dose PK of TAK-788 and its 
active metabolites (AP32960 and AP32914) in healthy adult subjects.
Part 2: To characterize the effect of rifampin, a strong CYP3A inducer, on the single-dose PK of TAK-788 and its 
active metabolites (AP32960 and AP32914) in healthy adult subjects.
Exploratory Objective:
Part 1 and Part 2: To assess the safety data of TAK-788 following single oral dose with/without strong CYP3A 
inhibitor or inducer in healthy adult subjects.
Study Subject Population: Healthy male and female subjects aged 18 to 55 years inclusive, at screening. Body Mass 
Index (BMI) 18.0-32.0 kg/m2, inclusive, at screening.
Planned Number of Subjects:
Up to 28 healthy adult subjects will be enrolled in 
2 parts (up to 16 in Part 1, and 12 in Part 2) in the 
drug-drug interaction study to get at least 
10 PK-evaluable subjects for estimation of drug-drug 
interaction magnitude in each part of study.
Planned Number of Sites:
1
Dose Levels:
Part 1: 
Cohort 1: 20 mg TAK-788, 2 single doses
Cohort 2: dose TBD TAK-788, 2 single doses
Cohorts 1 and 2: 200 mg itraconazole solution QD, 
14 doses
Part 2: 
160 mg TAK-788, 2 single doses
600 mg rifampin (3 x 200 mg capsules) QD, 13 doses
Route of Administration:
oral
Duration of Treatment:
Part 1: TAK-788 assessment with Itraconazole
Cohort 1: Period 1 Day 1, subjects will receive a single 
oral dose of 20 mg TAK-788; Period 2 Day 1 to 
Day 14, subjects will receive 200 mg itraconazole QD 
and coadministered on Day 5 with a single oral 20 mg 
TAK-788.
Cohort 2: Period 1 Day 1, subjects will receive a single 
oral TBD dose of TAK-788; Period 2 Day 1 to Day 14, 
subjects will receive 200 mg itraconazole QD and 
coadministered on Day 5 with a single oral TBD dose 
of TAK-788.
There will be a washout period of 7 days between the 
dose of TAK-788 on Period 1 and the first dose of 
itraconazole in Period 2.
Part 2: TAK-788 assessment with Rifampin
Period 1 Day 1, subjects will receive a single oral 
160 mg dose of TAK-788; Period 2 Day 1 to Day 13, 
subjects will receive 600 mg rifampin QD and 
coadministered on Day 7 with a single oral dose of 
160 mg TAK-788.
Planned Study Duration:
Approximately 60 days ± 2 days including screening period 
and follow-up for Part 1.
Approximately 60 days ± 2 days including screening period 
and follow-up for Part 2.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 9 of 85
Protocol Final
16 April 2019
There will be a washout period of 7 days between the 
dose of TAK-788 on Period 1 and the first dose of 
rifampin in Period 2. 
Part 1 and Part 2:
All doses will be administered in the CRU (either 
during confinement or on an outpatient basis)
Criteria for Inclusion:
Subjects must fulfill the following inclusion criteria to be eligible for participation in the study: 
1.
Healthy, adult, male or female, 18 - 55 years of age, inclusive, at screening. 
2.
Continuous non-smoker who has not used nicotine-containing products for at least 18 years prior to the first 
dosing and throughout the study, based on subject self-reporting.
3.
Body mass index (BMI) ≥18.0 and ≤32.0 kg/m2, at screening.
4.
Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital 
signs, or electrocardiograms (ECGs), as deemed by the Investigator or designee. Has liver function tests (LFTs) 
including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and 
total bilirubin within the upper limit of normal at screening and at first check-in.
5.
Normal baseline spirometry for FVC and FEV1/FVC within 7 days prior to the first dosing based on the following 
normal FVC and FEV1/FVC range:
a)
18 – 39 years of age: ≥80%
b)
40 – 55 years of age: ≥75%
6.
For a female of nonchildbearing potential, must have undergone one of the following sterilization procedures at 
least 6 months prior to the first dosing:

hysteroscopic sterilization;

bilateral tubal ligation or bilateral salpingectomy;

hysterectomy;

bilateral oophorectomy;
or be postmenopausal with amenorrhea for at least 1 year prior to the first dosing and follicle stimulating hormone 
(FSH) serum levels consistent with postmenopausal status.
7.
Part 1 only: Female subjects of childbearing potential will be advised to remain sexually inactive or to keep the 
same birth control method for at least 60 days following the last TAK-788 dosing as indicated in Appendix D.
8.
Part 2 only: Female subjects of childbearing potential will be advised to remain sexually inactive or to keep the 
same birth control method for at least 30 days following the last TAK-788 dosing as indicated in Appendix D.
9.
Part 1 only: Males subjects who are sexually active with a female partner of childbearing potential must use 
barrier contraception as indicated in Appendix D or abstain from sexual intercourse during the study until 94 days 
after the last TAK-788 dosing. Total abstinence (no sexual intercourse) may be considered an acceptable method 
of birth control if it agrees with his preferred and usual lifestyle.
10. Part 1 only: Male subjects must agree not to donate sperm from the first dosing until 94 days after the last 
TAK-788 dosing.
11. Part 2 only: Males subjects who are sexually active with a female partner of childbearing potential must use 
barrier contraception as indicated in Appendix D or abstain from sexual intercourse during the study until 30 days 
after the last TAK-788 dosing. Total abstinence (no sexual intercourse) may be considered an acceptable method 
of birth control if it agrees with his preferred and usual lifestyle.
12. Part 2 only: Male subjects must agree not to donate sperm from the first dosing until 30 days after the last 
TAK-788 dosing.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 10 of 85
Protocol Final
16 April 2019
13. Understands the study procedures in the informed consent form (ICF) and be willing and able to comply with the 
protocol.
Criteria for Exclusion:
The subject must be excluded from participating in the study if the subject: 
1.
Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or 
expected during the conduct of the study.
2.
History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the 
Investigator or designee.
3.
History of any illness that, in the opinion of the Investigator or designee, might confound the results of the study 
or poses an additional risk to the subjects by their participation in the study.
4.
History or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing.
5.
History or presence of hypersensitivity or idiosyncratic reaction to the study drugs or related compounds.
6.
History or presence of any previous chronic lung disease.
7.
History or presence of an acute lung infection, within 3 months of screening.
8.
Part 1 only: History or presence of any of the following, deemed clinically significant by the Investigator or 
designee, and as confirmed by the Sponsor:

Ventricular dysfunction or risk factors for Torsades de Pointes (e.g., heart failure, cardiomyopathy, family 
history of Long QT Syndrome);

Uncorrected hypokalemia (potassium levels <3.7) and/or hypomagnesemia (magnesium levels <1.9);

Myasthenia gravis.
9.
Female subjects with a positive pregnancy test or who are lactating.
10. Positive urine drug or alcohol results at screening or first check-in.
11. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or 
hepatitis C virus (HCV).
12. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening.
13. Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.
14. QTcF interval is >460 msec (males) or >470 msec (females) or ECG findings are deemed abnormal with clinical 
significance by the Investigator or designee at screening.
15. Estimated creatinine clearance <90 mL/min at screening.
16. Unable to refrain from or anticipates the use of:

Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements 
within 14 days prior to the first dosing and throughout the study. Medication listed as part of acceptable birth 
control methods will be allowed (refer to Appendix D). Thyroid hormone replacement medication may be 
permitted if the subject has been on the same stable dose for the immediate 3 months prior to the first dosing. 
Acetaminophen (up to 2 g per 24 hour period) may be permitted during the study, only after initial dosing.

Any drugs known to be inhibitors or inducers of CYP3A enzymes and/or p-glycoprotein (P-gp), including St. 
John’s Wort, within 28 days prior to the first dosing and throughout the study. Appropriate sources (e.g., 
Flockhart Table™) will be consulted to confirm lack of PK/pharmacodynamics interaction with study drugs.
17. Has been on a diet incompatible with the on-study diet, in the opinion of the Investigator or designee, within the 
30 days prior to the first dosing and throughout the study.
18. Donation of blood or significant blood loss within 56 days prior to the first dosing.
19. Plasma donation within 7 days prior to the first dosing.
20. Participation in another clinical study within 30 days prior to the first dosing. The 30-day window will be derived 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 11 of 85
Protocol Final
16 April 2019
from the date of the last blood collection or dosing, whichever is later, in the previous study to Period 1 Day 1 of 
the current study.
Main Criteria for Evaluation and Analyses:
The following PK parameters will be analyzed for TAK-788 and its active metabolites, AP32960 and AP32914, when 
administered alone and when coadministered with itraconazole (Part 1) or with rifampin (Part 2):
Pharmacokinetic Endpoints
The primary endpoints of the study are:

Maximum observed concentration (Cmax).

Area under the concentration-time curve from time 0 to infinity, calculated using the observed value of the last 
quantifiable concentration (AUC).

Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration (AUClast). 

Time of first occurrence of Cmax (Tmax).
Additional Endpoints
In addition, the following plasma PK parameters for TAK-788 and its active metabolites, AP32960 and AP32914 will 
be calculated:

Terminal disposition phase half-life (t½),

Terminal disposition phase rate constant (λz),

Apparent clearance after extravascular administration (CL/F) for TAK-788 only,

Apparent volume of distribution during the terminal disposition phase after extravascular administration (Vz/F) 
for TAK-788 only.
Safety Endpoints
Safety will be assessed by summarizing the incidence of treatment emergent AEs (TEAEs), clinical laboratory values, 
physical examinations, ECGs, and vital signs
Statistical Considerations:
Pharmacokinetics:
The PK parameters of TAK-788 and its active metabolites (AP32960 and AP32914) will be calculated based on 
plasma concentration - time profiles of TAK-788 and metabolites (AP32960 and AP32914) will be calculated as 
described in Section 11.0, and outlined in the SAP.
A linear mixed-effects model will be used for the analysis on the ln transformed Cmax and AUC(AUClast or AUCt if 
AUCis not available) for TAK-788 and ln transformed combined molar Cmax and AUC∞ for TAK-788, AP32960, and 
AP32914. The model will include treatment as a fixed-effect and subject as a random-effect. Each model will include 
calculation of least squares means (LSMs) as well as the difference between treatment LSMs.
Gemetric mean ratios and 90% confidence intervals, consistent with the two one sided test [Schuirmann 1987], will be 
calculated using the exponentiation of the difference between treatment LSMs from the analyses on the 
ln -transformed Cmax and AUC(AUClast or AUCt if AUCis not available) for TAK-788 as well as the combined 
molar Cmax and AUC∞ of TAK-788, AP32960, and AP32914. These ratios will be expressed as a percentage of the 
following comparisons:
Treatment B (itraconazole+20 mg TAK-788) relative to Treatment A (20 mg TAK-788)
Treatment D (rifampin+160 mg TAK-788) relative to Treatment C (160 mg TAK-788)
And if applicable Treatment F (itraconazole+TBD TAK-788 dose) relative to Treatment E (TBD TAK-788 dose)
Safety:
Quantitative safety data as well as the difference to baseline, when appropriate, will be summarized using the 
appropriate descriptive statistics.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 12 of 85
Protocol Final
16 April 2019
Sample Size Justification:
The sample size calculation was based on the expected 2-sided 90% confidence interval (CI) for the difference in the 
paired, log-transformed AUCmeans of TAK-788 in the absence and presence of itraconazole or rifampin. The 
within-patient coefficient of variation for TAK-788 AUCwas estimated to be 17.2% on the basis of data from a 
clinical study conducted in healthy subjects (TAK-788-1001). If the AUCratio for TAK-788 in the presence versus 
absence of itraconazole or rifampin is X (an AUCgeometric mean ratios (GMR) to be determined in this study), with 
a sample size of 10, the 90% CI for the AUCratio is expected to be 0.868X to 1.15X on the basis of the variance 
assumptions.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study No. TAK-788-1006
Page 13 of 85
Protocol Final
16 April 2019
2.0
STUDY SCHEMATIC
Part 1
Screening
Period 1
Period 2
Follow-up
Check-in 
and Predose 
Assessments
TAK-788 
Dosing and 
Study 
Assessments
PK sampling and 
Study Assessments
Itraconazole 
Dosing and 
Study 
Assessments
Itraconazole 
Dosing and 
Study 
Assessments
Coadministrati
on 
(Itraconazole 
and TAK-788) 
and Study 
Assessments
Itraconazole 
dosing and 
PK sampling 
and Study 
Assessments
PK sampling 
and Study 
Assessments
Within 
28 days 
prior to first 
dosing
Day -1 
Day 1
Day 2-4
Day 
5-8 a
Day 1 a-3 
Day 4 b
Day 5
Day 
6-8
Day 
9-14
Day 15
30 days ± 2 
following 
last 
TAK-788 
dose 
Outpatient 
Visit
Confinement c
Outpatient Visit
Confinement d
Outpatient Visit
a Period 2 Day 1 will also be considered Period 1 Day 8. There is a washout of 7 days between TAK-788 dose in Period 1 and first itraconazole dosing in Period 2.
b Subjects will be confined to the clinical research unit in the morning at the time indicated by the staff.
c Subjects will start the confinement on Day -1 and be released from confinement after the 72-hour study assessments (Period 1 Day 4) are complete and will return to the study site 
for subsequent study procedures as per the scheduled of study procedures (Section 9.0). At all times, subject may be required to remain at the clinical research unit for longer at the 
discretion of the Investigator or designee.
d Subjects will start the confinement on the morning of Day 4 and be released from confinement after the 72-hour study assessments (Period 2 Day 8) are complete and will return to 
the study site for subsequent dosing and/or study procedures as per the scheduled of study procedures (Section 9.0). At all times, subject may be required to remain at the clinical 
research unit for longer at the discretion of the Investigator or designee.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study No. TAK-788-1006
Page 14 of 85
Protocol Final
16 April 2019
Part 2
Screening
Period 1
Period 2
Follow-up
Check-in and 
Predose 
Assessments
TAK-788 
Dosing and 
Study 
Assessments
PK sampling 
and Study 
Assessments
Rifampin 
Dosing and 
Study 
Assessments
Rifampin 
Dosing and 
Study 
Assessments
Coadministrati
on (Rifampin 
and TAK-788) 
and Study 
Assessments
Rifampin dosing 
and PK sampling 
and Study 
Assessments
PK sampling 
and Study 
Assessments
Within 
28 days 
prior to first 
dosing
Day -1
Day 1
Day 
2-4
Day 
5-8 a
Day 1 a-5 
Day 6 b
Day 7
Day 
8-10
Day 
11-13
Day 14
30 days ± 2 
following 
last 
TAK-788 
dose 
Outpatient 
Visit
Confinement c
Outpatient Visit
Confinement d
Outpatient Visit
a Period 2 Day 1 will also be considered Period 1 Day 8. There is a washout of 7 days between TAK-788 dose in Period 1 and first rifampin dosing in Period 2.
b Subjects will be confined to the clinical research unit in the morning at the time indicated by the staff.
c Subjects will start the confinement on Day -1 and be released from confinement after the 72-hour study assessments (Period 1 Day 4) are complete and will return to the study site 
for subsequent study procedures as per the scheduled of study procedures (Section 9.0). At all times, subject may be required to remain at the clinical research unit for longer at the 
discretion of the Investigator or designee.
d Subjects will start the confinement on the morning of Day 6 and be released from confinement after the 72-hour study assessments (Period 2 Day 10) are complete and will return to 
the study site for subsequent dosing and/or study procedures as per the scheduled of study procedures (Section 9.0). At all times, subject may be required to remain at the clinical 
research unit for longer at the discretion of the Investigator or designee.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study No. TAK-788-1006
Page 15 of 85
Protocol Final
16 April 2019
3.0
SCHEDULE OF STUDY PROCEDURES 
Part 1
Study Procedures a
S b
Study Days in Period 1 c – PART 1
Days in Period →
-1
1
2
3
4
5
6
8
Hours →
C-I d
0
0.5
1
2
4
6
8
12
24
36
48
72
96
120 
168 e
Administrative Procedures
Informed Consent
X
Inclusion/Exclusion Criteria
X
X
Medical History
X
Safety Evaluations 
Full Physical Examination f
X
Height
X
Weight
X
X g
12-Lead Safety ECG
X
X j
X
X
Vital Signs (HR and BP)
X
X j
X
X
X
Vital Signs (RR and T)
X
Pulmonary function test h
X
Hem, Serum Chem i, and UA 
X
X
X
Serum Pregnancy Test (♀only)
X
X
Serum FSH (PMP ♀only)
X
Urine Drug and Alcohol Screen
X
X
HIV/Hepatitis Screen
X
AE Monitoring
X
ConMeds Monitoring
X
Study Drug Administration / PK
TAK-788 Administration
X
Blood for TAK-788 and metabolites 
(AP32960 and AP32914) PK
X k
X
X
X
X
X
X
X
X
X
X
X
X
X
X k
Other Procedures
Confinement in the CRU l
X
Visit and Return Visits
X
X
X
X
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study No. TAK-788-1006
Page 16 of 85
Protocol Final
16 April 2019
Study Procedures a
Study Days in Period 2 c – PART 1
ET m
FU n
Days in Period→
1 e
2 - 3
4 d
5
6
7
8
9
10
11 
12
13
14
15
Hours →
0
0
0
0
0.5
1
2
4
6
8
12
24
36
48
72
96
120
144
168
192
216
240
Safety Evaluations 
12-Lead Safety ECG
X k
X k
X
X k
X
X
Vital Signs (HR and BP)
X k
X k
X
X
X k
X
X
Vital Signs (RR and T)
X
X
Hem, Serum Chem i, and 
UA 
X k
X k
X k
X
X
Serum Pregnancy Test (♀ 
only)
X k
Urine Drug and Alcohol 
Screen
X k
AE Monitoring
X
X
ConMeds Monitoring
X
Study Drug 
Administration / PK
Itraconazole QD 
Administration
X
X
X
X
X
X
X
X
X
X
X
X
X
TAK-788 Administration
X
Blood for TAK-788 and 
metabolites (AP32960 and 
AP32914) PK
X k
X k
X
X
X
X
X
X
X
X k
X
X k
X k
X k
X k
X k
X k
X
Other Procedures
Confinement in the CRU l
X
Return Visits
X
X
X
X
X
X
X
X
X
Footnotes are on the following page.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study No. TAK-788-1006
Page 17 of 85
Protocol Final
16 April 2019
a For details on Procedures, refer to Section 9.0.
b Within 28 days prior to the first study drug administration.
c There will be a washout period of 7 days between the dose of TAK-788 in Period 1 and the first dose of itraconazole in Period 2. As per site preference in agreement with Sponsor, 
subjects may be confined throughout the washout period and/or for the whole study. If the CRU decides to confine the subjects throughout the study, the site will still perform safety 
events scheduled at check-in.
d Subjects will be admitted to the CRU on Day -1 of Period 1 and in the morning of Day 4 of Period 2, at the time indicated by the CRU. 
e Day 8 of Period 1 is the same as Day 1 of Period 2. Study procedures will only be performed once.
f Symptom-driven physical examination may be performed, at the Investigator’s or designee’s discretion.
g If the screening assessment was conducted within 4-7 days prior to dosing (Day 1), assessment will be conducted at check-in only if, in the opinion of the Investigator, there is reason 
to believe they have substantially changed.
h To be conducted within 7 days prior to first dosing.
i Samples for serum chemistry will be obtained following a fast of at least 8 hours, however, in case of dropouts or rechecks, subjects may not have fasted for 8 hours prior to the serum 
chemistry sample is taken.
j To be performed within 24 hours prior to dosing.
k Prior to dosing.
l As per site preference in agreement with Sponsor, subjects may be confined throughout the washout period and/or for the whole study.
m To be performed prior to early termination from the study.
n The CRU will contact all subjects (including subjects who terminate the study early) 30 ±2 days after the last TAK-788 dose to determine if any adverse events have occurred since 
the last study visit.
Abbreviations: ♀= Females, AE = Adverse events, BP = Blood pressure, C-I = Check-in, Chem = Chemistry, ConMeds = Concomitant medication, CRU = Clinical research unit, 
ECG = Electrocardiogram, ET = early termination, FSH = Follicle-stimulating hormone, FU = Follow-up, Hem = Hematology, HIV = Human immunodeficiency virus, HR = Heart 
rate, PK = Pharmacokinetics, PMP = Postmenopausal, RR = Respiratory rate, S = Screening, T = Temperature, UA = Urinalysis. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study No. TAK-788-1006
Page 18 of 85
Protocol Final
16 April 2019
Part 2
Study Procedures a
S b
Study Days in Period 1 c– PART 2
Days in Period →
-1
1
2
3
4
5
6
8
Hours →
C-I d
0
0.5
1
2
4
6
8
12
24
36
48
72
96
120 
168 e
Administrative Procedures
Informed Consent
X
Inclusion/Exclusion Criteria
X
X
Medical History
X
Safety Evaluations 
Full Physical Examination f
X
Height
X
Weight
X
X g
12-Lead Safety ECG
X
X j
X
X
Vital Signs (HR and BP)
X
X j
X
X
X
Vital Signs (RR and T)
X
Pulmonary function test h
X
Hem, Serum Chem i, and UA 
X
X
X
Serum Pregnancy Test (♀only)
X
X
Serum FSH (PMP ♀only)
X
Urine Drug and Alcohol Screen
X
X
HIV/Hepatitis Screen
X
AE Monitoring
X
ConMeds Monitoring
X
Study Drug Administration / PK
TAK-788 Administration
X
Blood for TAK-788 and metabolites PK
X k
X
X
X
X
X
X
X
X
X
X
X
X
X
X k
Other Procedures
Confinement in the CRU l
X
Visit and Return Visits
X
X
X
X
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study No. TAK-788-1006
Page 19 of 85
Protocol Final
16 April 2019
Study Procedures a
Study Days in Period 2 c– PART 2
ET m
FU n
Days in Period→
1 e
2 - 5
6 d
7
8
9
10
11
12
13
14
Hours →
0
0
0
0
0.5
1
2
4
6
8
12
24
36
48
72
96
120
144
168
Safety Evaluations 
12-Lead Safety ECG
X k
X k
X
X k
X
X
Vital Signs (HR and BP)
X k
X k
X
X
X k
X
X
Vital Signs (RR and T)
X
X
Hem, Serum Chem i, and UA 
X k
X k
X k
X
X
Serum Pregnancy Test (♀only)
X k
Urine Drug and Alcohol Screen
X k
AE Monitoring
X
X
X
ConMeds Monitoring
X
X
Study Drug Administration / 
PK
Rifampin Administration
X
X
X
X
X
X
X
X
X
X
TAK-788 Administration
X
Blood for TAK-788 and 
metabolites (AP32960 and 
AP32914) PK
X k
X k
X
X
X
X
X
X
X
X k
X
X k
X k
X k
X k
X
Other Procedures
Confinement in the CRU l
X
Return Visits
X
X
X
X
X
X
Footnotes are on the following page.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study No. TAK-788-1006
Page 20 of 85
Protocol Final
16 April 2019
a For details on Procedures, refer to Section 9.0.
b Within 28 days prior to the first study drug administration.
c There will be a washout period of 7 days between the dose of TAK-788 in Period 1 and the first dose of rifampin in Period 2. As per site preference in agreement with Sponsor, 
subjects may be confined throughout the washout period and/or for the whole study. If the CRU decides to confine the subjects throughout the study, the site will still perform safety 
events scheduled at check-in.
d Subjects will be admitted to the CRU on Day -1 of Period 1 and in the morning of Day 6 of Period 2, at the time indicated by the CRU.
e Day 8 of Period 1 is the same as Day 1 of Period 2. Study procedures will only be performed once.
f Symptom-driven- physical examination may be performed, at the Investigator’s or designee’s discretion.
g If the screening assessment was conducted within 4-7 days prior to dosing (Day 1), assessment will be conducted at check-in only if, in the opinion of the Investigator, there is reason 
to believe they have substantially changed
h To be conducted within 7 days prior to first dosing.
i Samples for serum chemistry will be obtained following a fast of at least 8 hours, however, in case of dropouts or rechecks, subjects may not have fasted for 8 hours prior to the serum 
chemistry sample is taken.
j To be performed within 24 hours prior to dosing. 
k Prior to dosing.
l As per site preference in agreement with Sponsor, subjects may be confined throughout the washout period and/or for the whole study.
m To be performed prior to early termination from the study.
n The CRU will contact all subjects (including subjects who terminate the study early) 30 ±2 days after the last TAK-788 dose to determine if any adverse events have occurred since 
the last study visit.
Abbreviations: ♀= Females, AE = Adverse events, BP = Blood pressure, C-I = Check-in, Chem = Chemistry, ConMeds = Concomitant medication, CRU = Clinical research unit, 
ECG = Electrocardiogram, ET = Early termination, FSH = Follicle-stimulating hormone, FU = Follow-up, Hem = Hematology, HIV = Human immunodeficiency virus, HR = Heart 
rate, PK = Pharmacokinetics, PMP = Postmenopausal, = Respiratory rate, S = Screening, T = Temperature, UA = Urinalysis. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study No. TAK-788-1006
Page 21 of 85
Protocol Final
16 April 2019
Table 3.a
Pharmacokinetic Plasma Concentration Sampling Schedule (Part 1)
Study Day
Sample Collection 
Time
Time 
(Relative to Dosing)
h:min
Plasma Concentrations of 
TAK-788, AP32960, and 
AP32914
Period 1 Day 1
0 h
(predose)
00:00
(predose)

0.5 h
00:30 (±5 min)

1 h
01:00 (±10 min)

2 h
02:00 (±10 min)

4 h
04:00 (±10 min)

6 h
06:00 (±20 min)

8 h
08:00 (±20 min)

12 h
12:00 (±20 min)

2
0 h
24:00 (±30 min)

12 h
36:00 (±30 min)

3
0 h
48:00 (±30 min)

4
0 h
72:00 (±60 min)

5
0 h
96:00 (±60 min)

6
0 h
120:00 (±60 min)

8
0 h
168:00 (- 60 min)
Drawn prior to dosing of next 
period

Period 2 Day 5
0 h
00:00
(predose)

0.5 h
00:30 (±5 min)

1 h
01:00 (±10 min)

2 h
02:00 (±10 min)

4 h
04:00 (±10 min)

6 h
06:00 (±20 min)

8 h
08:00 (±20 min)

12 h
12:00 (±20 min)

6
0 h
24:00 (±30 min)

12 h
36:00 (±30 min)

7
0 h
48:00 (±30 min)

8
0 h
72:00 (±60 min)

9
0 h
96:00 (±60 min)

10
0 h
120:00 (±60 min)

12
0 h
168:00:00 (±60 min) 

13
0 h
192:00 (±60 min) 

15
0 h
240:00 (±60 min)

Number of samples per subject: 
32
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study No. TAK-788-1006
Page 22 of 85
Protocol Final
16 April 2019
Table 3.b
Pharmacokinetic Plasma Concentration Sampling Schedule (Part 2)
Study Day
Sample Collection 
Time
Time 
(Relative to Dosing)
h:min
Plasma Concentrations of 
TAK-788, AP32960, and 
AP32914
Period 1 Day 1
0 h
(predose)
00:00
(predose)

0.5 h
00:30 (±5 min)

1 h
01:00 (±10 min)

2 h
02:00 (±10 min)

4 h
04:00 (±10 min)

6 h
06:00 (±20 min)

8 h
08:00 (±20 min)

12 h
12:00 (±20 min)

2
0 h
24:00 (±30 min)

12 h
36:00 (±30 min)

3
0 h
48:00 (±30 min)

4
0 h
72:00 (±60 min)

5
0 h
96:00 (±60 min)

6
0 h
120:00 (±60 min)

8
0 h
168:00 (-60 min) drawn prior to 
dosing of next period 

Period 2, Day 7
0 h
00:00
(predose)

0.5 h
00:30 (±5 min)

1 h
01:00 (±10 min)

2 h
02:00 (±10 min)

4 h
04:00 (±10 min)

6 h
06:00 (±20 min)

8 h
08:00 (±20 min)

12 h
12:00 (±20 min)

8
0 h
24:00 (±30 min)

12 h
36:00 (±30 min)

9
0 h
48:00 (±30 min)

10
0 h
72:00 (±60 min)

11
0 h
96:00 (±60 min)

12
0 h
120:00 (±60 min) 

14
0 h
168:00 (±60 min) 

Number of samples per subject: 
30
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 23 of 85
Protocol Final
16 April 2019
4.0
INTRODUCTION
4.1
Background
4.1.1
TAK-788
Aberrant activation of epidermal growth factor receptor (EGFR) and human epidermal growth 
factor 2 (HER2) plays a causal role in a subset of non–small cell lung cancer (NSCLC) and other 
cancers. As inhibition of wild-type (WT) EGFR is associated with dose-limiting toxicities, a 
tyrosine kinase inhibitor (TKI) that inhibits oncogenic EGFR and HER2 variants more potently 
than WT EGFR is more likely to be dosed at the more efficacious levels. Multiple classes of 
activating mutations have been identified in EGFR and HER2 that vary widely in their sensitivity 
to available TKIs. TAK-788, formerly known as AP32788, was designed to be a potent, selective 
inhibitor of all activated forms of EGFR and HER2, including exon 20 insertions (not targeted by 
any approved TKI), more potently than it inhibits WT EGFR.
Non-Clinical Pharmacokinetics
Clinical Pharmacokinetics
CCI
CCI
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
l growth
growth
LC) and 
LC) an
toxicit
oxicitiei
ants more
nts mor
Mult
ultiple c
iple c
widely i
widely 
gned to b
ned to 
on 20 ins
n 20 in
inetics
netic
ommercial use only and su
on-c
of Takeda: For non


TAK-788
Study ID TAK-788-1006
Page 24 of 85
Protocol Final
16 April 2019
Refer to the Investigator’s Brochure (IB) for detailed background information and safety data on 
TAK-788 (IB Edition 3, 04-Jan-2019).
4.1.2
Itraconazole
Itraconazole, a synthetic triazole-derivative, is a broad spectrum antifungal agent which exerts its 
pharmacological action by inhibiting cytochrome P450s (CYPs)-dependent enzymes resulting in 
blocked ergosterol synthesis. It is indicated for the treatment of oropharyngeal and esophageal 
candidiasis. For patients with oropharyngeal candidiasis unresponsive/refractory to treatment with 
fluconazole tablets, the recommended dose is 100 mg (10 mL) twice a day. The recommended 
dosage of Sporanox® Oral Solution for esophageal candidiasis is 100 mg (10 mL) daily for a 
minimum treatment of 3 weeks. Treatment should continue for 2 weeks following resolution of 
symptoms. Doses up to 200 mg (20 mL) per day may be used based on medical judgment of the 
patient’s response to therapy (Sporanox 2011).
Itraconazole is highly protein bound (>99%) and penetrates extensively into human tissue, but it 
has limited penetration into the cerebral spinal fluid. Itraconazole is extensively metabolized, 
predominantly by the CYP3A4 enzymes, and is known to undergo enterohepatic recirculation. 
Hydroxyitraconazole is the major metabolite and shows antifungal activity equal to that of the 
parent (Brüggemann et al. 2009).
Metabolism of itraconazole is saturable and might explain the more than proportional increase in 
itraconazole plasma concentration with increasing single doses and after chronic dosing. 
Following multiple oral dose administration of itraconazole capsules, peak concentrations are 
observed at approximately 4.5 hours, with an elimination half-life of about 64 hours (compared to 
about 21 hours following a single oral dose). Metabolites of itraconazole are excreted into the 
urine (40% of metabolites) and bile (55% of metabolites) (Brüggemann et al. 2009). Itraconazole 
is a substrate for and an inhibitor of CYP3A4 and an inhibitor of P-gp (Sporanox 2011).
CCI
Property of Takeda: For non-commercial use only and su
backgrou
ackgr
ve, is a b
e, is a
ytochrom
ochro
y
dicated f
dicate
pharyng
haryng
mended 
mende
Sololutut
l ioion
weeks. T
weeks
to 200 m
200 m
to therap
o ther
 highly p
highly
penetrati
penetra
nant
an ly 
ly by
oxyiyitraco
trac
i
rent 
ent (Brü
Br
Metabo
Metab
iti rac
F
of Use
subject to the applicable Terms of


TAK-788
Study ID TAK-788-1006
Page 25 of 85
Protocol Final
16 April 2019
Itraconazole will be used as a strong CYP3A inhibitor in this study, as it is listed as a strong index 
inhibitor of CYP3A4 in the recommendations of the FDA guidance Clinical Drug Interaction 
Studies - Study Design, Data Analysis, and Clinical Implications Guidance for Industry 
(FDA 2017). An oral solution of itraconazole showed higher oral absorption than an oral capsule 
formulation and dosing on an empty stomach will ensure the greatest oral absorption as 
determined by pharmacokinetic profiles (Willems et al. 2001). The maximal inhibition of CYP3A 
enzymes is visible with doses of 200 mg or 400 mg (Peng et al. 2011). However, 200 mg was 
chosen to reduce subject exposure to unnecessary drug. Oral administration of 100 –200 mg per 
day of itraconazole with a 3-day lead-in have shown adequately strong CYP3A4 inhibitor in 
several itraconazole DDI studies (Liu et al. 2016).
4.1.3
Rifampin
Rifampin is a semi-synthetic antibiotic derivative of rifamycin SV which acts by inhibiting 
deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase activity in 
susceptible species of Mycobacterium tuberculosis. Its activity does not impede mammalian 
enzyme RNA polymerase, therefore it is an effective treatment for both tuberculosis and 
meningococcus infections. Rifampin can be administered by oral route or by an IV infusion of 
30 minutes to 3 hours. The IV doses are the same as oral doses (Rifadin 2013).
Rifampin is readily absorbed from the gastrointestinal tract and is considered to be a highly 
variable drug in healthy adults and pediatric populations. A single oral dose of 600 mg of rifampin 
in healthy adults has an average peak serum concentration of 7 μg/mL ranging from 4 to 32 μg/mL 
with an average half-life of 3.35 ±0.66 hours. Gastric absorption with food reduces the 
bioavailability of rifampin by about 30%. Rifampin is widely distributed throughout the body and 
can reach effective concentrations in various organs and cerebrospinal fluid. Rifampin is 80% 
protein bound in the blood while the remaining unbound fraction is not ionized and can readily 
diffuse into tissues (Rifadin 2013).
Rifampin is rapidly eliminated in the bile and undergoes enterohepatic recirculation; during this 
process, gradual deacetylation of the drug occurs so that nearly all the drug in the bile is in this 
form 6 hours postdose. The deacetylated form of rifampin is active and exhibits antibacterial 
properties. Moreover, intestinal reabsorption is reduced by deacetylation thus promoting drug 
elimination. 
Rifampin will be used as a strong CYP3A inducer as per the recommended in the FDA guidance 
Clinical Drug Interaction Studies - Study Design, Data Analysis, and Clinical Implications 
Guidance for Industry (FDA 2017). Rifampin dose of 600 mg QD and lead-in doses of 5 – 7 days 
have shown to achieve the maximal induction of CYP3A4 in humans for drug interaction studies 
(Duus et al. 2018, Upreti et al. 2011, Srinivas 2016). Furthermore, the level of CYP3A4 activity in 
modeling simulations becomes stable with 6-day dosing. Since most of the clinical DDI 
evaluations were carried out for approximately 5 half-life of victim drug, dosing of rifampin will 
continue after coadministration with a victim drug for sustainable induction of CYP3A enzymes 
(Duus et al. 2018).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 26 of 85
Protocol Final
16 April 2019
4.2
Rationale for the Proposed Study
TAK-788, formerly known as AP32788, was designed to be a selective inhibitor of all mutant 
forms of EGFR and HER2, including exon 20 insertions (not targeted by any approved TKI), more 
potently than it inhibits WT EGFR. Although TAK-788 is intended for the treatment of NSCLC, it 
is neither a mutagenic nor genotoxic agent and was generally well tolerated in the previous clinical 
pharmacology studies (TAK-788-1001 and TAK-788-1002, a total of 64 subjects) in healthy 
subjects in the single dose range of 20 – 160 mg. 
The purpose of this study is to assess the effect of co-administration of the strong CYP3A inhibitor 
itraconazole or the strong CYP3A inducer rifampin on the pharmacokinetics of TAK-788 to 
inform strategies for management of potential drug-drug interactions with strong CYP3A 
inhibitors or inducers in future clinical studies of TAK-788. 
Itraconazole is a well characterized, competitive, strong inhibitor of CYP3A4. An oral solution of 
itraconazole is used in the current study instead of the capsule formulation and is administered on 
an empty stomach to ensure the highest oral absorption under fasting conditions and minimize 
gastrointestinal tract irritation during fasting. The maximal inhibition of CYP3A enzymes will be 
achieved with repeated doses of 200 mg itraconazole. The 4 days of lead-in administration of 
itraconazole ensure that CYP3A4 is maximally inhibited prior to coadministration with TAK-788. 
Rifampin will be used as a strong CYP3A inducer in this study per the recommendations of the 
FDA guidance Clinical Drug Interaction Studies - Study Design, Data Analysis, and Clinical 
Implications Guidance for Industry (FDA 2017). Rifampin was selected as a 600 mg dose QD with 
7 days of lead-in dosing prior to the concomitantly administered with TAK-788 in this study. 
Because the half-life of AP32960 was approximately 28 hours, the longest among TAK-788 and 
its active metabolites, oral administration of rifampin will continue for 6 days after 
coadministration of TAK-788 for sustainable induction of CYP3A enzymes.
Because TAK-788 is mainly metabolized by CYP3A, it is anticipated that TAK-788 exposure will 
likely be increased significantly when TAK-788 is concomitantly administered with itraconazole. 
The itraconazole drug-drug interaction assessment portion of this study (Part 1) will consist of two 
CCI
Property of Takeda: For non-commercial use o
effect o
effect o
ducer rif
ucer ri
of poten
f pote
clinical s
inical
acterized
terize
he curren
curr
ensure th
sure 
ct irritati
t irrit
epeated 
peated
ensure th
ensur
n will be
will b
guidance
uidanc
plicati
plication
7 day
7 days o
s
Becau
ec
itits
licable Terms of Use
more
more
CLC, it 
LC, it 
us clinica
clin
healt
ealthy 
hy
only and subject to the applic


TAK-788
Study ID TAK-788-1006
Page 27 of 85
Protocol Final
16 April 2019
cohorts. As the magnitude of the effect of strong CYP3A inhibition on the PK of TAK-788 and its 
active metabolites (AP32960 and AP32914) is currently unknown, the planned dose of TAK-788 
(with itraconazole) for Cohort 1 of this study will be 20 mg TAK-788, which is 8 times below the 
highest single dose of 160 mg evaluated in healthy subjects. PK data will be reviewed after dosing 
a cohort of 4 subjects in order to confirm the dose for the second cohort. TAK-788 dose in the 
second cohort may be modified (based on data from Cohort 1) to select a dose that would be 
anticipated during co-administration with itraconazole to achieve exposures similar to the 
previously observed exposures at the 160 mg single dose alone in healthy subjects. The dose of 
TAK-788 selected for the drug-drug interaction study with rifampin (Part 2) will be 160 mg 
(recommended Phase 2 dose).
Similar to most oncology drugs, ≤25% loss in TAK-788 exposure when concomitantly 
administered with a CYP inducer and ≤30% increase in exposure when concomitantly 
administered with a CYP inhibitor can be inferred not to be clinically relevant to efficacy and 
safety when viewed in context of moderate TAK-788 PK variability (43% CV for AUC in cancer 
patients) (Teo et al. 2014, IB 2019).
4.3
Benefit/Risk Profile
The clinical safety data available as of 14 September 2018 indicated no particular safety findings 
that are unique to TAK-788 compared with other approved EGFR TKIs. The most common 
treatment-emergent AEs (TEAE) occurring in ≥20% of patients by preferred term overall were 
diarrhea 79 (78.2%), nausea 40 (39.6%), decreased appetite 31 (30.7%), rash 30 (29.7%), vomiting 
24 (23.8%) and fatigue 23 (22.8%). The most common TEAE occurring in ≥20% of patients 
overall by preferred term was diarrhea 69 (68.3%), nausea 30 (29.7%), rash 26 (25.7%), and 
decreased appetite 21 (20.8%) which are commonly observed with other EGFR TKIs (IB 2019).
There will be no direct health benefit for study participants from receipt of study drugs. An indirect 
health benefit to the healthy subjects enrolled in this study is the free medical tests received at 
screening and during the study.
The risk of dosing itraconazole and rifampin in combination with TAK-788 is unknown in this 
study. However, the risk of dose of itraconazole plus TAK-788 administered in Part 1 and the dose
or rifampin plus TAK-788 administered in Part 2 are anticipated to be similar to those previously 
reported for each of the individual drugs as reported in the TAK-788 IB, and in the full prescribing 
information for Sporanox® and Rifadin® since itraconazole and rifampin are administered 
according to the dosing recommendations found therein.
The inclusion and exclusion criteria, screening, and safety monitoring practices employed by this 
protocol (i.e., 12 lead ECG, vital signs, clinical laboratory tests, AE questioning, PFT 
(spirometry), and physical examination are adequate to protect the subject’s safety and should 
detect all TEAEs.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 28 of 85
Protocol Final
16 April 2019
5.0
STUDY OBJECTIVES AND ENDPOINTS
5.1
Hypothesis
Not applicable
5.2
Study Objectives
5.2.1
Study Primary Objective
Part 1: To characterize the effect of itraconazole, a strong CYP3A inhibitor, on the single-dose PK 
of TAK-788 and its active metabolites (AP32960 and AP32914) in healthy adult subjects.
Part 2: To characterize the effect of rifampin, a strong CYP3A inducer, on the single-dose PK of
TAK-788 and its active metabolites (AP32960 and AP32914) in healthy adult subjects.
5.2.2
Study Exploratory Objective
Part 1 and Part 2: To assess the safety data of TAK-788 following single oral dose with/without 
strong CYP3A inhibitor or inducer in healthy adult subjects.
5.3
Endpoints
5.3.1
Primary Endpoint
The primary endpoints of the study are:

Maximum observed concentration (Cmax).

Area under the concentration-time curve from time 0 to infinity, calculated using the observed 
value of the last quantifiable concentration (AUC).

Area under the concentration-time curve from time 0 to the time of the last quantifiable 
concentration (AUClast). 

Time of first occurrence of Cmax (Tmax).
5.3.2
Exploratory Endpoints
The exploratory endpoints will be assessed through evaluation of the following parameters:

TEAEs assessments.

Clinical laboratory testing (hematology, serum chemistry and urinalysis).

Physical examinations.

12-lead ECG.

Vital signs.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 29 of 85
Protocol Final
16 April 2019
6.0
STUDY DESIGN AND DESCRIPTION
6.1
Study Design 
This is a 2-part study. Each part will be conducted as an open-label, 2-period, fixed sequence study 
with TAK-788 designed to characterize TAK-788 drug-drug interaction with either a strong 
CYP3A inhibitor, itraconazole (Part 1) or with a strong CYP3A inducer, rifampin (Part 2) in 
healthy adult subjects. Subjects participating in Part 1 will be different from those participating in 
Part 2. Additionally, Part 1 will be a sequential study design; Part 1 Cohort 2 will not start until PK 
data from Part 1 Cohort 1 (up to Period 2 Day 15) has been evaluated. The study parts may be 
conducted concurrently.
Part 1: TAK-788 assessment with Itraconazole
Part 1 will be conducted in 2 cohorts: Cohort 1 will enroll 4 subjects and will assess whether the 
20 mg dose of TAK-788 is an appropriate dose for the TAK-788/itraconazole drug-drug 
interaction study; depending on the PK results, Cohort 2 will either continue to enroll 8 more 
subjects at this same dose level or enroll 12 more subjects at a revised TAK-788 dose level. Other 
than the dose of TAK-788, the study design will be exactly the same for each cohort. 
This study part will comprise of a screening period, 2 treatment periods and a follow-up phone call 
in up to 16 healthy subjects. Dose administration and PK collection scheme for the treatment 
period is outlined in the Table 6.a below.
Table 6.a
Part 1 TAK-788 assessment with Itraconazole
Treatment Period 1
Treatment Period 2
Study Day
-1
1
2
3
4
5
6
8*
1*
2
3
4
5
6
7
8
9
10
11
12
13
14
15
TAK-788 PO 
X
X
Itraconazole 
200 mg QD PO
X
X
X
X
X
X
X
X
X
X
X
X
X
X
PK Blood 
Samples 
X
X
X
X
X
X
X*
X*
X
X
X
X
X
X
X
X
X
Overnight in 
Clinics
X
X
X
X
X
X
X
X
* Since the washout period is 7 days the timing of the last PK blood draw of Period 1 will occur within 60 minutes prior to the first 
dose of itraconazole on Period 2 Day 1; only one PK sample will be taken.
Abbreviation: PK=Pharmacokinetics; PO=per oral; QD=once daily
On Period 1 Day 1, subjects will receive a single 20 mg oral dose of TAK-788 or a TAK-788 oral 
dose TBD (Cohort 2) as capsules (fasting). A standardized meal will be provided at least 4 hours 
postdose. Subjects will remain in the CRU until the morning of Day 4 after the 72-hour PK sample 
is collected. Additional PK samples will be taken as an outpatient up to 168 hours postdose 
(Period 1 Day 8, which is the same as Period 2 Day 1). 
In Period 2, subjects will receive 200 mg itraconazole QD alone as an oral solution on an empty 
stomach (no food from at least 1 hour prior until at least 2 hours after dosing). Subjects will be 
admitted to the CRU on Period 2 Day 4. In the morning of Period 2 Day 5, subjects will receive 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 30 of 85
Protocol Final
16 April 2019
200 mg itraconazole together with 20 mg oral TAK-788 or a TBD oral dose of TAK-788 (fasting). 
A standardized meal will be provided at least 4 hours postdose. Subjects will be furloughed from 
the CRU after the 72-hour PK sample is collected in the morning of Period 2 Day 8. There will be 
outpatient visits to the CRU for dosing itraconazole and/or PK sampling from Day 1 to Day 3 and 
Day 9 to Day 14. A final post-treatment follow-up and last PK sampling (Table 3.a) will occur at 
240 hours post-Day 5 TAK-788 dose (Period 2 Day 15).
All PK data (TAK-788 and its 2 active metabolites, AP32960 and AP32914) collected in Cohort 1 
(up to Day 15) will be evaluated to determine the dose of TAK-788 administered to subjects in 
Cohort 2 of the study. The TAK-788 dose in Cohort 2 may remain at 20 mg or may be modified to 
an appropriate level to approximate a similar exposure compared to the geometric mean of 
single-dose exposure previously observed at 160 mg single dose TAK-788 alone in healthy 
subjects.
Part 2: TAK-788 assessment with Rifampin
Part 2 will comprise of a screening period, 2 treatment periods, and a follow-up phone call in 
12 subjects. Dose administration and PK collection scheme for the treatment periods are outlined 
in the table below.
Table 6.b
Part 2 TAK-788 assessment with Rifampin
Treatment Period 1
Treatment Period 2
Study Day
-1
1
2
3
4
5
6
8*
1*
2
3
4
5
6
7
8
9
10
11
12
13
14
TAK-788
160 mg PO 
X
X
Rifampin 
600 mg QD PO
X
X
X
X
X
X
X
X
X
X
X
X
X
PK Blood Samples 
X
X
X
X
X
X
X*
X*
X
X
X
X
X
X
X
Overnight in 
Clinics
X
X
X
X
X
X
X
X
*Since the washout period is 7 days the timing of the last PK blood draw of Period 1 will occur within 60 minutes prior to the first 
dose of rifampin on Period 2 Day 1; only one PK sample will be taken.
Abbreviation: PK=Pharmacokinetics; PO=per oral; QD=once daily.
On Period 1 Day 1, a different group of subjects from Part 1 will receive a single 160 mg oral dose 
of TAK-788 as capsules (fasting). A standardized meal will be provided at least 4 hours postdose. 
Subjects will remain in the CRU until the morning of Day 4 after the 72-hour PK sample is 
collected. Additional PK samples (Table 3.b) will be taken as an outpatient up to 168 hours 
postdose (Period 1 Day 8, which is the same as Period 2 Day 1). 
In Period 2, subjects will receive 600 mg rifampin QD alone as capsules (fasting). Subjects will be 
admitted to the CRU on Day 6. In the morning of Day 7, subjects will receive 160 mg oral 
TAK-788 together with 600 mg rifampin (fasting). A standardized meal will be provided at least 
4 hours postdose. Subjects will be furloughed from the CRU after the 72-hour PK sample is 
collected in the morning of Day 10. There will be outpatient visits to the CRU for dosing rifampin 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 31 of 85
Protocol Final
16 April 2019
and/or PK sampling from Day 1 to Day 5 and Day 11 to Day 13. A final post-treatment follow-up 
and last PK sampling will occur at 168 hours post Day 7 dose (Day 14). 
Part 1 and Part 2: 
All of study drugs will be orally administered with approximately 240 mL water or total aqueous
volume of approximately 240 mL when dosing with itraconazole oral solution. All doses of 
TAK-788, itraconazole, and rifampin will be administered at the CRU during this study, either 
during confinement or on an outpatient basis. 
Spirometry as the PFT are required to be performed and be assessed as normal at screening. 
Post-dose spirometry will be performed only if indicated on the basis of pulmonary symptoms, at 
the discretion of the Investigator or designee. 
A final safety follow-up phone call will occur 30 ± 2 days after the last TAK-788 dose to determine 
if any AEs have occurred since the last study visit.
Any subject who experiences emesis within 8 hours post dosing with TAK-788 will be excluded in 
the final data analysis. Replacement of discontinued or withdrawn subject due to any reason will 
be assessed on a case by case basis by the Sponsor and Investigator to ensure a minimum of 
10 PK-evaluable subjects complete the study in each part of study.
The planned dose levels of TAK-788, itraconazole, and rifampin to be evaluated are outlined in 
Table 6.c. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 32 of 85
Protocol Final
16 April 2019
Table 6.c
Planned Doses of TAK-788, Itraconazole (Part 1), and Rifampin (Part 2)
Cohort
Days
Dose
Route of Administration
Part 1
Cohort 1
Period 1
TAK-788
1
1
20 mg
oral capsule 
Period 2
Itraconazole
1
1-14
200 mg
oral solution
Period 2
TAK-788
1
5
20 mg
oral capsule
Cohort 2
Period 1
TAK-788
2
1
TBD
oral capsule
Period 2
Itraconazole
2
1-14
200 mg
oral solution
Period 2
TAK-788
2
5
TBD
oral capsule
Part 2
Period 1
TAK-788
NA
1
160 mg
oral capsule
Period 2
Rifampin
NA
1-13
600 mg
oral capsule
Period 2
TAK-788
NA
7
160 mg
oral capsule
NA = not applicable.
6.2
Dose Escalation
Part 1 will be conducted in 2 cohorts: Cohort 1 will enroll 4 subjects and will assess whether the 
20 mg dose of TAK-788 is an appropriate dose for the TAK-788/itraconazole drug-drug 
interaction study (see Section 4.2); depending on the PK results, Cohort 2 will either continue to 
enroll 8 more subjects at this same dose level (20 mg) or enroll 12 more subjects at a revised 
TAK-788 dose level (TBD dose TAK-788). Other than the dose of TAK-788, the study design will 
be exactly the same for each cohort. 
A sequential dosing design was selected to dose subjects in 2 cohorts. The first cohort of 4 subjects 
will be studied until the end of Period 2 Day 15 and PK will be reviewed. The dose may be 
maintained for Cohort 2 or raised to a maximum of 160 mg while ensuring the drug interaction 
between TAK-788 and itraconazole does not exceed the exposure of TAK-788 levels previously 
seen in healthy adult subjects. The dose level for TAK-788 in Cohort 2 will be a dose anticipated 
during coadministration with itraconazole to achieve exposures similar to the previously observed 
exposures at the 160 mg single dose alone in healthy subjects. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 33 of 85
Protocol Final
16 April 2019
There will be no dose modifications for Part 2.
6.3
Rationale for Study Design, Dose, and Endpoints
6.3.1
Rationale of Study Design and Dose
Part 1:
Because TAK-788 is mainly metabolized by CYP3A, it is anticipated that TAK-788 exposure will 
likely be increased significantly when TAK-788 is concomitantly administered with itraconazole. 
The itraconazole drug-drug interaction assessment portion of this study (Part 1) will consist of two 
cohorts. As the magnitude of the effect of strong CYP3A inhibition on the PK of TAK-788 and its 
active metabolites (AP32960 and AP32914) is currently unknown, the planned dose of TAK-788 
(with itraconazole) for Cohort 1 of this study will be 20 mg TAK-788, which is 8 times below the 
highest single dose of 160 mg evaluated in healthy subjects. PK data will be reviewed after dosing 
a cohort of 4 subjects in order to confirm the dose for the second cohort. TAK-788 dose in the 
second cohort may be modified (based on data from Cohort 1) to select a dose that would be 
anticipated during co-administration with itraconazole to achieve exposures similar to the 
previously observed exposures at the 160 mg single dose alone in healthy subjects. The dose of 
TAK-788 selected for the drug-drug interaction study with rifampin (Part 2) will be 160 mg 
(recommended Phase 2 dose).
In this first study part, subjects will be dosed with TAK-788 alone and then in combination with 
itraconazole after 4 consecutive days of dosing itraconazole alone. It has been well established in 
the literature that itraconazole is a strong CYP3A inhibitor and that dosing 200 mg of itraconazole 
for 3 to 5 days to achieve maximum CYP3A inhibition in order to detect a drug-drug interaction 
[Varis et al. 2000, Yoshitzato et al. 2012]. Dosing of itraconazole after Day 5 until the end of the 
PK sampling time will ensure continued inhibition of CYP3A.Varis_2000Yoshizato_2012
No clinically significant drug-drug interaction may be conclusive if ≤30% increase in exposure to 
TAK-788 or combined molar exposure to TAK-788, AP32960, and AP32914 will occur when 
concomitantly administered with a strong CYP3A inhibitor. A change of this magnitude may be 
inferred not to be clinically relevant to safety when viewed in the context of moderate TAK-788 
PK variability (approximately 43% CV for AUC24 in cancer patients).
Part 2:
In the second study part, subjects will be dosed with TAK-788 alone and then in combination with 
600 mg rifampin after 6 consecutive days of dosing rifampin alone. It has been well established in 
the literature that rifampin has maximum CYP3A induction after 5 – 7 days of lead-in dosing 
[Duus et al. 2018, Upreti et al. 2011, Srinivas 2016]. A dose of 600 mg oral rifampin daily is used 
to achieve CYP3A induction in previous literature. Rifampin will continue to be administered until 
the end of the PK sampling time in Period 2 to maintain induction levels. 
The dose of TAK-788 selected for the drug-drug interaction study with rifampin (Part 2) will be 
160 mg (recommended Phase 2 dose). Since a reduction in exposure is anticipated the 
coadministration of these two study drugs should be well-tolerated.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 34 of 85
Protocol Final
16 April 2019
A ≤25% loss in TAK-788 exposure or combined molar exposure to TAK-788, AP32960, and 
AP32914 when concomitantly administered with a strong CYP inducer may be inferred not to be 
clinically relevant to efficacy when viewed in context of moderate TAK-788 PK variability 
(approximately 43% CV for AUC24 in cancer patients).
Part 1 and Part 2:
On PK days, all study medication (TAK-788 alone, TAK-788 plus itraconazole, or TAK-788 plus 
rifampin) will be given after an overnight fast of at least 10 hours followed by at least a 4-hour fast 
after dosing to avoid interference of food. On other dosing days, itraconazole will be administered 
on an empty stomach (no food from at least 1-hour prior until at least 2 hours after dosing) and 
rifampin will be administered under fasted conditions. 
6.3.2
Rationale for Endpoints
6.3.2.1
Pharmacokinetic Endpoints
The pharmacokinetic endpoints are standard for this type of study.
6.3.2.2
Safety Endpoints 
The key safety endpoints are typical for Phase 1 studies and will be assessed through monitoring of 
adverse events, vital signs, ECGs, laboratory assessments and physical examinations.
6.3.3
Future Biomedical Research
Any residual plasma samples will be stored by the Sponsor or Bioanalytical facility for the 
maximal 5 years determined by Sponsor following the last dosing and may be used in the future to 
perform metabolite profiling. Tubes or container will be identified with a barcode using an 
appropriate label.
No diseases/conditions, deoxyribonucleic acid, or ribonucleic acid will be the focus of these 
analyses. The analyses will focus on metabolite profiling for TAK-788 compound. Samples will 
not be submitted to a public database. The Sponsor and contract research organizations involved in 
the clinical conduct, bioanalytical analyses and PK and statistical analysis of the data will have 
access to the samples and/or the data that resulted from the analysis, if performed. 
By signing the ICF, subjects agree to the possible future analysis of these samples. At any time, the 
subjects can contact the CRU staff to request destruction of the residual samples once PK 
assessments required to meet the primary objective of the study are completed. Any additional 
research on these samples unspecified by this protocol will require approval from the subjects.
6.3.4
Critical Procedures Based on Study Objectives: Timing of Procedures 
For this study, the critical component is the blood collection for plasma concentrations of 
TAK-788 its active metabolites (AP32960 and AP32914) and samples are required to be collected, 
as appropriate, as close to the scheduled times defined in this protocol as possible.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 35 of 85
Protocol Final
16 April 2019
6.4
Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters
Part 1 only: The dose of TAK-788 for Cohort 2 will be determined based on the exposure data of 
Cohort 1. 
For itraconazole in Part 1 and rifampin and TAK-788 in Part 2, the dose and administration of the 
study drugs to any subject may not be modified. If necessary, a subject may be discontinued for the 
reasons described in Section 7.3 and Section 7.4.
6.5
Study Beginning and End/Completion
6.5.1
Definition of Beginning of the Study
The beginning of the study will be defined as the beginning of the screening (i.e., signing of the 
ICF) of the first subject.
6.5.2
Definition of End of the Study
The end of study is defined as the date of the last scheduled study procedure as outlined in the 
Schedule of Study Procedures (Section 3.0)
6.5.3
Definition of Study Completion
The end of the study is scheduled after completion of the evaluations in the follow-up phone call 
for the last subject in the study.
This time period may change in the event that the study is terminated early or the last subject is lost 
to follow-up.
6.5.4
Definition of Study Discontinuation
Celerion reserves the right to terminate the study in the interest of subject welfare.
The Sponsor reserves the right to suspend or terminate the study at any time.
6.5.5
Criteria for Premature Termination or Suspension of the Study
The study will be completed as planned unless one or more of the following criteria are satisfied 
that require temporary suspension or early termination of the study:

New information or other evaluation regarding the safety or efficacy of the study medication 
that indicates a change in the known risk/benefit profile for the product, such that the risk is no 
longer acceptable for subjects participating in the study.

Significant violation of Good Clinical Practice (GCP) that compromises the ability to achieve 
the primary study objectives or compromises subject safety.
6.5.6
Criteria for Premature Termination or Suspension of a Site
Not applicable.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 36 of 85
Protocol Final
16 April 2019
7.0
SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
7.1
Excluded Medications, Supplements, Dietary Products
Concomitant medications will be prohibited as listed in the exclusion criteria in Section 9.1.2.2. 
After the first dose, acetaminophen (up to 2 g per 24 hour period) may be administered at the 
discretion of the Investigator or designee. Thyroid hormone replacement medication may be 
permitted if the subject has been on the same stable dose for the immediate 3 months prior to the 
first dosing.
If deviations occur, the Investigator or designee in consultation with the Sponsor if needed will 
decide on a case by case basis whether the subject may continue participation in the study.
All medications taken by subjects during the course of the study will be recorded.
Use of excluded agents (prescription or non-prescription) or dietary products is outlined in Table 
7.a.
Table 7.a
Excluded Medications, Supplements, and Dietary Products
Category
Between Screening and First Dosing (Days 
-28 to predose [Day 1])
After First Dosing (Day 1) to 
Follow-Up 
Alcohol
Prohibited from 48 hours prior to first dosing
Prohibited throughout the study.
Xanthine and/or caffeine
Prohibited from 24 hours prior to first dosing a
Prohibited throughout the study a.
Medications 
See Sections 7.1 and 9.1.2.2
See Sections 7.1 and 9.1.2.2
Food substance
Grapefruit/Seville orange
Prohibited from 28 days prior to first dosing
Prohibited until end of PK 
collection in Period 2.
Other Fruit Juice
Prohibited from 72 hours prior to first dosing
Prohibited until end of PK 
collection in Period 2.
Vegetables from the 
mustard green family 
(eg, kale, broccoli, 
watercress, collard greens, 
kohlrabi, Brussels sprouts, 
mustard), and charbroiled 
meats
Prohibited from 7 days prior to first dosing
Prohibited until end of PK 
collection in Period 2.
a small amounts of caffeine derived from normal foodstuffs e.g., 250 mL/8 oz./1 cup decaffeinated coffee or other 
decaffeinated beverage, per day, with the exception of espresso; 45 g/1.5 oz. chocolate bar, per day, would not be 
considered a deviation to this restriction.
7.2
Diet, Fluid, Activity 
7.2.1
Diet and Fluid
Water (except water provided with each oral dosing) will be restricted 1 hour prior to and 1 hour 
after each study drug administration, but will be allowed ad libitum at all other times. Other fluids 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 37 of 85
Protocol Final
16 April 2019
may be given as part of meals and snacks but will be restricted at all other times throughout the 
confinement period.
On Period 1 Day 1 and Period 2 Day 5 (Part 1) or Period 1 Day 1 and Period 2 Day 7 (Part 2): 
subjects will fast overnight for at least 10 hours prior to each oral study drug administration and 
will continue to fast for at least 4 hours postdose.
On all other dosing days in Period 2 in Part 1 subjects will administer itraconazole on an empty 
stomach (no food from at least 1-hour prior until at least 2 hours after dosing). On all other dosing 
days in Period 2 in Part 2 subjects will administer rifampin after an overnight fast of at least 
10 hours followed by at least a 4-hour fast after dosing to avoid interference of food. 
When confined, standard meals and snacks will be provided at appropriate times, except when 
they are required to fast. When confined in the CRU, subjects will be required to fast from all food 
and drink except water between meals and snacks.
7.2.2
Activity
Subjects will remain ambulatory or seated upright for the first 4 hours postdose on Period 1 Day 1 
(Part 1 and Part 2) and Period 2 Day 5 (Part 1) or Day 7 (Part 2), except when they are supine or 
semi-reclined for study procedures or AEs. There is no activity restriction on other dosing days.
Subjects will be instructed to refrain from strenuous physical activity which could cause muscle 
aches or injury, including contact sports at any time from screening until completion of the study. 
7.3
Criteria for Discontinuation or Withdrawal of a Subject
Subjects are free to withdraw from the study at any time for any reason. 
In addition, subjects may be withdrawn from the study by the Investigator or designee for the 
following reasons:

AEs.

A positive pregnancy test for females.

Positive urine drug or alcohol results.

Difficulties in blood collection.
A subject may be withdrawn by the Investigator (or designee) or the Sponsor if enrollment into the 
study is inappropriate, the study plan is violated, or for administrative and/or other safety reasons
7.4
Procedures for Discontinuation or Withdrawal of a Subject
The Investigator may discontinue a subject’s study participation at any time during the study when 
the subject meets the study termination criteria described in Section 7.3. In addition, a subject may 
discontinue his or her participation without giving a reason at any time during the study. Should a 
subject’s participation be discontinued, the primary criterion for termination must be recorded by 
the Investigator. In addition, efforts should be made to perform all procedures scheduled for the 
end-of-study or early termination as described in Section 3.0.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 38 of 85
Protocol Final
16 April 2019
7.5
Subject Replacement
Replacement of discontinued or withdrawn subjects due to any reason will be assessed on a case 
by case basis by the Sponsor and PI to ensure a minimum of 10 PK-evaluable subjects complete in 
each part of study.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 39 of 85
Protocol Final
16 April 2019
8.0
CLINICAL STUDY MATERIAL MANAGEMENT
8.1
Clinical Study Drug 
8.1.1
TAK-788 Capsules 
Part 1:
A single 20 mg TAK-788 capsule (1 x 20 mg TAK-788) or a dose up to 160 mg dose of 1 or more 
capsules of TAK-788 will be administered on Period 1 Day 1 and Period 2 Day 5 for Cohorts 1 and 
2, respectively. 
Part 2:
A single 160 mg dose of TAK-788 capsules (4 x 40 mg TAK-788) will be administered on 
Period 1 Day 1 and Period 2 Day 7.
Oral dose of TAK-788 drug product is a nonsterile, oral, capsule dosage form, supplied in a hard 
gelatin capsule of TAK-788 succinate salt. TAK-788 succinate salt is the active pharmaceutical 
ingredient. The drug product is supplied as a hard gelatin capsule shell. No other ingredients are 
included in the drug product.
TAK-788 (AP32788) 20 mg: Size 2, Swedish-orange, opaque, gelatin capsules, 30 capsules per 
bottle
TAK-788 (AP32788) 40 mg: Size 1, white, opaque, hard gelatin capsules 30 capsules per bottle
Capsules are packaged in: White, 60-cc, round HDPE bottles that are induction sealed with a silver 
foil, tamper evident seal. White, child-resistant caps with pictorial instructions.
Bottles will be labelled with a single panel label with a minimum of the following information:

Protocol number.

Contents.

Storage conditions.

Lot Number.

A caution and warning statement.

Sponsor information.
Investigational Product Shipment Receipt

Open box, remove and stop the Temptale temperature recorder.

Inspect the Temptale according to the Temptale instructions.

Verify that the number, dosage, and lot numbers of the TAK-788 (AP32788) bottles match the 
packing list.

Inspect the TAK-788 (AP32788) for any signs of damage.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 40 of 85
Protocol Final
16 April 2019

Verify the bottle ID numbers against the packing list and file the forms in the site files.

Properly store the bottles of TAK-788 (AP32788). Store below 30°C (86°F).
–
Do not refrigerate or freeze.
If there are signs of damage, please do the following:

Physically quarantine the shipment (quarantine according to the required storage).

Email the packing list to Clinical Supply Chain at ClinicalSupply788@takeda.com to describe 
the observation.

Clinical Supply Chain will confirm receipt of issue.

Clinical Supply Chain will generate an email to the site on outcome.

Any and all discrepancies are to be reported to TAKEDA Pharmaceuticals and XERIMIS 
without delay, they should be listed on the packing list.
8.1.2
Itraconazole Solution
Itraconazole will be supplied as a 10 mg/mL Sporanox® oral solution (brandname only). 
Itraconazole 200 mg (approximately 20 mL) will be administered QD in Period 2 Part 1 at each 
dosing. Itraconazole will be stored and prepared according to the product label.
Subjects will be dosed with itraconazole and the dosing container will be rinsed with dosing water 
twice. The remaining volume of the 240 mL of dosing water will be ingested by the subject 
subsequently.
8.1.3
Rifampin Capsules
Rifampin will be supplied as 200 mg Rifadin® capsules (brandname only).
Rifampin 600 mg (3 x 200 mg capsules) will be dosed QD in Period 2 Part 2. Rifampin will be 
stored according to the product label.
8.1.4
Clinical Study Drug Labeling
TAK-788 capsule containers will be affixed with a clinical label in accordance with local 
regulatory requirements.
Itraconazole and rifampin will be affixed with a clinical label in accordance with local regulatory 
requirements.
The pharmacy at the CRU will provide each dose in individual unit dose containers for each 
subject and for each study period.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 41 of 85
Protocol Final
16 April 2019
8.1.5
Clinical Study Drug Inventory and Storage
TAK-788 capsules
The Sponsor will supply sufficient quantities of TAK-788 products to allow completion of this 
study. 

Store below 30°C (86°F).

Do not refrigerate or freeze – Normal room temperature.

Keep away from cold or heat sources.

Keep out of reach and sight of children.
Rifampin capsules and Itraconazole solution
Celerion will provide sufficient quantities of the Sporanox® itraconazole oral solution and 
Rifadin® rifampin capsules to allow completion of the study. The same lot number will be used 
throughout the study. The lot numbers and expiration dates (where available) of the study drugs 
supplied will be recorded in the final report. Rifampin and itraconazole will be stored according to 
the product labels provided with the product.
Records will be made of the receipt, preparation, dispensing, and final disposition of the study 
drugs supplied.
8.1.6
Clinical Study Drug Blinding
This is an open-label study.
8.1.7
Randomization Code Creation and Storage 
Not applicable
8.1.8
Clinical Study Blind Maintenance/Unblinding Procedure
Not applicable
8.1.9
Accountability and Destruction of Sponsor-Supplied Drugs
At the conclusion of the study, any unused TAK-788 study drug will be retained by Celerion, 
returned to the Sponsor or designee, or destroyed, as per Sponsor instructions (see Section 8.1.1). 
Any remaining supplies that were purchased by Celerion will be destroyed. If no supplies remain, 
this fact will be documented in the pharmacy product accountability records.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 42 of 85
Protocol Final
16 April 2019
9.0
STUDY PROCEDURES
9.1
Administrative Procedures
9.1.1
Informed Consent Procedure
The purpose of the study, the procedures to be carried out and the potential hazards will be 
described to the subjects in non-technical terms. Subjects will be required to read, sign and date an 
ICF summarizing the discussion prior to screening, and will be assured that they may withdraw 
from the study at any time without jeopardizing their medical care.
Subjects will be given a copy of their signed ICF.
9.1.1.1
Assignment of Screening and Allocation Numbers 
Each subject will be assigned a unique identification number upon screening. Subjects who 
complete the study screening assessments and meet all the eligibility criteria will be assigned a 
unique identification number at the time of the first dosing, different from the screening number.
If replacement subjects are used, the replacement subject number will be 100 more than the 
original (eg, Subject No. 101 will replace Subject No. 1).
9.1.1.2
Study Drug Assignment
This is a fixed-sequence study. Within each study part/cohort, all subjects will receive the 
treatments as detailed in Section 8.1.
9.1.2
Inclusion and Exclusion 
9.1.2.1
Inclusion Criteria 
Subjects must fulfill the following inclusion criteria to be eligible for participation in the study: 
1. Healthy, adult, male or female, 18 - 55 years of age, inclusive, at screening. 
2. Continuous non-smoker who has not used nicotine-containing products for at least 18 years 
prior to the first dosing and throughout the study, based on subject self-reporting.
3. BMI ≥18.0 and ≤32.0 kg/m2, at screening.
4. Medically healthy with no clinically significant medical history, physical examination, 
laboratory profiles, vital signs, or ECGs, as deemed by the Investigator or designee. Has LFTs 
including ALT, AST, ALP, and total bilirubin within the upper limit of normal at screening 
and at first check-in.
5. Normal baseline spirometry for FVC and FEV1/FVC within 7 days prior to the first dosing 
based on the following normal FVC and FEV1/FVC range:
c) 18 – 39 years of age: ≥80%
d) 40 – 55 years of age: ≥75%
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 43 of 85
Protocol Final
16 April 2019
6. For a female of nonchildbearing potential, must have undergone one of the following 
sterilization procedures at least 6 months prior to the first dosing:

hysteroscopic sterilization;

bilateral tubal ligation or bilateral salpingectomy;

hysterectomy;

bilateral oophorectomy;
or be postmenopausal with amenorrhea for at least 1 year prior to the first dosing and FSH 
serum levels consistent with postmenopausal status. 
7. Part 1 only: Female subjects of childbearing potential will be advised to remain sexually 
inactive or to keep the same birth control method for at least 60 days following the last 
TAK-788 dosing as indicated in Appendix D.
8. Part 2 only: Female subjects of childbearing potential will be advised to remain sexually 
inactive or to keep the same birth control method for at least 30 days following the last 
TAK-788 dosing as indicated in Appendix D.
9. Part 1 only: Males subjects who are sexually active with a female partner of childbearing 
potential must use barrier contraception as indicated in Appendix D or abstain from sexual 
intercourse during the study until 94 days after the last TAK-788 dosing. Total abstinence (no 
sexual intercourse) may be considered an acceptable method of birth control if it agrees with 
his preferred and usual lifestyle.
10. Part 1 only: Male subjects must agree not to donate sperm from the first dosing until 94 days 
after the last TAK-788 dosing.
11. Part 2 only: Males subjects who are sexually active with a female partner of childbearing 
potential must use barrier contraception as indicated in Appendix D or abstain from sexual 
intercourse during the study until 30 days after the last TAK-788 dosing. Total abstinence (no 
sexual intercourse) may be considered an acceptable method of birth control if it agrees with 
his preferred and usual lifestyle.
12. Part 2 only: Male subjects must agree not to donate sperm from the first dosing until 30 days 
after the last TAK-788 dosing.
13. Understands the study procedures in the ICF and be willing and able to comply with the 
protocol.
9.1.2.2
Exclusion Criteria
The subject must be excluded from participating in the study if the subject: 
1. Is mentally or legally incapacitated or has significant emotional problems at the time of the 
screening visit or expected during the conduct of the study.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 44 of 85
Protocol Final
16 April 2019
2. History or presence of clinically significant medical or psychiatric condition or disease in the 
opinion of the Investigator or designee.
3. History of any illness that, in the opinion of the Investigator or designee, might confound the 
results of the study or poses an additional risk to the subject by their participation in the study.
4. History or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing.
5. History or presence of hypersensitivity or idiosyncratic reaction to the study drugs or related 
compounds.
6. History or presence of any previous chronic lung disease.
7. Presence of an acute lung infection, within 3 months of screening.
8. Part 1 only: History or presence of any of the following, deemed clinically significant by the 
Investigator or designee, and as confirmed by the Sponsor:

Ventricular dysfunction or risk factors for Torsades de Pointes (e.g., heart failure, 
cardiomyopathy, family history of Long QT Syndrome);

Uncorrected hypokalemia (potassium levels <3.7) and/or hypomagnesemia (magnesium 
levels <1.9);

Myasthenia gravis.
9. Female subjects with a positive pregnancy test or who are lactating.
10. Positive urine drug or alcohol results at screening or first check-in.
11. Positive results at screening for HIV, HBsAg, or HCV.
12. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening.
13. Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.
14. QTcF interval is >460 msec (males) or >470 msec (females) or ECG findings are deemed 
abnormal with clinical significance by the Investigator or designee at screening.
15. Estimated creatinine clearance <90 mL/min at screening.
16. Unable to refrain from or anticipates the use of:

Any drug, including prescription and non-prescription medications, herbal remedies, or 
vitamin supplements within 14 days prior to the first dosing and throughout the study. 
Medication listed as part of acceptable birth control methods will be allowed (refer to 
Appendix D). Thyroid hormone replacement medication may be permitted if the subject 
has been on the same stable dose for the immediate 3 months prior to the first dosing. 
Acetaminophen (up to 2 g per 24 hour period) may be permitted during the study, only 
after initial dosing.

Any drugs known to be inhibitors or inducers of CYP3A enzymes and/or P-gp, including 
St. John’s Wort, within 28 days prior to the first dosing and throughout the study. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 45 of 85
Protocol Final
16 April 2019
Appropriate sources (e.g., Flockhart Table™) will be consulted to confirm lack of 
PK/pharmacodynamics interaction with study drugs.
17. Has been on a diet incompatible with the on-study diet, in the opinion of the Investigator or 
designee, within the 30 days prior to the first dosing and throughout the study.
18. Donation of blood or significant blood loss within 56 days prior to the first dosing.
19. Plasma donation within 7 days prior to the first dosing.
20. Participation in another clinical study within 30 days prior to the first dosing. The 30-day 
window will be derived from the date of the last blood collection or dosing, whichever is later, 
in the previous study to Period 1 Day 1 of the current study.
9.1.3
Medical History/Demography
Medical history and demographic data, including name, sex, age, race, ethnicity, and history of 
tobacco use will be recorded.
9.1.4
Concomitant Medications
Concomitant medications will be prohibited as listed in Section 7.1 and 9.1.2.2. All medications 
taken by subjects during the course of the study will be recorded.
9.2
Clinical Procedures and Assessments
The Schedule of Study Procedures (Section 3.0) summarizes the clinical procedures to be 
performed at each visit. Individual clinical procedures are described in detail below. Additional 
evaluations/testing may be deemed necessary by the Investigator or designee and/or the Sponsor 
for reasons related to subject safety.
For this study, the collection of blood for TAK-788 PK is the critical parameter and needs to be 
collected as close to the exact time point as possible. All other procedures should be completed as 
close to the prescribed/scheduled time as possible, but can be performed prior to or after the 
prescribed/scheduled time (refer to Table 6.a and Table 6.b).
Any nonscheduled procedures required for urgent evaluation of safety concerns take precedence 
over all routine scheduled procedures.
9.2.1
Full Physical Exam
A full physical examination will be performed as outlined in the Schedule of Study Procedures 
(Section 3.0). Symptom-driven physical examinations may be performed at other times, if deemed 
necessary by the Investigator or designee.
9.2.2
Height and Weight
Body height (cm) and weight (kg) will be reported as outlined in the Schedule of Study Procedures 
(Section 3.0).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 46 of 85
Protocol Final
16 April 2019
9.2.3
BMI
BMI will be calculated based on the height and weight measured at screening.
9.2.4
Vital Signs
Single measurements of body temperature, respiratory rate, blood pressure, and heart rate, will be 
measured as outlined in the Schedule of Study Procedures (Section 3.0). Additional vital signs 
may be taken at any other times, if deemed necessary.
Blood pressure and heart rate measurements will be performed with subjects in a seated position, 
except when they are supine or semi-reclined because of study procedures and/or AEs 
(e.g., nausea, dizziness) or if deemed necessary by the investigator or designee.
Blood pressure and heart rate will be measured within 24 hours prior to Period 1 Day 1 dosing for 
the predose time point. At all other predose time points blood pressure and heart rate will be 
measured within 2 hours prior to dosing. When scheduled postdose, vital signs will be performed 
within approximately 15 minutes of the scheduled time point.
9.2.5
12-Lead ECG
Single 12-lead ECGs will be performed as outlined in the Schedule of Study Procedures 
(Section 3.0). Additional ECGs may be taken at any other times, if deemed necessary by the 
investigator or designee.
ECGs will be performed with subjects in a supine position. All ECG tracings will be reviewed by 
the investigator or designee.
ECGs will be measured within 24 hours prior to Day 1 dosing Period 1 for the predose time point. 
At all other predose time points ECG will be measured within 2 hours prior to dosing. When 
scheduled postdose, ECGs will be performed within approximately 20 minutes of the scheduled 
time point.
9.2.6
Pulmonary Function Test
9.2.6.1
Spirometry
Spirometry measures will be taken at screening (within 7 days prior to first dosing) using a 
standard calibrated spirometer to determine the parameters detailed below. Spirometry may be 
repeated during the study in response to pulmonary symptoms at the discretion of the Investigator 
or designee.

FEV1 (forced expiratory volume);

FVC (forced vital capacity);

FEV1/FVC.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 47 of 85
Protocol Final
16 April 2019
9.2.7
Study Drug Administration
TAK-788 oral capsules, itraconazole oral solution, and rifampin capsules will be provided as 
described in Section 8.0.
Subjects will be instructed not to crush, split, or chew the TAK-788 capsules or rifampin capsules.
Treatments A - F are described as: 
Part 1:
Treatment A
Cohort 1, Period 1:
20 mg TAK-788 (1 x 20 mg) administered at Hour 0 on Day 1 following an 
overnight fast.
Treatment B
Cohort 1, Period 2:
200 mg itraconazole oral solution administered every 24 hours for 
14 consecutive days (within ±1 hour of Day 1 dosing) with a single dose of 
20 mg TAK-788 administered at Hour 0 on Day 5 following an overnight 
fast.
Treatment A or E
Cohort 2, Period 1:
TBD TAK-788 administered at Hour 0 on Day 1 following an overnight fast.
Treatment B or F
Cohort 2, Period 2:
200 mg itraconazole oral solution administered every 24 hours for 
14 consecutive days (within ±1 hour of Day 1 dosing) with a single dose of 
TBD TAK-788 administered at Hour 0 on Day 5 following an overnight fast.
Part 2:
Treatment C
Period 1: 160 mg TAK-788 (4 x 40 mg) capsule administered at Hour 0 on 
Day 1 following an overnight fast.
Treatment D
Period 2: 600 mg rifampin (3 x 200 mg capsules) administered every 
24 hours for 13 consecutive days (within ±1 hour of Day 1 dosing) with a 
single dose of 160 mg TAK-788 (4 x 40 mg) capsule administered at Hour 0 
on Day 7 following an overnight fast.
TAK-788 will be administered following an overnight fast. When itraconazole is administered 
alone, it will be administered on an empty stomach with no food from at least 1 hour prior to 
dosing and for at least 2 hours after dosing. When rifampin is administered alone, it will be 
administered following an overnight fast.
All study drugs will be administered with approximately 240 mL of water or a total aqueous 
volume of approximately 240 mL for itraconazole oral solution plus water. The exact clock time of 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 48 of 85
Protocol Final
16 April 2019
oral dosing will be recorded. Itraconazole will be dosed with a container which will be rinsed twice 
with water ingested by subjects and the remaining dosing water will be ingested by subjects.
The pharmacy at the CRU will provide each dose of study drug(s) in individual unit dose 
containers and the oral solution dose in a glass bottle for each subject as appropriate.
9.2.8
AE Monitoring
Subjects will be monitored throughout the study for adverse reactions to the study drugs and/or 
procedures as described in Section 10.0.
9.2.9
Laboratory Procedures and Assessments
All tests listed below will be performed as outlined in the Schedule of Study Procedures 
(Section 3.0). In addition, laboratory safety tests may be performed at various unscheduled time 
points, if deemed necessary by the investigator or designee.
9.2.9.1
Clinical Laboratory Tests
Hematology
Hematology will consist of the following tests:
Hemoglobin
Red blood cell count
Hematocrit 
Platelet count
Total and differential leukocyte count
Chemistry 
Serum chemistry tests will be performed after at least an 8-hour fast; however, in case of dropouts 
or rechecks, subjects may not have fasted for 8 hours prior to when the serum chemistry sample is 
taken.
Chemistry evaluations will consist of the following standard chemistry panel:
Amylase
Albumin
Lipase
Sodium
Blood Urea Nitrogen
Potassium
Bilirubin (total and direct)
Chloride
Alkaline phosphatase
Glucose 
Aspartate aminotransferase
Creatinine *
Alanine aminotransferase (ALT)
Magnesium
* At screening, creatinine clearance will be calculated using the Cockcroft-Gault formula.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 49 of 85
Protocol Final
16 April 2019
Urinalysis
Urinalysis will consist of the following tests:
pH
Bilirubin
Specific gravity
Blood *
Protein *
Nitrite *
Glucose
Urobilinogen
Ketones
Leukocyte esterase *
* If urinalysis is positive for protein, blood, nitrite and/or leukocyte esterase, a microscopic examination (for red blood 
cells, white blood cells, bacteria, casts, and epithelial cells) will be performed.
Other 
HIV test
Urine drug screen
–
Opiates (includes morphine, heroin 
(diacetylmorphine), codeine, 6-acetylmorphine, 
dihydrocodeine, hydrocodone, thebaine, and, 
hydromorphone)
–
Amphetamines
–
Barbiturates
–
Benzodiazepines
–
Cocaine
–
Cannabinoids
HBsAg
HCV (if antibody positive, confirm RNA negative)
Urine alcohol screen
Serum pregnancy test (for females only)
FSH (for postmenopausal females only)
9.3
Pharmacokinetic Samples
Instructions for plasma samples processing and handling will be provided in a separate document. 
Primary specimen collection parameters are provided in Table 9.a.
Table 9.a
Primary Specimen Collections
Specimen Name
Primary 
Specimen
Description of Intended Use
Sample 
Collection
Plasma sample for TAK-788 and 
metabolites PK
Plasma
Plasma sample for TAK-788 and 
metabolites PK analysis
Mandatory
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 50 of 85
Protocol Final
16 April 2019
9.3.1
PK Measurements 
9.3.1.1
Plasma PK Measurements
PK parameters for plasma TAK-788 and metabolites AP32960 and AP32914 concentrations will 
be calculated as follows, as appropriate, following oral administration:
AUClast:
The area under the concentration versus time curve, from time 0 to the last 
observed non-zero concentration, as calculated by the linear trapezoidal 
method.
AUCt
Area under the concentration-time curve from time 0 to time t
AUC:
The area under the concentration versus time curve, from time 0 
extrapolated to infinity. AUCis calculated as AUCt or AUClast plus the ratio 
of the last measurable blood concentration to the elimination rate constant.
AUC%extrap:
Percent of AUCextrapolated, represented as (1 - AUCt or 
AUClast/AUC)*100.
CL/F
Apparent total plasma clearance after oral (extravascular) administration, 
calculated as Dose/AUC(TAK-788 only).
Cmax:
Maximum observed concentration.
tmax:
Time to reach Cmax. If the maximum value occurs at more than one time 
point, tmax is defined as the first time point with this value.
t½:
Apparent first-order terminal elimination half-life will be calculated as 
0.693/λz.
Where λz is the apparent first order terminal elimination rate constant 
calculated from a semilog plot of the plasma concentration versus time 
curve. The parameter will be calculated by linear least-squares- regression 
analysis using the maximum number of points in the terminal log-linear 
phase (e.g., three or more non-zero plasma concentrations).
Vz/F
Apparent volume of distribution during the terminal elimination phase after 
oral (extravascular) administration, calculated as Dose/(AUCx λz) 
(TAK-788 only).
No value for λz, AUC, AUC%extrap, CL/F, Vz/F, or t½ will be reported for cases that do not exhibit 
a terminal log-linear phase in the concentration versus time profile. 
No PK parameters will be calculated for subjects with detectable concentrations at 2 or fewer 
consecutive time points. 
Individual and mean plasma concentration-curves (both linear and log-linear) will be included in 
the final report.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 51 of 85
Protocol Final
16 April 2019
9.3.2
Biomarker Measurements 
Not applicable
9.3.3
PGx Measurements 
Not applicable 
9.3.4
Confinement
Part 1:
In Period 1, subjects will be housed on Day -1, at the time indicated by the CRU, until the morning 
of Day 4 after the 72-hour PK sample is collected.
In Period 2, subjects will be housed on Day 4, in the morning, at the time indicated by the CRU, 
until the morning of Day 8 after the 72-hour PK sample is collected.
Part 2:
In Period 1, subjects will be housed on Day -1, at the time indicated by the CRU, until the morning 
of Day 4 after the 72-hour PK sample is collected.
In Period 2, subjects will be housed on Day 6 Period 2, in the morning, at the time indicated by the 
CRU, until the morning of Day 10 after the 72-hour PK sample is collected.
Part 1 and 2:
Subjects will return for dosing and/or study procedures as indicated in the Section 3.0. At all times, 
a subject may be required to remain at the CRU for longer at the discretion of the Investigator or 
designee.
The CRU will contact all subjects (including subjects who terminate the study early) 30 ± 2 days 
after the last TAK-788 administration to determine if any adverse events have occurred since the 
last study visit.
As per site preference and in agreement of Sponsor, subjects may be confined throughout the 
washout period and/or for the whole study. If the CRU decides to confine the subjects throughout 
the study, the site will still perform safety events scheduled at check-in.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 52 of 85
Protocol Final
16 April 2019
10.0
ADVERSE EVENTS
10.1
Definitions and Elements of AEs
An AE is defined as any untoward medical occurrence in a clinical investigation subject who has 
signed informed consent to participate in a study; it does not necessarily have to have a causal 
relationship with the treatment.
An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or 
not it is considered related to the drug.
An untoward finding generally may:

Indicate a new diagnosis or unexpected worsening of a preexisting condition. (Intermittent 
events for pre-existing conditions or underlying disease should not be considered AEs.)

Necessitate therapeutic intervention.

Require an invasive diagnostic procedure.

Require discontinuation or a change in dose of study medication or a concomitant medication.

Be considered unfavorable by the Investigator for any reason.
Diagnoses versus signs and symptoms:

Each event should be recorded to represent a single diagnosis. Accompanying signs (including 
abnormal laboratory values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If a diagnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately as an AE(s).
Laboratory values and ECG findings:

Changes in laboratory values or ECG parameters maybe considered AEs if they are judged to 
be clinically significant (ie, if some action or intervention is required or if the Investigator 
judges the change to be beyond the range of normal physiologic fluctuation). A laboratory 
re-test and/or continued monitoring of an abnormal value are not considered an intervention. In 
addition, repeated or additional noninvasive testing for verification, evaluation or monitoring 
of an abnormality is not considered an intervention.

If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creatinine in renal failure), the diagnosis only should be 
reported appropriately as an AE.
Pre-existing conditions:

A pre-existing condition (present at the time of signing of informed consent) is considered a 
concurrent medical history condition and should NOT be recorded as an AE. A baseline 
evaluation (eg, laboratory test, ECG, X-ray, etc) should NOT be recorded as an AE unless 
related to a study procedure. However, if the subject experiences a worsening or complication 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 53 of 85
Protocol Final
16 April 2019
of such a concurrent medical history condition, the worsening or complication should be 
recorded appropriately as an AE (worsening or complication occurs after informed consent is 
signed). Investigators should ensure that the event term recorded captures the change in the 
condition (eg, “worsening of…”).

If a subject has a pre-existing episodic condition (eg, asthma, epilepsy), any occurrence of an 
episode should only be captured as an AE if the episodes become more frequent, serious, or 
severe in nature, that is, Investigators should ensure that the AE term recorded captures the 
change from Baseline in the condition (eg “worsening of…”).

If a subject has a degenerative concurrent condition (eg, cataracts, rheumatoid arthritis), 
worsening of the condition should only be captured as an AE if occurring to a greater extent to 
that which would be expected. Again, Investigators should ensure that the AE term recorded 
captures the change in the condition (eg, “worsening of…”).
Worsening of AEs:

If the subject experiences a worsening or complication of an AE after the first administration of 
study medication or after any change in study medication, the worsening or complication 
should be recorded as a new AE. Investigators should ensure that the AE term recorded 
captures the change in the condition (eg, “worsening of…”).
Changes in severity of AEs:

If the subject experiences a change in the severity of an AE that is not associated with a change 
in study medication, the event should be captured once with the maximum severity recorded.
Preplanned surgeries or procedures:

Preplanned procedures (surgeries or therapies) that were scheduled prior to signing of 
informed consent are not considered AEs. However, if a preplanned procedure is performed 
early (eg, as an emergency) due to a worsening of the pre-existing condition, the worsening of 
the condition should be captured appropriately as an AE. Complications resulting from any 
planned surgery should be reported as AEs.
Elective surgeries or procedures:

Elective procedures performed where there is no change in the subject’s medical condition 
should not be recorded as AEs but should be documented in the subject’s source documents. 
Complications resulting from an elective surgery should be reported as AEs.
Overdose:

An overdose is defined as a known deliberate or accidental administration of investigational 
drug, to or by a study subject, at a dose above that which is assigned to that individual subject 
according to the study protocol. It is up to the Investigator or the reporting physician to decide 
whether a dose is to be considered an overdose, in consultation with the Sponsor.

All cases of overdose (with or without associated AEs) will be documented on an Overdose 
page of the CRF, in order to capture this important safety information consistently in the 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 54 of 85
Protocol Final
16 April 2019
database. AEs associated with an overdose will be documented on AE CRF(s) according to 
Section 10.0.

Serious adverse events (SAEs) of overdose should be reported according to the procedure 
outlined in Section 10.2.7.

In the event of drug overdose, the subject should be treated symptomatically.
10.1.1
SAEs
An SAE is defined as any untoward medical occurrence that at any dose:
1. Results in DEATH.
2. Is LIFE THREATENING.

The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were more severe.
3. Requires inpatient HOSPITALIZATION or prolongation of existing hospitalization.
4. Results in persistent or significant DISABILITY/INCAPACITY.
5. Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6. Is an IMPORTANT MEDICAL EVENT that satisfies any of the following:

May require intervention to prevent items 1 through 5 above.

May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalization.
AEs that fulfill 1 or more of the serious criteria above are to be considered SAEs and should be 
reported and followed up in the same manner (see Sections 10.1.1 and 10.2.7.3).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 55 of 85
Protocol Final
16 April 2019
Table 10.a
Takeda Medically Significant AE List 
Term
Acute respiratory failure/acute respiratory 
distress syndrome
Hepatic necrosis
Acute liver failure
Torsade de pointes / ventricular fibrillation / 
ventricular tachycardia
Anaphylactic shock
Acute renal failure
Malignant hypertension
Pulmonary hypertension
Convulsive seizures
Pulmonary fibrosis
Agranulocytosis
Confirmed or suspected endotoxin shock
Aplastic anemia
Confirmed or suspected transmission of infectious agent by 
a medicinal product
Toxic epidermal necrolysis/
Stevens-Johnson syndrome
Neuroleptic malignant syndrome / malignant hyperthermia
Spontaneous abortion / stillbirth and fetal death
AEs that fulfill 1 or more of the serious criteria above are to be considered SAEs and should be 
reported and followed up in the same manner (see Sections 10.1 and 10.1.1).
10.1.2
Special Interest AEs
There are no AEs of Special Interest for this study.
10.2
AE Procedures
10.2.1
Assigning Severity/Intensity of AEs
In this study, intensity for each AE, including any laboratory abnormality, will be determined 
using the National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI 
CTCAE), version 5.0, dated 27 November 2017 [CTCAE 2017]. Clarification should be made 
between an SAE and an AE that is considered severe in intensity (Grade 3 or 4) because the terms 
serious and severe are NOT synonymous. The general term severe is often used to describe the 
intensity (severity) of a specific event; the event itself, however, may be of relatively minor 
medical significance (such as a Grade 3 headache). This is NOT the same as serious, which is 
based on subject/event outcome or action criteria described above and is usually associated with 
events that pose a threat to a subject’s life or ability to function. A severe AE (Grade 3 or 4) does 
not necessarily need to be considered serious. For example, a white blood cell count of 1000/mm3
to <2000/mm3 is considered Grade 3 (severe) but may not be considered serious. Seriousness (not 
intensity) serves as a guide for defining regulatory reporting obligations.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 56 of 85
Protocol Final
16 April 2019
10.2.2
Assigning Causality of AEs
The relationship of each AE to study medication(s) will be assessed using the following 
categories:
Related:
An AE that follows a reasonable temporal sequence from administration of a 
drug (including the course after withdrawal of the drug), or for which a causal 
relationship is at least a reasonable possibility, i.e., the relationship cannot be 
ruled out, although factors other than the drug, such as underlying diseases, 
complications, concomitant drugs and concurrent treatments, may also be 
responsible.
Not Related:
An AE that does not follow a reasonable temporal sequence from administration 
of a drug and/or that can reasonably be explained by other factors, such as 
underlying diseases, complications, concomitant medications and concurrent 
treatments.
10.2.3
Start Date 
The start date of the AE is the date that the first signs/symptoms were noted by the subject and/or 
Investigator.
10.2.4
End Date 
The end date of the AE is the date at which the subject recovered, the event resolved but with 
sequelae or the subject died.
10.2.5
Action Taken With Study Treatment

Drug withdrawn – a study medication is stopped due to the particular AE.

Dose not changed – the particular AE did not require stopping a study medication.

Unknown – only to be used if it has not been possible to determine what action has been taken.

Not applicable – a study medication was stopped for a reason other than the particular AE 
eg, the study has been terminated, the subject died, dosing with study medication had not yet 
started or dosing with study medication was already stopped before the onset of the AE.

Dose reduced – the dose was reduced due to the particular AE.

Dose increased – the dose was increased due to the particular AE.

Drug interrupted – the dose was interrupted due to the particular AE.
10.2.6
Outcome 

Recovered/resolved – subject returned to first assessment status with respect to the AE.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 57 of 85
Protocol Final
16 April 2019

Recovering/resolving – the intensity is lowered by one or more stages: the diagnosis has or 
signs/symptoms have almost disappeared; the abnormal laboratory value improved, but has 
not returned to the normal range or to the baseline value; the subject died from a cause other 
than the particular AE with the condition remaining “recovering/resolving.”

Not recovered/not resolved – there is no change in the diagnosis, signs or symptoms; the 
intensity of the diagnosis, signs/symptoms or laboratory value on the last day of the observed 
study period has become worse than when it started; is an irreversible congenital anomaly; the 
subject died from another cause with the particular AE state remaining “Not recovered/not 
resolved.”

Recovered/Resolved with sequelae – the subject recovered from an acute AE but was left with 
permanent/significant impairment (eg, recovered from a cardiovascular accident but with 
some persisting paresis).

Fatal – an AE that is considered as the cause of death.

Unknown – the course of the AE cannot be followed up due to hospital change or residence 
change at the end of the subject’s participation in the study.
10.2.7
Collection and Reporting of AEs, SAEs, Special Interest AEs, and Abnormal LFTs
10.2.7.1 Collection Period
Collection of AEs (ie, AEs, SAEs, Special Interest AEs, and Abnormal LFTs) will commence at 
the time the subject signs the informed consent. Routine collection of AEs will continue until the 
follow-up phone call 30 days ± 2 days after the last dose of TAK-788. For subjects who 
discontinue prior to the administration of TAK-788, AEs will be followed until the subject 
discontinues study participation. 
10.2.7.2 Reporting AEs
At each study visit, the Investigator will assess whether any subjective AEs have occurred. A 
neutral question, such as “How have you been feeling since your last visit?” may be asked. 
Subjects may report AEs occurring at any other time during the study. Subjects experiencing an 
SAE prior to the first exposure to investigational product must be monitored until the symptoms 
subside and any clinically relevant changes in laboratory values have returned to Baseline or there 
is a satisfactory explanation for the change. Non-serious AEs that begin prior to the first exposure 
to investigational product, related or unrelated to the study procedure, need not be followed-up for 
the purposes of the protocol.
All subjects experiencing AEs, whether considered associated with the use of the study medication 
or not, must be monitored until the symptoms subside and any clinically relevant changes in 
laboratory values have returned to Baseline or until there is a satisfactory explanation for the 
changes observed. All AEs will be documented in the AE page of the CRF, whether or not the 
Investigator concludes that the event is related to the drug treatment. The following information 
will be documented for each event:
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 58 of 85
Protocol Final
16 April 2019

Event term.

Start and end date and time.

Pattern of AE (frequency).

Severity/Intensity.

Causality (Investigator’s opinion of the causal relationship between the event and 
administration of study drug[s]).

Action taken with Study drug.

Outcome of event.

Seriousness.
10.2.7.3 Reporting SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
procedure outlined below:
A Takeda SAE form must be completed, in English and signed by the Investigator immediately or 
within 24 hours of first onset or notification of the event. The information should be completed as 
fully as possible but contain, at a minimum:

A short description of the event and the reason why the event is categorized as serious.

Subject identification number.

Investigator’s name.

Name of the study medication(s).

Causality assessment.
The SAE form should be transmitted within 24 hours to the attention of the contact listed in 
Section 14.1.1.
Any SAE spontaneously reported to the Investigator following the AE collection period should be 
reported to the Sponsor if considered related to study participation.
Reporting of SAEs that begin before first administration of investigational product will follow the 
same procedure for SAEs occurring on treatment.
SAE Follow-Up
If information is not available at the time of the first report becomes available at a later date, the 
Investigator should complete a follow-up SAE form or provide other written documentation and 
fax it immediately within 24 hours of receipt. Copies of any relevant data from the hospital notes 
(eg, ECGs, laboratory tests, discharge summary, postmortem results) should be sent to the 
addressee, if requested.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 59 of 85
Protocol Final
16 April 2019
All SAEs should be followed up until resolution or permanent outcome of the event. The timelines 
and procedure for follow-up reports are the same as those for the initial report.
10.2.7.4 Reporting Special Interest AEs 
Not applicable
10.2.7.5 Reporting of Abnormal LFTs
If a subject has elevated ALT ≥3x upper limit of normal (ULN) with concurrent elevated total 
bilirubin >2× ULN or elevated international normalized ratio (INR) >1.5, contact the sponsor’s 
medical monitor within 24 hours. 
For any subject with ALT ≥3x ULN and total bilirubin >2x ULN or INR >1.5x ULN for which an 
alternative etiology has not been found, report the event as an SAE (Section 10.2.7.3) and contact 
the sponsor immediately.
10.2.8
Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities 
The Sponsor will be responsible for reporting all suspected unexpected serious adverse reactions 
(SUSARs) and any other applicable SAEs to regulatory authorities, Investigators and IRBs or 
IECs, as applicable, in accordance with national regulations in the countries where the study is 
conducted. Relative to the first awareness of the event by/or further provision to the Sponsor or 
Sponsor’s designee, SUSARs will be submitted within 7 days for fatal and life-threatening events 
and 15 days for other serious events, unless otherwise required by national regulations. The 
Sponsor will also prepare an expedited report for other safety issues where these might materially 
alter the current benefit-risk assessment of an investigational medicinal product or that would be 
sufficient to consider changes in the investigational medicinal products administration or in the 
overall conduct of the Study. The investigational site also will forward a copy of all expedited 
reports to his or her IRB or IEC in accordance with national regulations.
10.2.9
Procedures for Reporting Product Complaints or Medication Errors (Including 
Overdose)
A product complaint is a verbal, written, or electronic expression that implies dissatisfaction 
regarding the identity, strength, purity, quality, or stability of a drug product. Individuals who 
identify a potential product complaint situation should immediately report this via the phone 
numbers or email addresses provided below.
A medication error is a preventable event that involves an identifiable patient and leads to 
inappropriate medication use, which may result in patient harm. Whereas overdoses and 
underdoses constitute medication errors, doses missed inadvertently by a patient do not. 
Individuals who identify a potential medication error (including overdose) situation should 
immediately report this via the phone numbers or email addresses provided below.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 60 of 85
Protocol Final
16 April 2019
Product
Call Center
Phone Number
Email
Fax
TAK-788
 
 
 
 
 
 
Product complaints and medication errors in and of themselves are not AEs. If a product complaint
or a medication error results in an SAE, the SAE should be reported.
PPD
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
le
duct com
duct com


TAK-788
Study ID TAK-788-1006
Page 61 of 85
Protocol Final
16 April 2019
11.0
STATISTICAL METHODS
11.1
Statistical and Analytical Plans
Detailed methodology for summary and statistical analyses of the data collected in this study will 
be documented in a statistical analysis plan (SAP). The SAP will be prepared by Celerion and 
agreed upon with the Sponsor. This document may modify the plans outlined in the protocol; 
however, any major modifications of the primary endpoints definition and/or its analysis will also 
be reflected in a protocol amendment. Additional statistical analyses other than those described in 
this section may be performed if deemed appropriate.
11.1.1
Analysis Sets
11.1.1.1 PK Set
Samples from all subjects will be assayed even if the subjects do not complete the study. All 
subjects who comply sufficiently with the protocol and display an evaluable PK profile (e.g., 
exposure to treatment, availability of measurements and absence of major protocol violations) will 
be included in the statistical analyses. Any subject who experiences emesis within 8 hours post 
dosing with TAK-788 will be excluded in the final data analysis.
11.1.1.2 Safety Set
All subjects who received at least one dose of a study drug will be included in the safety 
evaluations.
11.1.1.3 Pharmacodynamic Set 
Not applicable.
11.1.2
Analysis of Demography and Other Baseline Characteristics
Continuous demographic data (i.e., age, weight, height, and BMI) will be listed and summarized 
using appropriate summary statistics. Categorical demographic data (i.e., gender, race, and 
ethnicity) will also be listed and tabulated.
11.1.3
PK Analysis
Values will be calculated for the plasma TAK-788 and metabolites concentrations. PK parameters 
for plasma concentrations of TAK-788 and metabolites (AP32960 and AP32914) will be 
calculated as described in Section 9.3.1.1, and outlined in the SAP.
11.1.3.1 Analysis of Variance
A linear mixed-effects model will be used for the analysis on the ln transformed Cmax and AUC
(AUClast or AUCt if AUCis not available) for TAK-788 and ln transformed combined molar Cmax
and AUC∞ for TAK-788, AP32960, and AP32914. The model will include treatment as a 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 62 of 85
Protocol Final
16 April 2019
fixed-effect and subject as a random-effect. Each model will include calculation of LSMs as well 
as the difference between treatment LSMs.
11.1.3.2 Ratios and Confidence Intervals
Geometric mean ratios (GMR) and 90% confidence intervals, consistent with the two one sided 
test [Schuirmann 1987], will be calculated using the exponentiation of the difference between 
treatment LSMs from the analyses on the ln -transformed Cmax and AUC(AUClast or AUCt if 
AUCis not available) for TAK-788 and ln transformed combined molar Cmax and AUC∞for 
TAK-788, AP32960, and AP32914. These ratios will be expressed as a percentage of the 
following comparisons:
Treatment B (itraconazole+20 mg TAK-788) relative to Treatment A (20 mg TAK-788)
Treatment D (rifampin+160 mg TAK-788) relative to Treatment C (160 mg TAK-788)
And if applicable Treatment F (itraconazole+TBD TAK-788) relative to Treatment E 
(TBD TAK-788)
11.1.4
Pharmacodynamic Analysis 
Not applicable.
11.1.5
Safety Analysis
All safety data will be populated in the individual CRFs. 
Dosing dates and times will be listed by subject.
Quantitative safety data as well as the difference to baseline, when appropriate, will be 
summarized using the appropriate descriptive statistics.
11.1.5.1 AEs
AEs will be coded using the most current version of Medical Dictionary for Regulatory Activities 
(MedDRA®) available at Celerion and summarized by treatment for the number of subjects 
reporting the TEAE and the number of TEAEs reported. A by-subject AE data listing including 
verbatim term, coded term, treatment, severity, and relationship to treatment will be provided.
11.1.5.2 Clinical Laboratory Evaluation
Clinical laboratory results will be summarized by treatment and point of time of collection and a 
shift table describing out of normal range shifts will be provided.
11.1.5.3 Vital Signs
Vital signs assessments will be summarized by treatment and point of time of collection.
11.1.5.4 Other Safety Parameters
Physical examination findings will be presented in the data listings.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 63 of 85
Protocol Final
16 April 2019
ECGs will be summarized by treatment and point of time of collection.
Medical history, and concurrent conditions will be coded using the MedDRA® and concomitant 
medications will be coded using the World Health Organization drug and will be listed by subject.
11.2
Interim Analysis and Criteria for Early Termination
Interim PK will be provided after completion of Part 1 Cohort 1 to confirm the dose to be used for 
Part 1 Cohort 2.
11.3
Determination of Sample Size
The sample size calculation was based on the expected 2-sided 90% CI for the difference in the 
paired, log-transformed AUCmeans of TAK-788 in the absence and presence of itraconazole or 
rifampin. The within-patient coefficient of variation for TAK-788 AUCwas estimated to be 
17.2% on the basis of data from a clinical study conducted in healthy subjects (TAK-788-1001). If 
the AUCratio for TAK-788 in the presence versus absence of itraconazole or rifampin is X (an 
AUCGMR to be determined in this study), with a sample size of 10, the 90% CI for the AUC
ratio is expected to be 0.868X to 1.15X on the basis of the variance assumptions.
Up to 28 healthy adult subjects will be enrolled into 2 Parts (up to 16 in Part 1, and 12 in Part 2) to 
get 10 PK-evaluable subjects for estimation of DDI magnitude in each part of study.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 64 of 85
Protocol Final
16 April 2019
12.0
QUALITY CONTROL AND QUALITY ASSURANCE
12.1
Study-Site Monitoring Visits
Monitoring visits to the study site will be made periodically during the study to ensure that all 
aspects of the protocol are followed. Source documents will be reviewed for verification of data 
recorded on the CRFs. Source documents are defined as original documents, data, and records. 
The Investigator and study site guarantee access to source documents by the Sponsor or its 
designee (Clinical Research Organization) and by the IRB or IEC.
All aspects of the study and its documentation will be subject to review by the Sponsor or the 
Sponsor’s designee (as long as blinding is not jeopardized), including but not limited to the 
Investigator’s Binder, Study drug, subject medical records, informed consent documentation, and 
review of CRFs and associated source documents. It is important that the Investigator and other 
study personnel are available during the monitoring visits and that sufficient time is devoted to the 
process.
12.2
Protocol Deviations
The Investigator should not deviate from the protocol, except where necessary to eliminate an 
immediate hazard to Study subjects. Should other unexpected circumstances arise that will require 
deviation from protocol-specified procedures, the Investigator should consult with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exemptions (a prospectively approved deviation) from the inclusion or exclusion criteria.
Significant deviations include, but are not limited to, those that involve fraud or misconduct, 
increase the health risk to the subject, or confound interpretation of primary study assessment. 
12.3
Quality Assurance Audits and Regulatory Agency Inspections
The study site also may be subject to quality assurance audits by the Sponsor or designees. In this 
circumstance, the Sponsor-designated auditor will contact the site in advance to arrange an 
auditing visit. The auditor may ask to visit the facilities where laboratory samples are collected, 
where the medication is stored and prepared, and any other facility used during the study. In 
addition, there is the possibility that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg, the FDA, the United Kingdom Medicines and Healthcare 
products Regulatory Agency, the Pharmaceuticals and Medical Devices Agency of Japan). If the 
study site is contacted for an inspection by a regulatory body, the Sponsor should be notified 
immediately. The Investigator guarantees access for quality assurance auditors to all study 
documents as described in Section 12.1.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 65 of 85
Protocol Final
16 April 2019
13.0
ETHICAL ASPECTS OF THE STUDY
This study will be conducted with the highest respect for the individual subjects (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration of 
Helsinki, and the International Council on Harmonisation (ICH) Harmonised Tripartite Guideline 
for GCP. Each Investigator will conduct the study according to applicable local or regional 
regulatory requirements and align his or her conduct in accordance with the “Responsibilities of 
the Investigator” that are listed in Appendix A. The principles of Helsinki are addressed through 
the protocol and through appendices containing requirements for informed consent and 
Investigator responsibilities.
13.1
IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local requirements 
of each participating region. The Sponsor or designee will require documentation noting all names 
and titles of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has direct participation in this study, written notification regarding his or her abstinence from 
voting must also be obtained. Those Americas sites unwilling to provide names and titles of all 
members due to privacy and conflict of interest concerns should instead provide a Federal Wide 
Assurance Number or comparable number assigned by the Department of Health and Human 
Services.
The Sponsor or designee will supply relevant documents for submission to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the Investigator’s Brochure, a copy of 
the informed consent form, and, if applicable, subject recruitment materials and/or advertisements 
and other documents required by all applicable laws and regulations, must be submitted to a 
central or local IRB or IEC for approval. The IRB’s or IEC’s written approval of the protocol and 
subject informed consent must be obtained and submitted to the Sponsor or designee before 
commencement of the study (ie, before shipment of the Sponsor-supplied drug or study specific 
screening activity). The IRB or IEC approval must refer to the study by exact protocol title, 
number, and version date; identify versions of other documents (eg, informed consent form) 
reviewed; and state the approval date. The Sponsor will ship drug/notify site once the Sponsor has 
confirmed the adequacy of site regulatory documentation and, when applicable, the Sponsor has 
received permission from competent authority to begin the Study. Until the site receives 
drug/notification no protocol activities, including screening, may occur.
Sites must adhere to all requirements stipulated by their respective IRB or IEC. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the informed consent 
form, recruitment materials intended for viewing by subjects, local safety reporting requirements, 
reports and updates regarding the ongoing review of the study at intervals specified by the 
respective IRB or IEC, and submission of the Investigator’s final status report to IRB or IEC. All 
IRB and IEC approvals and relevant documentation for these items must be provided to the 
Sponsor or its designee.
Subject incentives should not exert undue influence for participation. Payments to subjects must 
be approved by the IRB or IEC and Sponsor.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 66 of 85
Protocol Final
16 April 2019
13.2
Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The informed consent form, subject authorization form (if 
applicable), and subject information sheet (if applicable) describe the planned and permitted uses, 
transfers, and disclosures of the subject’s personal and personal health information for purposes of 
conducting the study. The informed consent form and the subject information sheet (if applicable) 
further explain the nature of the study, its objectives, and potential risks and benefits, as well as the 
date informed consent is given. The informed consent form will detail the requirements of the 
participant and the fact that he or she is free to withdraw at any time without giving a reason and 
without prejudice to his or her further medical care.
The Investigator is responsible for the preparation, content, and IRB or IEC approval of the 
informed consent form and, if applicable, the subject authorization form. The informed consent 
form, subject authorization form (if applicable), and subject information sheet (if applicable) must 
be approved by both the IRB or IEC and the Sponsor prior to use.
The informed consent form, subject authorization form (if applicable), and subject information 
sheet (if applicable) must be written in a language fully comprehensible to the prospective subject. 
It is the responsibility of the Investigator to explain the detailed elements of the informed consent 
form, subject authorization form (if applicable), and subject information sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appropriate by the IRB or IEC. In the event the subject is not capable of rendering 
adequate written informed consent, then the subject’s legally acceptable representative may 
provide such consent for the subject in accordance with applicable laws and regulations.
The subject, or the subject’s legally acceptable representative, must be given ample opportunity to: 
(1) inquire about details of the study, and (2) decide whether or not to participate in the study. If the 
subject, or the subject’s legally acceptable representative, determines he or she will participate in 
the study, then the informed consent form and subject authorization form (if applicable) must be 
signed and dated by the subject, or the subject’s legally acceptable representative, at the time of 
consent and prior to the subject entering into the study. The subject or the subject’s legally 
acceptable representative should be instructed to sign using their legal names, not nicknames, 
using blue or black ballpoint ink. The Investigator must also sign and date the informed consent 
form and subject authorization (if applicable) at the time of consent and prior to subject entering 
into the study; however, the Sponsor may allow a designee of the Investigator to sign to the extent 
permitted by applicable law.
Once signed, the original informed consent form, subject authorization form (if applicable), and 
subject information sheet (if applicable) will be stored in the Investigator’s site file. The 
Investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copies of the signed informed consent form, the signed subject authorization form 
(if applicable), and subject information sheet (if applicable) shall be given to the subject.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 67 of 85
Protocol Final
16 April 2019
All revised informed consent forms must be reviewed and signed by relevant subjects or the 
relevant subject’s legally acceptable representative in the same manner as the original informed 
consent. The date the revised consent was obtained should be recorded in the subject’s medical 
record, and the subject should receive a copy of the revised informed consent form.
13.3
Subject Confidentiality
The Sponsor and designees affirm and uphold the principle of the subject’s right to protection 
against invasion of privacy. Throughout this study, a subject’s source data will only be linked to 
the Sponsor’s clinical study database or documentation via a unique identification number. As 
permitted by all applicable laws and regulations, limited subject attributes, such as sex, age, or date 
of birth, and subject initials may be used to verify the subject and accuracy of the subject’s unique 
identification number.
To comply with ICH Guidelines for GCP and to verify compliance with this protocol, the Sponsor 
requires the Investigator to permit its monitor or designee’s monitor, representatives from any 
regulatory authority (eg, FDA, Medicines and Healthcare products Regulatory Agency, 
Pharmaceuticals and Medical Devices Agency), the Sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
documents), including, but not limited to, laboratory test result reports, ECG reports, admission 
and discharge summaries for hospital admissions occurring during a subject’s study participation, 
and autopsy reports. Access to a subject’s original medical records requires the specific 
authorization of the subject as part of the informed consent process (see Section 13.2).
Copies of any subject source documents that are provided to the Sponsor must have certain 
personally identifiable information removed (eg, subject name, address, and other identifier fields 
not collected on the subject’s CRF).
13.4
Publication, Disclosure, and Clinical Study Registration Policy
13.4.1 Publication and Disclosure
The Investigator is obliged to provide the Sponsor with complete test results and all data derived 
by the Investigator from the study. During and after the study, only the Sponsor may make study 
information available to other study Investigators or to regulatory agencies, except as required by 
law or regulation. Except as otherwise allowable in the clinical study site agreement, any public 
disclosure (including publicly accessible websites) related to the protocol or study results, other 
than study recruitment materials and/or advertisements, is the sole responsibility of the Sponsor.
The Sponsor may publish any data and information from the study (including data and information 
generated by the Investigator) without the consent of the Investigator. Manuscript authorship for 
any peer-reviewed publication will appropriately reflect contributions to the production and 
review of the document. All publications and presentations must be prepared in accordance with 
this section and the Clinical Study Site Agreement. In the event of any discrepancy between the 
protocol and the Clinical Study Site Agreement, the Clinical Study Site Agreement will prevail.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 68 of 85
Protocol Final
16 April 2019
13.4.2 Clinical Study Registration 
In order to ensure that information on clinical Studys reaches the public in a timely manner and to 
comply with applicable laws, regulations and guidance, Takeda will, at a minimum register all 
interventional clinical Studys it Sponsors anywhere in the world on ClinicalStudys.gov and/or 
other publicly accessible websites before start of study, as defined in Takeda Policy/Standard. 
Takeda contact information, along with Investigator’s city, state (for Americas investigators), 
country, and recruiting status will be registered and available for public viewing. 
For some registries, Takeda will assist callers in locating study sites closest to their homes by 
providing the Investigator name, address, and phone number to the callers requesting Study 
information. Once subjects receive Investigator contact information, they may call the site 
requesting enrollment into the Study. The investigative sites are encouraged to handle the Study 
inquiries according to their established subject screening process. If the caller asks additional 
questions beyond the topic of Study enrollment, they should be referred to the Sponsor.
Any Investigator who objects to the Sponsor providing this information to callers must provide the 
Sponsor with a written notice requesting that their information not be listed on the registry site.
13.4.3 Clinical Study Results Disclosure 
Takeda will post the results of clinical Studys on ClinicalStudys.gov or other publicly accessible 
websites, as required by Takeda Policy/Standard, applicable laws and/or regulations.
13.5
Insurance and Compensation for Injury
Each subject in the study must be insured in accordance with the regulations applicable to the site 
where the subject is participating. If a local underwriter is required, then the Sponsor or Sponsor’s 
designee will obtain clinical study insurance against the risk of injury to study subjects. Refer to 
the study site agreement regarding the Sponsor’s policy on subject compensation and treatment for 
injury. If the Investigator has questions regarding this policy, he or she should contact the Sponsor 
or Sponsor’s designee.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 69 of 85
Protocol Final
16 April 2019
14.0
ADMINISTRATIVE AND REFERENCE INFORMATION
14.1
Administrative Information
14.1.1 Study Contact Information 
Contact Type/Role
Contact
Serious adverse event and pregnancy reporting
Please refer to Safety Management Plan.
PPD
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
ble
ab
the
the a


TAK-788
Study ID TAK-788-1006
Page 70 of 85
Protocol Final
16 April 2019
14.1.2 INVESTIGATOR AGREEMENT 
I confirm that I have read and that I understand this protocol, the Investigator’s Brochure, package 
insert and any other product information provided by the Sponsor. I agree to conduct this study in 
accordance with the requirements of this protocol and also to protect the rights, safety, privacy, 
and well-being of study subjects in accordance with the following:

The ethical principles that have their origin in the Declaration of Helsinki.

International Council on Harmonisation, E6 [R2] Good Clinical Practice: Consolidated 
Guideline.

All applicable laws and regulations, including, without limitation, data privacy laws and 
regulations.

Regulatory requirements for reporting serious adverse events defined in Section 10.2.8 of this 
protocol.

Terms outlined in the study site agreement.

Responsibilities of the Investigator (Appendix B).
I further authorize that my personal information may be processed and transferred in accordance 
with the uses contemplated in Appendix D of this protocol.
Signature of Investigator
Date
Investigator Name (print or type)
Investigator’s Title
Location of Facility (City, State/Provence)
Location of Facility (Country)
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 71 of 85
Protocol Final
16 April 2019
14.1.3 Study-Related Responsibilities 
The Sponsor will perform all study-related activities with the exception of those identified in the 
Study-Related Responsibilities template. The vendors identified for specific study-related 
activities will perform these activities in full or in partnership with the Sponsor.
14.1.4 List of Abbreviations
AE
Adverse event
ALP
Alkaline phosphatase
ALT
Alanine aminotransferase
AST
Aspartate aminotransferase
AUC
Area under the concentration-time curve
AUCt
Area under the concentration-time curve from time 0 to time t
AUClast
Area under the concentration-time curve, from time 0 to the last observed non-zero 
concentration
AUC
Area under the concentration-time curve, from time 0 extrapolated to infinity
BMI
Body mass index
bpm
Beats per minute
Cav
Average concentration 
CFR
Code of Federal Regulations
CI
Confidence interval
CL/F
Apparent clearance after extravascular administration
cm
Centimeter
Cmax
Maximum observed concentration 
CRA
Clinical Research Associate
CRF
Case report form
CRU
Clinical Research Unit
CYP
Cytochrome P450
DDI
Drug-drug interaction 
DNA
Deoxyribonucleic acid 
ECG
Electrocardiogram
EGFR
Epidermal growth factor receptor 
FEV1
Forced expiratory volume
FSH
Follicle stimulating hormone
FVC
Forced vital capacity
g
Gram
GCP
Good Clinical Practice
HBsAg
Hepatitis B surface antigen
HCV
Hepatitis C virus 
HER2
Human epidermal growth factor 2
HIV
Human immunodeficiency virus
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 72 of 85
Protocol Final
16 April 2019
IB
Investigator’s Brochure
ICF
Informed Consent Form
ICH
International Council for Harmonisation
IEC
Independent Ethics Committee
IRB
Institutional Review Board
kg
Kilogram
LFT
Liver function test
m2
Meters squared
MedDRA®
Medical Dictionary for Regulatory Activities®
mg
Milligram
min
Minute
mL
Milliliter
mmHg
Millimeter of mercury
msec
Millisecond
NSCLC
Non–small cell lung cancer
P-gp
P-glycoprotein
PK
Pharmacokinetic(s)
PFT
Pulmonary function test
QD
Once daily
QTcF
QT interval corrected for heart rate using Fridericia’s formula
RNA
Ribonucleic acid
SAE
Serious adverse event
SAP
Statistical analysis plan
SUSAR
Suspected unexpected serious adverse reaction
t½
Apparent first-order terminal elimination half-life
TBD
To be determined
TEAE
Treatment-emergent adverse event
TKI
Tyrosine kinase inhibitor
ULN
Upper limit of normal
US
United States
USA
United States of America
Vz/F
Apparent volume of distribution after extravascular administration
WHO
World Health Organization
WT
Wild-type
λz
Apparent first order terminal elimination rate constant
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 73 of 85
Protocol Final
16 April 2019
15.0
DATA HANDLING AND RECORDKEEPING
The full details of procedures for data handling will be documented in the Data Management Plan.
15.1
CRFs
The Sponsor or its designee will supply investigative sites with access to CRFs. The Sponsor or its 
designee will train appropriate site staff in the use of the CRF. These forms are used to transmit the 
information collected in the performance of this study to the Sponsor and regulatory authorities. 
CRFs must be completed in English.
After completion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site. 
Corrections are recorded in an audit trail that captures the old information, the new information, 
identification of the person making the correction, the date the correction was made, and the reason 
for change. Reasons for significant corrections should additionally be included. 
The principal Investigator must review the CRFs for completeness and accuracy and must sign and 
date the appropriate CRFs as indicated. Furthermore, the Investigator must retain full 
responsibility for the accuracy and authenticity of all data entered on the CRFs.
After the lock of the clinical study database, any change of, modification of, or addition to the data 
on the CRFs should be made by the Investigator/designee with use of change and modification 
records of the CRFs. The Principal Investigator must review the data change for completeness and 
accuracy, and must sign and date. 
CRFs will be reviewed for completeness and acceptability at the study site during periodic visits 
by study monitors. The Sponsor or its designee will be permitted to review the subject’s medical 
and hospital records pertinent to the study to ensure accuracy of the CRFs. The completed CRFs 
are the sole property of the Sponsor and should not be made available in any form to third parties, 
except for authorized representatives of appropriate governmental health or regulatory authorities, 
without written permission of the Sponsor.
15.2
Record Retention
The Investigator agrees to keep the records stipulated in Section 15.1 and those documents that 
include (but are not limited to) the study-specific documents, the identification log of all 
participating subjects, medical records, temporary media such as thermal sensitive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorization forms 
regarding the use of personal health information (if separate from the informed consent forms), 
electronic copy of CRFs, including the audit trail, and detailed records of drug disposition to 
enable evaluations or audits from regulatory authorities, the Sponsor or its designees. Any source 
documentation printed on degradable thermal sensitive paper should be photocopied by the site 
and filed with the original in the subject’s chart to ensure long-term legibility. Furthermore, ICH 
E6 [R2] Section 4.9.5 requires the Investigator to retain essential documents specified in ICH E6 
[R2] (Section 8) until at least 2 years after the last approval of a marketing application for a 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 74 of 85
Protocol Final
16 April 2019
specified drug indication being investigated or, if an application is not approved, until at least 
2 years after the investigation is discontinued and regulatory authorities are notified. In addition, 
ICH E6 [R2] Section 4.9.5 states that the study records should be retained until an amount of time 
specified by applicable regulatory requirements or for a time specified in the Clinical Study Site 
Agreement between the Investigator and Sponsor.
Refer to the Clinical Study Site Agreement for the Sponsor’s requirements on record retention. 
The Investigator and the head of the institution should contact and receive written approval from 
the Sponsor before disposing of any such documents.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 75 of 85
Protocol Final
16 April 2019
16.0
REFERENCES
Brüggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic 
interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 
2009;15;48:1441-1458.
Duus E, Matson MA, and Bernareggi A. Effects of strong cytochrome P450 (CYP)3A4 
inducers/inhibitors on the pharmacokinetic (PK) profile of anamorelin in healthy volunteers. 
Journal of Clinical Oncology 2018 36:15_suppl, e22180-e22180
Liu L, Bello A, Dresser MJ, Heald D, Komjathy SF, O'Mara E, Rogge M, Stoch SA, Robertson 
SM. Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug 
interaction studies. J Clin Pharmacol. 2016 Feb;56(2):143-51. doi: 10.1002/jcph.562.
National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE), Revised: 
Nov-2017 (v5.0). Available at: 
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_R
eference_8.5x11.pdf.
Peng CC, Templeton I, Thummel KE, Davis C, Kunze KL, and Isoherranen N. Evaluation of 
6β-hydroxycortisol, 6β-hydroxycortisone and their combination as endogenous probes for 
inhibition of CYP3A4 in vivo. Clin Pharmacol Ther. 2011 Jun; 89(6): 888–895. 
Rifadin® (Rifampin capsules or for injection), monograph by Sanofi-Aventis U.S. LLC, full 
prescribing information (electronic monograph/revised Febuary 2013) published on the FDA 
website at http://www.accessdata.fda.gov/scripts/cder/drugsatfda
Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for 
assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15: 
657-680.
Sporanox® (itraconazole oral solution) product monograph from Ortho-McNeil-Janssen 
Pharmaceuticals, Inc., (revised November 2011). Available at:
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
Srinivas RN, Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer 
Drugs: Challengers, Dilemmas and Paradoxical Effects Due to Multiple Mechanisms. Drug R D 
(2016) 16:141-148. 
TAK-788. Millennium Pharmaceuticals, Inc. Global Investigator Brochure. Edition 3.0, January 
2019.
Teo YL, Han Kiat Ho, and Alexandre Chan. Metabolism-related pharmacokinetic drug−drug 
interactions with tyrosine kinase inhibitors: current understanding, challenges and 
recommendations. Br J Clin Pharmacol. 2014 Feb; 79(2): 241–253.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 76 of 85
Protocol Final
16 April 2019
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug 
Evaluation and Research (CDER) Draft Guidance Clinical Drug Interaction Studies — Study 
Design, Data Analysis, and Clinical Implications Guidance for Industry October 2017 
https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf (accessed on 26 March 2019).
Upreti VV, Boulton DW, Li L, Ching A, Su H, LaCreta FP, and Patel CG. Effect of rifampicin on 
the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in 
healthy subjects. Br J Clin Pharmacol. 2011 Jul; 72(1): 92–102.
Varis T, Kivistö KT, Backman JT, and Neuvonen PJ. The cytochrome P450 3A4 inhibitor 
itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its 
adrenal-suppressant effect. Clin Pharmacol Ther. 2000 Nov;68(5):487-94.
Willems L, van der Geest R, de Beule K. Itraconazole oral solution and intravenous formulations: 
a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther. 2001 Jun;26(3):159-69. 
Review.
Yoshizato T, Kotegawa T, Imai H, Tsutsumi K, Imanaga J, Ohyama T, Ohashi K. Itraconazole and 
domperidone: a placebo-controlled drug interaction study. Eur J Clin Pharmacol. 2012 
Sep;68(9):1287-94.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 77 of 85
Protocol Final
16 April 2019
17.0
APPENDICES
Appendix A
Responsibilities of the Investigator
Clinical research studies sponsored by the Sponsor are subject to ICH GCP and all the applicable 
local laws and regulations. The responsibilities imposed on Investigators by the FDA are 
summarized in the “Statement of Investigator” (Form FDA 1572), which must be completed and 
signed before the Investigator may participate in this study.
The Investigator agrees to assume the following responsibilities by signing a Form FDA 1572:
1. Conduct the study in accordance with the protocol.
2. Personally conduct or supervise the staff that will assist in the protocol.
3. If the Investigator/institution retains the services of any individual or party to perform 
Study-related duties and functions, the Investigator/institution should ensure that this 
individual or party is qualified to perform those Study-related duties and functions and should 
implement procedures to ensure the integrity of the Study-related duties and functions 
performed and any data generated.
4. Ensure that study related procedures, including study specific (nonroutine/nonstandard panel) 
screening assessments are NOT performed on potential subjects, prior to the receipt of written 
approval from relevant governing bodies/authorities.
5. Ensure that all colleagues and employees assisting in the conduct of the study are informed of 
these obligations.
6. Secure prior approval of the study and any changes by an appropriate IRB/IEC that conform to 
21 CFR Part 56, ICH, and local regulatory requirements.
7. Ensure that the IRB/IEC will be responsible for initial review, continuing review, and approval 
of the protocol. Promptly report to the IRB/IEC all changes in research activity and all 
anticipated risks to subjects. Make at least yearly reports on the progress of the study to the 
IRB/IEC, and issue a final report within 3 months of study completion.
8. Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH and local 
regulations, are met.
9. Obtain valid informed consent from each subject who participates in the study, and document 
the date of consent in the subject’s medical chart. Valid informed consent is the most current 
version approved by the IRB/IEC. Each informed consent form should contain a subject 
authorization section that describes the uses and disclosures of a subject’s personal 
information (including personal health information) that will take place in connection with the 
study. If an informed consent form does not include such a subject authorization, then the 
Investigator must obtain a separate subject authorization form from each subject or the 
subject’s legally acceptable representative.
10. Prepare and maintain adequate case histories of all persons entered into the study, including 
CRFs, hospital records, laboratory results, etc, and maintain these data for a minimum of 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 78 of 85
Protocol Final
16 April 2019
2 years following notification by the Sponsor that all investigations have been discontinued or 
that the regulatory authority has approved the marketing application. The Investigator should 
contact and receive written approval from the Sponsor before disposing of any such 
documents.
11. Allow possible inspection and copying by the regulatory authority of GCP-specified essential 
documents.
12. Maintain current records of the receipt, administration, and disposition of Sponsor-supplied 
drugs, and return all unused Sponsor-supplied drugs to the Sponsor. 
13. Report adverse reactions to the Sponsor promptly. In the event of an SAE, notify the Sponsor 
within 24 hours.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 79 of 85
Protocol Final
16 April 2019
Appendix B
Elements of the Subject Informed Consent
In seeking informed consent, the following information shall be provided to each subject:
1. A statement that the study involves research.
2. An explanation of the purposes of the research.
3. The expected duration of the subject’s participation.
4. A description of the procedures to be followed, including invasive procedures.
5. The identification of any procedures that are experimental.
6. The estimated number of subjects involved in the study.
7. A description of the subject’s responsibilities.
8. A description of the conduct of the study.
9. A statement describing the treatment(s).
10. A description of the possible side effects of the treatment that the subject may receive.
11. A description of any reasonably foreseeable risks or discomforts to the subject and, when 
applicable, to an embryo, fetus, or nursing infant.
12. A description of any benefits to the subject or to others that reasonably may be expected from 
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13. Disclosures of appropriate alternative procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potential risks and benefits.
14. A statement describing the extent to which confidentiality of records identifying the subject 
will be maintained, and a note of the possibility that regulatory agencies, auditor(s), IRB/IEC, 
and the monitor may inspect the records. By signing a written informed consent form, the 
subject or the subject’s legally acceptable representative is authorizing such access.
15. For research involving more than minimal risk, an explanation as to whether any compensation 
and an explanation as to whether any medical treatments are available if injury occurs and, if 
so, what they consist of or where further information may be obtained.
16. The anticipated prorated payment(s), if any, to the subject for participating in the study.
17. The anticipated expenses, if any, to the subject for participating in the study.
18. An explanation of whom to contact for answers to pertinent questions about the research 
(Investigator), subject’s rights, and IRB/IEC and whom to contact in the event of a 
research-related injury to the subject.
19. A statement that participation is voluntary, that refusal to participate will involve no penalty or 
loss of benefits to which the subject otherwise is entitled, and that the subject or the subject’s 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 80 of 85
Protocol Final
16 April 2019
legally acceptable representative may discontinue participation at any time without penalty or 
loss of benefits to which the subject is otherwise entitled.
20. The consequences of a subject’s decision to withdraw from the research and procedures for 
orderly termination of participation by the subject.
21. A statement that the subject or the subject’s legally acceptable representative will be informed 
in a timely manner if information becomes available that may be relevant to the subject’s 
willingness to continue participation in the study.
22. A statement that results of PGx analysis will not be disclosed to an individual, unless 
prevailing laws require the Sponsor to do so.
23. The foreseeable circumstances or reasons under which the subject’s participation in the study 
may be terminated.
24. A written subject authorization (either contained within the informed consent form or provided 
as a separate document) describing to the subject the contemplated and permissible uses and 
disclosures of the subject’s personal information (including personal health information) for 
purposes of conducting the study. The subject authorization must contain the following 
statements regarding the uses and disclosures of the subject’s personal information:
a) that personal information (including personal health information) may be processed by or 
transferred to other parties in other countries for clinical research and safety reporting 
purposes, including, without limitation, to the following: (1) Takeda, its affiliates, and 
licensing partners; (2) business partners assisting Takeda, its affiliates, and licensing 
partners; (3) regulatory agencies and other health authorities; and (4) IRBs/IECs;
b) it is possible that personal information (including personal health information) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level of protection as the data protection laws within this country; 
however, Takeda will make every effort to keep your personal information confidential, 
and your name will not be disclosed outside the clinic unless required by law;
c) that personal information (including personal health information) may be added to 
Takeda’s research databases for purposes of developing a better understanding of the 
safety and effectiveness of the study medication(s), studying other therapies for patients, 
developing a better understanding of disease, and improving the efficiency of future 
clinical studies;
d) that subjects agree not to restrict the use and disclosure of their personal information 
(including personal health information) upon withdrawal from the study to the extent that 
the restricted use or disclosure of such information may impact the scientific integrity of 
the research; and
e) that the subject’s identity will remain confidential in the event that study results are 
published.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 81 of 85
Protocol Final
16 April 2019
25. Female subjects of childbearing potential (eg, nonsterilized, premenopausal female subjects) 
who are sexually active must use highly effective contraception (as defined in the informed 
consent) from signing the informed consent and throughout the duration of the study, and for 
28 days after the last dose of study drug. Regular pregnancy tests will be performed throughout 
the study for all female subjects of childbearing potential. If a subject is found to be pregnant 
during study, study drug will be discontinued and the Investigator will offer the subject the 
choice to receive unblinded treatment information. 
26. Male subjects must use highly effective contraception (as defined in the informed consent) 
from signing the informed consent throughout the duration of the study and for 94 days after 
the last dose of study drug. If the partner or wife of the subject is found to be pregnant during 
the study, the Investigator will offer the subject the choice to receive unblinded treatment 
information. 
27. A statement that clinical Study information from this Study will be publicly disclosed in a 
publicly accessible website, such as ClinicalStudys.gov.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 82 of 85
Protocol Final
16 April 2019
Appendix C
Investigator Consent to the Use of Personal Information 
Takeda will collect and retain personal information of Investigator, including his or her name, 
address, and other personally identifiable information. In addition, Investigator’s personal 
information may be transferred to other parties located in countries throughout the world (eg, the 
United Kingdom, United States, and Japan), including the following:

Takeda, its affiliates, and licensing partners.

Business partners assisting Takeda, its affiliates, and licensing partners.

Regulatory agencies and other health authorities.

IRBs and IECs.
Investigator’s personal information may be retained, processed, and transferred by Takeda and 
these other parties for research purposes including the following:

Assessment of the suitability of Investigator for the study and/or other clinical studies.

Management, monitoring, inspection, and audit of the study.

Analysis, review, and verification of the study results.

Safety reporting and pharmacovigilance relating to the study.

Preparation and submission of regulatory filings, correspondence, and communications to 
regulatory agencies relating to the study.

Preparation and submission of regulatory filings, correspondence, and communications to 
regulatory agencies relating to other medications used in other clinical studies that may contain 
the same chemical compound present in the study medication.

Inspections and investigations by regulatory authorities relating to the study.

Self-inspection and internal audit within Takeda, its affiliates, and licensing partners.

Archiving and audit of study records.

Posting Investigator site contact information, study details and results on publicly accessible 
clinical Study registries, databases, and websites.
Investigator’s personal information may be transferred to other countries that do not have data 
protection laws that offer the same level of protection as data protection laws in Investigator’s own 
country.
Investigator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the purposes described above.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 83 of 85
Protocol Final
16 April 2019
Appendix D
Pregnancy and Contraception 
Contraception and Pregnancy Avoidance Procedure
TAK-788 may pose a risk to developing fetuses or to babies who are being breastfed. Because 
TAK-788 may affect an unborn baby, female participants should not become pregnant while in 
this study, and male participants should not conceive with their female partner(s) while in this 
study. Women who are pregnant or breastfeeding will not be allowed to take part in this study.
Women of childbearing potential and male patients must use medically acceptable birth control. 
Avoiding sexual activity is the only certain way to prevent pregnancy. 
Males Subjects and Their Female Partners:
Part 1:
It is not known whether the study medication will affect sperm or an unborn baby. Based on animal 
studies, taking TAK-788 may lead to testicular changes that could impact reproduction. For this 
reason, to be in the study males must agree not to father a child or donate sperm during the study 
and for 94 days after the last dose of TAK-788. 
If a male has not had a vasectomy and are sexually active with any person who is pregnant, or 
could get pregnant, he must use a condom with spermicidal cream or jelly each time he has sex 
during the study and for 94 days after last dose of TAK-788. If a male is surgically sterilized (i.e., 
have had a vasectomy) he must agree to use an appropriate method of barrier contraception (latex 
condom with a spermicidal agent) during the entire study, and for 94 days after his last dose of 
TAK-788. Or, he should completely avoid having heterosexual intercourse.
Part 2:
It is not known whether the study medication will affect sperm or an unborn baby. Based on animal 
studies, taking TAK-788 may lead to testicular changes that could impact reproduction. For this 
reason, to be in the study males must agree not to father a child or donate sperm during the study 
and for 30 days after the last dose of TAK-788. 
If a male has not had a vasectomy and are sexually active with any person who is pregnant, or 
could get pregnant, he must use a condom with spermicidal cream or jelly each time he has sex 
during the study and for 30 days after last dose of TAK-788. If a male is surgically sterilized (i.e., 
have had a vasectomy) he must agree to use an appropriate method of barrier contraception (latex 
condom with a spermicidal agent) during the entire study, and for 30 days after his last dose of 
TAK-788. Or, he should completely avoid having heterosexual intercourse.
Part 1 and 2:
If a female partner does become pregnant while a male subject is taking part in the study, the 
subject must tell the study doctor immediately.
In this situation, the female partner should be under medical supervision during her pregnancy, and 
the baby should be under supervision after it is born. The female partner may be asked to give her 
consent to the collection of information related to both herself as well as the baby.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 84 of 85
Protocol Final
16 April 2019
Acceptable birth control for males with female partners includes any of the following:

total abstinence (no sexual intercourse) if it agrees with his preferred and usual lifestyle.

a barrier method (latex condom with a spermicidal agent).
Males must use acceptable birth control during the study treatment period and for at least 94 days 
(Part 1) or for at least 30 days (Part 2) after their last dose of TAK-788 and should tell their female 
partner(s) that they are in research study.
Females:
Part 1
Females must agree not to become pregnant, breastfeed a baby or donate an egg or eggs (ova) 
during the study and for 60 days after the last dose of TAK-788. Women of childbearing potential 
must use acceptable birth control from the time of signing the informed consent form until at least 
60 days after their last dose of TAK-788.
If a female has been surgically sterilized or is postmenopausal, she does not need to meet any 
contraception requirements to take part in this study. If a female is of childbearing potential and is 
sexually active with a male partner, she must be willing to use an acceptable method of 
contraception during the study and for 60 days after the last dose of TAK-788.
Part 2:
Females must agree not to become pregnant, breastfeed a baby or donate an egg or eggs (ova) 
during the study and for 30 days after the last dose of TAK-788. Women of childbearing potential 
must use acceptable birth control from the time of signing the informed consent form until at least 
30 days after their last dose of TAK-788.
If a female has been surgically sterilized or is postmenopausal, she does not need to meet any 
contraception requirements to take part in this study. If a female is of childbearing potential and is 
sexually active with a male partner, she must be willing to use an acceptable method of 
contraception during the study and for 30 days after the last dose of TAK-788.
Part 1 and 2:
TAK-788 may decrease effectiveness of hormonal contraceptives, therefore, women must use an 
effective non-hormonal methods of contraception. Acceptable birth control for women of 
childbearing potential with male partners must include one form of highly effective non-hormonal 
contraception and one additional effective (barrier) method, as described below:
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788
Study ID TAK-788-1006
Page 85 of 85
Protocol Final
16 April 2019
Highly effective non-hormonal methods
Additional effective (barrier) methods 
Nonhormonal intrauterine device 
Male or female condom with or without spermicide 
(female and male condoms should not be used together)
Bilateral tubal occlusion (a surgical procedure that blocks 
the fallopian tubes to prevent the ovum (egg) from being 
fertilized) or bilateral salpingectomy
Hysteroscopic sterilization
Hysterectomy
Bilateral oophorectomy
Vasectomised sole sexual partner (removal of the tube 
that carries sperm from the testicle to the penis)
Sexual abstinence (no sexual intercourse)
Cap, diaphragm or sponge with spermicide
Total abstinence (no sexual intercourse) may be considered an acceptable method of birth control 
if it agrees with her preferred and usual lifestyle. 
In order to enter the study, all females must have a pregnancy test to confirm that she is not 
pregnant. This test will be repeated just before she starts taking the first study medication and then 
regularly throughout the study, at each check-in. If a pregnancy test during the study shows that 
she may be pregnant, she will be withdrawn from the study and the treatment will end. She will be 
asked for the results of any tests and procedures carried out during pregnancy and up to the birth. 
She may also be asked for the results from any evaluation of the baby after the birth.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use



䢢
䢢
䢢
䢢
䢢
䢢
䢢
䢢
(/(&7521,&6,*1$785(6
Signed by 
Meaning of Signature 
Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




GDHDG
䣃䢢䣒䣪䣣䣵䣧䢢䢳䢢䣕䣶䣷䣦䣻䢢䣱䣨䢢䣑䣴䣣䣮䢢䣖䣃䣍䢯䢹䢺䢺䢢䣶䣱䢢䣇䣸䣣䣮䣷䣣䣶䣧䢢䣶䣪䣧䢢䣆䣴䣷䣩䢯䣆䣴䣷䣩䢢䣋䣰䣶䣧䣴䣣䣥䣶䣫䣱䣰䢢䣹䣫䣶䣪䢢䣋䣶䣴䣣䣥䣱䣰䣣䣼䣱䣮䣧䢢䣣䣰䣦䢢䣔䣫䣨䣣䣯䣲䣫䣰䢢䣫䣰
䣊䣧䣣䣮䣶䣪䣻䢢䣃䣦䣷䣮䣶䢢䣕䣷䣤䣬䣧䣥䣶䣵
&OLQLFDO3KDUPDFRORJ\$SSURYDO
$SU87&
&OLQLFDO$SSURYDO
$SU87&
%LRVWDWLVWLFV$SSURYDO
$SU87&
PPD
PPD
PPD
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
ble T
ate 
ate 
abl
HH:mm ‘U
H:mm 
e T
ab
87&
87&


$SU
$SU

SAP_001.pdf: 


Other information as needed to protect confidentiality of Takeda or partners, personal
information, or to otherwise protect the integrity of the clinical study.
Title: A Phase 1 Study of Oral TAK-788 to Evaluate the Drug-Drug Interaction with 
Itraconazole and Rifampin in Healthy Adult Subjects
NCT Number: NCT03928327
SAP Approve Date: 06 June 2019
Certain information within this Statistical Analysis Plan has been redacted (ie, specific content is masked 
irreversibly from view with a black/blue bar) to protect either personally identifiable (PPD) information 
or company confidential information (CCI). 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential 
information under prior agreements with license holder.



	

			



	

 
!"#$%&'()*+",%)
-",&"%$%!$+&.+&./%$+"0%1)/21%!
%+"0)/"3),$ "/'1*"451/1/6$",%!('&,%&78$0%#
6

	


  
 
+$5"+$'7(
 #	

			# & 
PPD
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
. +
+&.
&.
'&,%&
'&,%




 


 
#	

#	

			
		
da: For non-commercial 
y 



$,$+1)/%&'(&47$+ 
".$ )*:
%"%1#%10",/",(#1#,"/91/",
;&/$ 

55+)-",1./"%&+$#
%&'(1%,$
&#%	+0*&12344	562(
	

.(	
/	
#7+"

8%&#-9

PPD
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


p


TAK-788-1006
Celerion Study Number CA24219
Page 3 of 25
Statistical Analysis Plan Final
06 June 2019
2.0
TABLE OF CONTENTS
1.0
TITLE PAGE ..................................................................................................................1
1.1
Approval Signatures ..................................................................................................2
2.0
TABLE OF CONTENTS.................................................................................................3
3.0
LIST OF ABBREVIATIONS..........................................................................................5
4.0
OBJECTIVES .................................................................................................................7
4.1
Primary Objectives ....................................................................................................7
4.2
Exploratory Objective................................................................................................7
4.3
Study Design .............................................................................................................7
5.0
ANALYSIS ENDPOINTS.............................................................................................11
5.1
Primary Endpoints ...................................................................................................11
5.2
Exploratory Endpoints .............................................................................................11
5.3
Additional Endpoints ...............................................................................................11
6.0
DETERMINATION OF SAMPLE SIZE.......................................................................12
7.0
METHODS OF ANALYSIS AND PRESENTATION...................................................13
7.1
General Principles....................................................................................................13
7.1.1
Study Definitions ...............................................................................................14
7.1.2
Definition of Study Days....................................................................................14
7.2
Analysis Sets ...........................................................................................................15
7.3
Study Information....................................................................................................15
7.4
Disposition of Subjects ............................................................................................15
7.5
Demographic and Other Baseline Characteristics.....................................................16
7.6
Medical History and Concurrent Medical Conditions...............................................16
7.7
Medication History and Concomitant Medications...................................................16
7.8
Study Drug Exposure and Compliance.....................................................................16
7.9
Efficacy Analysis.....................................................................................................17
7.10
Pharmacokinetic/Pharmacodynamic Analysis ..........................................................17
7.10.1 Pharmacokinetic Analysis ..................................................................................17
7.10.2 Pharmacodynamic Analysis ...............................................................................20
7.11
Other Outcomes.......................................................................................................20
7.12
Safety Analysis........................................................................................................20
7.12.1 Adverse Events ..................................................................................................21
7.12.2 Clinical Laboratory Evaluations .........................................................................22
7.12.3 Vital Signs .........................................................................................................22
7.12.4 12-Lead ECGs ...................................................................................................23
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 4 of 25
Statistical Analysis Plan Final
06 June 2019
7.12.5 Pulmonary Function Test (PFT).........................................................................23
7.12.6 Physical Exams..................................................................................................23
7.12.7 Overdose............................................................................................................23
7.13
Interim Analysis ......................................................................................................24
7.14
Preliminary Analysis................................................................................................24
7.15
Changes in the Statistical Analysis Plan...................................................................24
8.0
REFERENCES..............................................................................................................25
LIST OF IN-TEXT TABLES
Table 4.a
Part 1 TAK-788 Assessment with Itraconazole.....................................................8
Table 4.b
Part 2 TAK-788 Assessment with Rifampin.........................................................9
Table 4.c
Treatment Descriptions and Planned Dose Levels of TAK-788, Itraconazole 
(Part 1), and Rifampin (Part 2)...........................................................................10
Table 7.a
Collection of Blood Samples for Pharmacokinetic Analysis for Part 1................17
Table 7.b
Collection of Blood Samples for Pharmacokinetic Analysis for Part 2................18
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 5 of 25
Statistical Analysis Plan Final
06 June 2019
3.0
LIST OF ABBREVIATIONS
AE
adverse event
ANOVA
analysis of variance 
AUC
AUC∞
area under the curve
area under the plasma concentration-time curve from time 0 to infinity
AUClast
area under the plasma concentration-time curve from time 0 to time of the 
last quantifiable concentration
AUCt
area under the plasma concentration-time curve from time 0 to a specific 
time point across all subjects in the same study part
BLQ
BMI
below the limit of quantitation
body mass index
CI
CL/F
Cmax
confidence interval
apparent clearance after extravascular administration 
maximum observed plasma concentration
CPAP
CRF
Clinical Pharmacology Analysis Plan
case report form
CRU
clinical research unit
CS
CV
CYP
DDI
ECG
clinically significant
coefficient of variation
cytochrome P450
drug-drug interaction 
electrocardiogram
GMR
geometric mean ratio
ICF
ICH
informed consent form
International Conference on Harmonization
Lambda_z
ln
LSM
terminal disposition phase rate constant 
natural log
least-squares means
MedDRA
Medical Dictionary for Regulatory Activities
PFT
pulmonary function test
PI
PK
Principal Investigator
pharmacokinetics
PO
orally administered 
QD
once daily
SAE
serious adverse event
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 6 of 25
Statistical Analysis Plan Final
06 June 2019
SD
SOC
t½
standard deviation
system organ class
terminal disposition phase half-life
TBD
to be determined 
TEAE
treatment-emergent adverse event
TFL
tmax
tables, figures, and listings
time to first occurrence of Cmax
Vz/F
apparent volume of distribution during the terminal disposition phase after 
extravascular administration 
WHO
World Health Organization
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 7 of 25
Statistical Analysis Plan Final
06 June 2019
4.0
OBJECTIVES
4.1
Primary Objectives
Part 1
To characterize the effect of itraconazole, a strong cytochrome P450 (CYP) 3A inhibitor, on the 
single-dose pharmacokinetics (PK) of TAK-788 and its active metabolites (AP32960 and 
AP32914) in healthy adult subjects.
Part 2
To characterize the effect of rifampin, a strong CYP3A inducer, on the single-dose PK of
TAK-788 and its active metabolites (AP32960 and AP32914) in healthy adult subjects.
4.2
Exploratory Objective
Parts 1 and 2 
To assess the safety data of TAK-788 following single oral dose with/without strong CYP3A 
inhibitor or inducer in healthy adult subjects.
4.3
Study Design
This is a 2-part study. Each part will be conducted as an open-label, 2-period, fixed sequence 
study with TAK-788 designed to characterize TAK-788 drug-drug interaction (DDI) with either 
a strong CYP3A inhibitor, itraconazole (Part 1) or with a strong CYP3A inducer, rifampin (Part 
2) in healthy adult subjects. Subjects participating in Part 1 will be different from those 
participating in Part 2. Additionally, Part 1 will be a sequential study design; Part 1 Cohort 2 will 
not start until PK data from Part 1 Cohort 1 (up to Period 2 Day 15) has been evaluated. The 
study parts may be conducted concurrently.
Part 1: TAK-788 assessment with itraconazole
Part 1 will be conducted in 2 cohorts: Cohort 1 will enroll 4 subjects and will assess whether the 
20 mg dose of TAK-788 is an appropriate dose for the TAK-788/itraconazole DDI study; 
depending on the PK results, Cohort 2 will either continue to enroll 8 more subjects at this same 
dose level or enroll 12 more subjects at a revised TAK-788 dose level. Other than the dose of 
TAK-788, the study design will be exactly the same for each cohort.
This study part will comprise of a screening period, 2 treatment periods and a follow-up phone 
call in up to 16 healthy subjects. Dose administration and PK collection scheme for the treatment 
period is outlined in the table below.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 8 of 25
Statistical Analysis Plan Final
06 June 2019
Table 4.a
Part 1 TAK-788 Assessment with Itraconazole
Treatment Period 1
Treatment Period 2
Study Day
-1
1
2
3
4
5
6
8*
1*
2
3
4
5
6
7
8
9
10
11
12
13
14
15
TAK-788 PO 
X
X
Itraconazole 
200 mg QD PO
X
X
X
X
X
X
X
X
X
X
X
X
X
X
PK Blood 
Samples 
X
X
X
X
X
X
X*
X*
X
X
X
X
X
X
X
X
X
Overnight in 
Clinics
X
X
X
X
X
X
X
X
* Since the washout period is 7 days the timing of the last PK blood draw of Period 1 will occur within 60 minutes 
prior to the first dose of itraconazole on Period 2 Day 1; only one PK sample will be taken.
Abbreviation: PK=Pharmacokinetics; PO=per oral; QD=once daily
On Period 1 Day 1, subjects will receive a single 20 mg oral dose of TAK-788 or a TAK-788 
oral dose to be determined (TBD) (Cohort 2) as capsules (fasting). A standardized meal will be 
provided at least 4 hours postdose. Subjects will remain in the CRU until the morning of Day 4 
after the 72-hour PK sample is collected. Additional PK samples will be taken as an outpatient 
up to 168 hours postdose (Period 1 Day 8, which is the same as Period 2 Day 1). 
In Period 2, subjects will receive 200 mg itraconazole QD alone as an oral solution on an empty 
stomach (no food from at least 1 hour prior until at least 2 hours after dosing). Subjects will be 
admitted to the clinical research unit (CRU) on Period 2 Day 4. In the morning of Period 2 Day 
5, subjects will receive 200 mg itraconazole together with 20 mg oral TAK-788 or a TBD oral 
dose of TAK-788 (fasting). A standardized meal will be provided at least 4 hours postdose.
Subjects will be furloughed from the CRU after the 72-hour PK sample is collected in the 
morning of Period 2 Day 8. There will be outpatient visits to the CRU for dosing itraconazole 
and/or PK sampling from Day 1 to Day 3 and Day 9 to Day 14. A final post-treatment follow-up 
and last PK sampling will occur at 240 hours post-Day 5 TAK-788 dose (Period 2 Day 15).
All PK data (TAK-788 and its 2 active metabolites, AP32960 and AP32914) collected in Cohort 
1 (up to Day 15) will be evaluated to determine the dose of TAK-788 administered to subjects in 
Cohort 2 of the study. The TAK-788 dose in Cohort 2 may remain at 20 mg or may be modified 
to an appropriate level to approximate a similar exposure compared to the geometric mean of 
single-dose exposure previously observed at 160 mg single dose TAK-788 alone in healthy 
subjects.
Part 2: TAK-788 assessment with rifampin
Part 2 will comprise of a screening period, 2 treatment periods, and a follow-up phone call in 
12 subjects. Dose administration and PK collection scheme for the treatment periods are outlined 
in the table below.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 9 of 25
Statistical Analysis Plan Final
06 June 2019
Table 4.b
Part 2 TAK-788 Assessment with Rifampin
Treatment Period 1
Treatment Period 2
Study Day
-1
1
2
3
4
5
6
8*
1*
2
3
4
5
6
7
8
9
10
11
12
13
14
TAK-788
160 mg PO 
X
X
Rifampin 
600 mg QD PO
X
X
X
X
X
X
X
X
X
X
X
X
X
PK Blood Samples 
X
X
X
X
X
X
X*
X*
X
X
X
X
X
X
X
Overnight in 
Clinics
X
X
X
X
X
X
X
X
*Since the washout period is 7 days the timing of the last PK blood draw of Period 1 will occur within 60 minutes 
prior to the first dose of rifampin on Period 2 Day 1; only one PK sample will be taken.
Abbreviation: PK=Pharmacokinetics; PO=per oral; QD=once daily.
On Period 1 Day 1, a different group of subjects from Part 1 will receive a single 160 mg oral 
dose of TAK-788 as capsules (fasting). A standardized meal will be provided at least 4 hours 
postdose. Subjects will remain in the CRU until the morning of Day 4 after the 72-hour PK
sample is collected. Additional PK samples will be taken as an outpatient up to 168 hours 
postdose (Period 1 Day 8, which is the same as Period 2 Day 1). 
In Period 2, subjects will receive 600 mg rifampin once daily (QD) alone as capsules (fasting). 
Subjects will be admitted to the CRU on Day 6. In the morning of Day 7, subjects will receive 
160 mg oral TAK-788 together with 600 mg rifampin (fasting). A standardized meal will be 
provided at least 4 hours postdose. Subjects will be furloughed from the CRU after the 72-hour 
PK sample is collected in the morning of Day 10. There will be outpatient visits to the CRU for 
dosing rifampin and/or PK sampling from Day 1 to Day 5 and Day 11 to Day 13. A final 
post-treatment follow-up and last PK sampling will occur at 168 hours post Day 7 dose (Day 14). 
Parts 1 and 2: 
All of study drugs will be orally administered with approximately 240 mL water or total aqueous 
volume of approximately 240 mL when dosing with itraconazole oral solution. All doses of 
TAK-788, itraconazole, and rifampin will be administered at the CRU during this study, either 
during confinement or on an outpatient basis. 
Spirometry as the pulmonary function test (PFT) is required to be performed and be assessed as 
normal at screening. Post-dose spirometry will be performed only if indicated on the basis of 
pulmonary symptoms, at the discretion of the Investigator or designee. 
A final safety follow-up phone call will occur 30 ± 2 days after the last TAK-788 dose to 
determine if any adverse events (AEs) have occurred since the last study visit.
Any subject who experiences emesis within 8 hours post dosing with TAK-788 will be excluded 
in the final data analysis. Replacement of discontinued or withdrawn subject due to any reason 
will be assessed on a case by case basis by the Sponsor and Investigator to ensure a minimum of 
10 PK-evaluable subjects complete the study in each part of study.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 10 of 25
Statistical Analysis Plan Final
06 June 2019
The treatment description and planned dose levels of TAK-788, itraconazole, and rifampin to be 
evaluated are outlined in the table below. 
Table 4.c
Treatment Descriptions and Planned Dose Levels of TAK-788, Itraconazole 
(Part 1), and Rifampin (Part 2)
Part 1:
Treatment A
Cohort 1, Period 1:
A single oral dose of 20 mg TAK-788 (1 x 20 mg capsule) administered at Hour 0 on Day 
1 following an overnight fast.
Treatment B
Cohort 1, Period 2:
Multiple oral doses of 200 mg itraconazole oral solution administered every 24 hours for 
14 consecutive days (within ±1 hour of Day 1 dosing) with a single oral dose of 20 mg 
TAK-788 (1 x 20 mg capsule) administered at Hour 0 on Day 5 following an overnight 
fast.
Treatment A or E *
Cohort 2, Period 1:
A single oral dose of TBD mg TAK-788 (1 x TBD mg capsule) administered at Hour 0 on
Day 1 following an overnight fast.
Treatment B or F *
Cohort 2, Period 2:
Multiple oral doses of 200 mg itraconazole oral solution administered every 24 hours for 
14 consecutive days (within ±1 hour of Day 1 dosing) with a single oral dose of TBD mg
TAK-788 administered at Hour 0 on Day 5 following an overnight fast.
Part 2:
Treatment C
Period 1: 
A single oral dose of 160 mg TAK-788 (4 x 40 mg capsules) administered at Hour 0 on 
Day 1 following an overnight fast.
Treatment D
Period 2: 
Multiple oral doses of 600 mg rifampin (2 x 300 mg capsules) administered every 
24 hours for 13 consecutive days (within ±1 hour of Day 1 dosing) with a single oral dose 
of 160 mg TAK-788 (4 x 40 mg capsules) administered at Hour 0 on Day 7 following an 
overnight fast.
* Note: Interim PK will be provided after completion of Part 1 Cohort 1 to confirm the dose to be used for Part 1 
Cohort 2.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 11 of 25
Statistical Analysis Plan Final
06 June 2019
5.0
ANALYSIS ENDPOINTS
5.1
Primary Endpoints
The primary endpoints of the study are:

Maximum observed concentration (Cmax)

Area under the concentration-time curve from time 0 to infinity, calculated using the 
observed value of the last quantifiable concentration (AUC∞)

Area under the concentration-time curve from time 0 to the time of the last quantifiable 
concentration (AUClast)

Time of first occurrence of Cmax (tmax)
5.2
Exploratory Endpoints
The exploratory endpoints will be assessed through evaluation of the following parameters:

Treatment–emergent adverse event (TEAE) assessment

Clinical laboratory testing (hematology, serum chemistry and urinalysis).

Physical examinations

12-lead electrocardiograms (ECGs)

Vital signs
5.3
Additional Endpoints
In addition, the following plasma PK parameters for TAK-788 and its active metabolites, 
AP32960 and AP32914 will be calculated: 

Terminal disposition phase half-life (t½)

Terminal disposition phase rate constant (lambda_z),

Apparent clearance after extravascular administration (CL/F) for TAK-788 only

Apparent volume of distribution during the terminal disposition phase after extravascular 
administration (Vz/F) for TAK-788 only
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 12 of 25
Statistical Analysis Plan Final
06 June 2019
6.0
DETERMINATION OF SAMPLE SIZE
The sample size calculation was based on the expected 2-sided 90% confidence interval (CI) for 
the difference in the paired, log-transformed AUC∞means of TAK-788 in the absence and 
presence of itraconazole or rifampin. The within-patient coefficient of variation for TAK-788 
AUC∞was estimated to be 17.2% on the basis of data from a clinical study conducted in healthy 
subjects (TAK-788-1001). If the AUC∞ratio for TAK-788 in the presence versus absence of 
itraconazole or rifampin is X (an AUC∞geometric mean ratio [GMR] to be determined in this 
study), with a sample size of 10, the 90% CI for the AUC∞ratio is expected to be 0.868X to 
1.15X on the basis of the variance assumptions.
Up to 28 healthy adult subjects will be enrolled into 2 Parts (up to 16 in Part 1, and 12 in Part 2) 
to get 10 PK-evaluable subjects for estimation of DDI magnitude in each part of study.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 13 of 25
Statistical Analysis Plan Final
06 June 2019
7.0
METHODS OF ANALYSIS AND PRESENTATION
7.1
General Principles 
All PK analyses will be conducted using Phoenix® WinNonLin® Version 7.0, or higher. All 
statistical analyses will be conducted using SAS® Version 9.3, or higher. All data recorded on the 
case report form (CRF) will be listed by subject. All tables, figures and listings (TFLs) shells and 
numbering list specified in the Clinical Pharmacology Analysis Plan (CPAP) will be included.
The concentration data will be used as reported by the respective bioanalytical groups without 
rounding for all analyses. Concentration values below the limit of quantitation (BLQ) will be 
presented as ‘BLQ’ in the concentration table listings and footnoted accordingly. BLQ values 
will be treated as zero for the calculation of summary statistics, the generation of concentration 
plots, and the calculation of PK parameters, unless they are obvious outliers (e.g. BLQ value 
between 2 measurable values), in which case they will be treated as missing. In log-linear plots 
these values would not be presented. Missing concentration values will be flagged in the 
concentration tables and footnoted as missing or not reportable (i.e., for subjects withdrawn or 
dropped from the study, subjects missing blood draws). Plasma concentration data from subjects
excluded from PK parameter analysis will be included in the concentration tables and individual 
figures, but will be excluded from summary statistics and in the presentation of mean figures. 
All concentrations and PK parameter values will be presented to 3 significant figures Arithmetic 
mean (mean), median, and geometric mean (Geom Mean) values will be presented to 1 more 
level of precision than the individual concentration and PK parameter values. Standard deviation 
(SD) and standard error of the mean (SEM) will be presented to 2 more levels of precision than 
the individual concentration and PK parameter values. Minimum and maximum values will be 
presented to the same precision as the individual concentration and PK parameter values. 
Arithmetic percent coefficient of variation (CV%) and geometric percent coefficient of variation 
(Geom CV%) will be presented to 1 decimal place. 
Geometric least-squares means (LSMs) will be reported with 1 more level of precision than the 
recorded data. GMRs and 90% CIs around the ratio will be reported using 2 decimal places.
For the calculation of PK parameters, if actual times are missing, nominal times will be used 
instead.
A subject’s PK parameter data will be included in the listings but excluded from the descriptive 
statistics and statistical evaluation if one or more of the following criteria are met: 

A predose (0 hr) concentration is greater than 5% of that subject’s Cmax value in that period 

A subject did not meet inclusion/exclusion criteria that may have an effect on the PK (as 
determined by the Takeda Clinical Pharmacology Lead and Celerion Pharmacokinetic 
Scientist)

A subject deviates substantially from the protocol defined study procedures including but not 
limited to dosing, dose timing, sample collection, meal timing, etc. (as determined by the 
Takeda Clinical Pharmacology Lead and Celerion Pharmacokinetic Scientist)
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 14 of 25
Statistical Analysis Plan Final
06 June 2019
See Clinical Pharmacology Analysis Plan (CPAP) for details on the PK parameter calculations 
and data presentation including specifics on the following:

Insufficient data to determine a reliable t½ value and other terminal elimination rate constant 
dependent parameters

PK parameters presented by treatment, including the units, precision, and summary statistics 
that will be presented in in-text and end-of-text tables

Concentration data presented by treatment, including the units, precision, and summary 
statistics that will be presented in end-of-text tables

Concentration data file used for PK analysis

PK parameter WinNonLin® output file used to generate the tables, figures, and listings 
(TFLs)

Analysis of variance (ANOVA) results presented in in-text and end-of-text tables

Arithmetic mean concentration-time figures presented as in-text and end-of-text figures

Individual concentration-time figures presented in Appendix 16.2.6

Any subject, PK concentration, and PK parameter that are excluded in the PK data analyses 
or summary statistical analyses will be provided in end-of-text tables. 
For demographic data where appropriate, variables will be summarized descriptively. For the 
categorical variables, the count and proportions of each possible value will be tabulated, where 
applicable. The denominator for the proportion will be based on the number of subjects who 
provided non missing responses to the categorical variable. For continuous variables, the number 
of subjects with non-missing values, mean, standard deviation (SD), minimum, median, and 
maximum values will be tabulated.
7.1.1
Study Definitions
7.1.2
Definition of Study Days
Day 1 for the study is defined as the date on which a subject is administered their first dose of the 
study drug(s) in Period 1 (for Parts 1 and 2). Other study days are defined relative to Day 1 with 
Day -1 being the day prior to Day 1 of Period 1. Study day prior to the first dose in Period 1 will 
be calculated as: date of assessment-date of first dose in Period 1; study day on or after the date 
of first dose will be calculated as: date of assessment-date of first dose in Period 1 +1.
Day 1 for each period is defined as the date on which a subject is administered their first dose of 
the study drug(s) in each period (for Parts 1 and 2). Other study days are defined relative to Day 
1 with Day -1 being the day prior to Day 1 of each period. Study day prior to the first dose of 
each treatment will be calculated as: date of assessment-date of first dose in each period; study 
day on or after the date of first dose will be calculated as: date of assessment-date of first dose in 
each period +1.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 15 of 25
Statistical Analysis Plan Final
06 June 2019
For all clinical laboratory evaluations, for Period 1 of Parts and 2, baseline is defined as the last 
assessment including rechecks taken at check-in (Day -1) prior to TAK-788 dosing. For Period 2 
of Part 1, baseline is defined as the last assessment including rechecks taken prior to TAK-788 
dosing at Day 4, and for Period 2 of Part 2, baseline is defined as the last assessment including 
rechecks taken prior to TAK-788 dosing at Day 6.
For vital signs and 12-lead ECGs, for Period 1 of Parts 1 and 2, baseline is defined as the last 
assessment including rechecks taken prior to TAK-788 dosing. For Period 2 of Part 1, baseline is 
defined as the last assessment including rechecks taken prior to TAK-788 dosing at Day 5, and 
for Period 2 of Part 2, baseline is defined as the last assessment including rechecks taken prior to 
TAK-788 dosing at Day 7.
7.2
Analysis Sets
Safety Set:
All subjects who received at least one dose of a study drug will be included in the safety 
evaluations.
PK Set:
Samples from all subjects will be assayed even if the subjects do not complete the study. All
subjects who comply sufficiently with the protocol and display an evaluable PK profile (e.g., 
exposure to treatment, availability of measurements and absence of major protocol violations) 
will be included in the statistical analyses. Any subject who experiences emesis within 8 hours 
post dosing with TAK-788 will be excluded in the final data analysis. In terms of criteria for 
evaluable subjects, please see CPAP. 
7.3
Study Information
For each part, study information including date first subject signed informed consent form, date 
for the first dose, date for the last dose, date of last subject’s last visit/contact, date of last 
subject’s last procedure for collection of data for primary endpoint, the version of Medical 
Dictionary for Regulatory Activities (MedDRA®), the version of World Health Organization 
(WHO) Dictionary, and SAS version used for creating the datasets will be listed. 
7.4
Disposition of Subjects
For each part, disposition of subjects (number of subjects dosed, completed the study, subjects in 
the PK-evaluable population who discontinued from the study, and reason(s) for discontinuation) 
will be summarized. Study completion status, including reason for discontinuation, will also be 
listed by subject. Subjects will be considered to have completed the study if they have completed 
the protocol-specified assessments within the protocol. Percentages will be based on the number 
of subjects in the safety set.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 16 of 25
Statistical Analysis Plan Final
06 June 2019
7.5
Demographic and Other Baseline Characteristics
For each part, demographic and baseline characteristics will be summarized descriptively. 
Summary statistics (number of subjects [n], mean, SD, minimum, median, and maximum) will 
be generated for continuous variables (age [calculated from the date of signed Informed Consent 
Form [ICF], weight, height and body mass index [BMI]) and the number and percentage of 
subjects within each category will be presented for categorical variables (sex, race, and 
ethnicity). For height the screening measurement will be reported but for weight and BMI the 
baseline value, which is the last observation prior to dosing, will be reported. The demographics 
listing will also include protocol version and date, ICF version and date, the date of each signed 
the ICF. 
7.6
Medical History and Concurrent Medical Conditions
For each part, medical history to be obtained will include determining whether the subject has 
any significant conditions or diseases relevant to the disease under study that resolved at or 
before signing the ICF. Concurrent medical conditions are those significant ongoing conditions 
or diseases that are present at signing the ICF. Each subject’s medical history and concurrent 
medical conditions will be listed. Any medical condition started after taking the study drug will 
be classified as an adverse event. The medical history listing will include whether the event was 
medical or surgical, the body system or organ class involved, start date (if known) and end date 
or whether the condition was ongoing, and a description of the condition or event. All medical 
history of this study will be coded using the MedDRA® Version 22.0. There will be no statistical 
analysis of medical history.
7.7
Medication History and Concomitant Medications
For each part, medication history to be obtained includes any medication relevant to eligibility 
criteria and efficacy/safety evaluation stopped at or within 28 days prior to signing the ICF. 
Concomitant medication includes any medication other than study drug taken at any time 
between time of signing the ICF through the end of the study (including follow-up visit). All 
medication history and concomitant medications recorded during the study will be coded with 
the WHO Dictionary Version 01-Mar-2019_b3 and listed. The listing will include the medication 
name, dosage, route of administration, start date and time (if known), end date and time, or 
whether it continued after study completion, and indication for use. 
7.8
Study Drug Exposure and Compliance
For each part, the date, time, and dose of single oral dose of TAK-788 and multiple oral doses of 
itraconazole and rifampin will be respectively listed by subject. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 17 of 25
Statistical Analysis Plan Final
06 June 2019
7.9
Efficacy Analysis
Not applicable.
7.10
Pharmacokinetic/Pharmacodynamic Analysis
7.10.1 Pharmacokinetic Analysis
For Part 1, blood samples (one 3 mL sample per scheduled time) for PK analysis of TAK-788, 
AP32960, and AP32914 will be collected as specified in Table 7:1 following administration of 
TAK-788 alone (sampling Day 1 – Period 1) or coadministered with itraconazole (sampling Day 
5 – Period 2).
Table 7.a
Collection of Blood Samples for Pharmacokinetic Analysis for Part 1
Analytes
Matrix
Sampling Day
Scheduled Time (hours)
TAK-788, 
AP32960, and 
AP32914
Plasma
1
Predose, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours 
postdose (a) (b).
TAK-788, 
AP32960, and 
AP32914
Plasma
5
Predose, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168, 192, and 240
hours postdose (a) (c).
(a) If a subject experiences a serious adverse event (SAE), a blood sample for PK analysis should also be obtained at 
the unscheduled visit. PK samples will be collected at Early Termination at the discretion of the PI.
(b) The 168-hour postdose blood draw on sampling Day 1 of study Period 1 will be drawn prior to itraconazole 
dosing of Period 2.
(c) The collection times for analysis of TAK-788 PK parameters will be relative to TAK-788 dose on Day 5 for 
Period 2.
For Part 2, blood samples (one 4 mL sample per scheduled time) for PK analysis of TAK-788, 
AP32960, and AP32914 will be collected as specified in Table 7:2 following administration of 
TAK-788 alone (sampling Day 1 – Period 1) or coadministered with rifampin (sampling Day 7 –
Period 2).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 18 of 25
Statistical Analysis Plan Final
06 June 2019
Table 7.b
Collection of Blood Samples for Pharmacokinetic Analysis for Part 2
Analytes
Matrix
Sampling Day
Scheduled Time (hours)
TAK-788, 
AP32960, and 
AP32914
Plasma
1
Predose, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours 
postdose (a) (b).
TAK-788, 
AP32960, and 
AP32914
Plasma
7
Predose, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours 
postdose (a) (c).
(a) If a subject experiences a serious adverse event (SAE), a blood sample for PK analysis should also be obtained at 
the unscheduled visit. PK samples will be collected at Early Termination at the discretion of the PI.
(b) The 168-hour postdose blood draw on sampling Day 1 of study Period 1 will be drawn prior to rifampin dosing 
of Period 2.
(c) The collection times for analysis of TAK-788 PK parameters will be relative to TAK-788 dose on Day 7 for 
Period 2.
The actual date and time of sample collection will be recorded on the source document in the 
CRF. 
Concentrations will be listed and summarized descriptively by PK sampling time in mass units 
for plasma TAK-788, AP32960, and AP32914. Summary will be done by treatment using the 
summary statistics listed in the CPAP. Excluded concentrations will be presented and footnoted 
as such in the concentration table listings, and those values will be excluded from the descriptive 
summary statistics. Individual subject and arithmetic mean profiles of the concentration-time 
data will be plotted by treatment on linear (with and without SD) and semi-log scales in mass 
units for each analyte. For summary statistics and arithmetic mean plots by sampling time, the 
nominal PK sampling time will be used, for individual subject plots by time, the actual PK 
sampling time will be used. 
The PK parameters of TAK-788, AP32960, and AP32914 listed in the CPAP for this study will 
be determined from the concentration-time profiles for subjects in the PK set using a 
noncompartmental analysis method in mass units. The molar AUClast, AUC∞, and Cmax PK 
parameters will also be calculated for plasma TAK-788, AP32960, and AP32914 using the 
molecular weights of each analyte as outlined in the CPAP. Combined molar AUClast, AUC∞, 
and Cmax for plasma TAK-788, AP32960, and AP32914 will also be presented. Actual sampling 
times, rather than scheduled sampling times, will be used in all computations involving sampling 
times. If actual sample times are missing, nominal times may be used.
PK parameters will be summarized descriptively by treatment using the summary statistics listed 
in the CPAP in mass units and molar units. Excluded parameters will be presented and footnoted 
as such in the PK parameter table listings, and those values will be excluded from the descriptive 
summary statistics. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 19 of 25
Statistical Analysis Plan Final
06 June 2019
Drug-Drug Interaction 
For evaluation of potential effect of itraconazole (Part 1) and rifampin (Part 2), a linear 
mixed-effects model will be used for the analysis on the ln-transformed Cmax and AUC∞
(AUClast or AUCt if AUC∞is not available) for TAK-788, AP32960, and AP32914 and ln-
transformed combined molar Cmax and AUC∞for TAK-788, AP32960, and AP32914. The 
model will include treatment as a fixed-effect and subject as a random-effect. Each model will 
include calculation of LSMs as well as the difference between LSMs.
GMR and 90% confidence intervals, consistent with the two one-sided test, will be calculated 
using the exponentiation of the difference between treatment LSMs from the analyses on the 
ln-transformed Cmax and AUC∞(AUClast or AUCt if AUC∞is not available) for TAK-788,
AP32960, and AP32914 and ln-transformed combined molar Cmax and AUC∞for TAK-788, 
AP32960, and AP32914. These ratios will be expressed as a percentage of the following 
comparisons:
Part 1: 
Treatment B (itraconazole + 20 mg TAK-788) relative to Treatment A (20 mg TAK-788)
And if applicable Treatment F (itraconazole + TBD* mg TAK-788) relative to Treatment E
(TBD* mg TAK-788)
*Note: The dose of TAK-788 may be modified following results from interim analysis from 
Cohort 1 (Part 1). Cohorts 1 and 2 of Part 1 will be combined if 20 mg TAK-788 is the dose, and 
the comparison will be Treatment B versus Treatment A. However, if after interim analysis, a 
different dose of TAK-788 is used, only the 12 subjects in Cohort 2 receiving the TBD dose of 
TAK-788 will be used, and the comparison will be Treatment F versus Treatment E. If the dose 
of TAK-788 in Cohort 2 is different from Cohort 1, the concentrations and PK parameters for 
subjects receiving the 20 mg TAK-788 dose will be presented in post-text concentration and PK 
parameter tables only, as outlined in the CPAP. Consequently, no statistical comparisons will be 
performed for subjects receiving the 20 mg TAK-788 dose level. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 20 of 25
Statistical Analysis Plan Final
06 June 2019
Part 2:
Treatment D (rifampin + 160 mg TAK-788) relative to Treatment C (160 mg TAK-788)
The following SAS code will be used respectively for each part:
PROC MIXED DATA=XXXX;
CLASS Treatment Subject;
MODEL ln<PK_Parameter> = Treatment / DDFM=KR;
RANDOM Subject;
ESTIMATE ‘Treatment B vs A’ Treatment -1 1 / CL ALPHA = 0.10 E; (For Part 1 when the 
original dose of 20 mg TAK-788 is used.)
ESTIMATE ‘Treatment F vs E’ Treatment -1 1 / CL ALPHA = 0.10 E; (For Part 1 when after 
the interim analysis, a different TBD TAK-788 dose is used.)
ESTIMATE ‘Treatment D vs C’ Treatment -1 1 / CL ALPHA = 0.10 E; (For Part 2)
LSMEANS Treatment;
Run;
Nonparametric Analysis of Tmax
A nonparametric analysis for Tmax will be performed to compare treatment differences using the 
Wilcoxon Signed Rank test. Median difference (Test-Reference), the Hodges-Lehmann 
estimator, and estimated confidence interval will be used to examine the location shift in Tmax 
(Hollander and Wolf (1999)). Tmax will not be ln-transformed.
7.10.2 Pharmacodynamic Analysis
Not applicable.
7.11
Other Outcomes
Not applicable.
7.12
Safety Analysis
Safety will be evaluated by the incidence of TEAEs, severity and type of TEAEs, changes from 
baseline in the subjects’ clinical laboratory results, vital signs, and ECG’s using the safety set. 
All clinical safety data will be listed by subject and assessment time points, including rechecks, 
unscheduled assessments, and early termination, chronologically. 
Continuous variables will be summarized using n, mean, SD, minimum, median, and maximum. 
Frequency counts and percentages will be reported for categorical data when appropriate. Where 
individual data points are missing because of dropouts or other reasons, the data will be 
summarized based on reduced denominators.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 21 of 25
Statistical Analysis Plan Final
06 June 2019
7.12.1 Adverse Events 
All AEs captured in the database will be listed in by-subject data listings including verbatim 
term, coded term, severity (1=Grade 1: Mild, 2=Grade 2: Moderate, 3=Grade 3: Severe or 
medically significant but not immediately life-threatening, 4=Grade 4: Life-threatening 
consequences, 5=Grade 5: Death related to AE ), relationship to study drug (related or not 
related) and action relative to the study drug for both TAK-788 and itraconazole or rifampin. 
Study procedure taken due to AE will also be listed. All AEs occurring during this study will be 
coded using the MedDRA® Version 22.0. However, only TEAEs occurring after administration 
of the first dose of study drug and through the end of the study (approximately 30 (± 2) days 
after the last dose of TAK-788 administration) will be summarized. 
A TEAE is defined as an AE that is starting or worsening at the time of or after study drug 
administration. 
For each treatment of each part, TEAEs will be coded using MedDRA® Version22.0 and 
tabulated by System Organ Class (SOC) and Preferred Term. For each part, summary tables will 
include number of subjects reporting the AE and as percent of safety set by treatment. The most 
commonly reported non-serious TEAEs (i.e., those events reported by >5% of all subjects in 
each treatment group, excluding SAEs) will also be summarized. For the list of all AE summary 
table see CPAP.
In addition, TEAEs will be summarized as number of AEs and percentage of AEs for each 
treatment for the overview of TEAEs. 
Additional TEAE summary tables will be presented by severity and relationship to study drug
(TAK-788 and itraconazole or rifampin). If a subject has multiple AEs with different severity 
levels within the same term, the subject will be counted in the most severe category only. If a 
subject has both related and unrelated AEs with the same term, the subject will be counted as 
having related TEAEs.
For Treatment B, the TEAEs will be summarized separately for two segments (Treatment B1 and 
Treatment B2). Treatment B1 will be itraconazole which is started from the first itraconazole
dosing and prior to TAK-788 dosing. Treatment B2 will be itraconazole + TAK-788 which is 
after the dosing of TAK-788 on Day 5 of Period 2. Note: Treatments E and F (including F1 and 
F2) will be added, if after interim analysis, 12 subjects in Cohort 2 will be treated with E and F 
of the TBD dose.
For treatment D, the TEAEs will be summarized separately for two segments (Treatment D1 and 
Treatment D2). Treatment D1 will be rifampin which is started from the first rifampin dosing 
and prior to TAK-788 dosing. Treatment D2 will be rifampin + TAK-788 which is after the 
dosing of TAK-788 on Day 7 of Period 2.
Should any SAEs occur they will be summarized the same way as TEAE. All AEs will be 
displayed in the data listings and TEAEs will be discussed in the text of the study report.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 22 of 25
Statistical Analysis Plan Final
06 June 2019
7.12.2 Clinical Laboratory Evaluations
For Part 1, hematology, serum chemistry, and urinalysis will be performed at screening, check-in 
(Day -1), and 48 hours (Day 3) postdose of Period 1, Day 1 predose, Day 4 predose, 48 hours 
(Day 7), and 240 hours (Day 15) postdose of Period 2 (times relative to TAK-788 dose) or upon 
early termination. For Part 2, hematology, serum chemistry, and urinalysis will be performed at 
screening, check-in (Day -1), and 48 hours (Day 3) postdose of Period 1, Day 1 predose, Day 6 
predose, 48 hours (Day 9), and 168 hours (Day 14) postdose of Period 2 (times relative to 
TAK-788 dose) or upon early termination. In addition, laboratory safety tests may be performed 
at various unscheduled time points, if deemed necessary by the PI.
For all laboratory values that are numeric, summary statistics (n, mean, SD, minimum, median, 
and maximum) will be presented for each laboratory test by assessment time points. Change 
from baseline will be summarized. 
For each laboratory test, a shift table will be developed comparing the frequency of the results at 
baseline (above normal (H), normal (N), or below normal (L)) with those post-baseline time 
points. For urinalysis tests, the categories are normal (N) and abnormal (A). Out-of-range values 
and corresponding recheck results will be listed. 
Out-of-normal range flags will be recorded as follows: high (H) and low (L) for numerical 
results and did-not-match (*) for categorical results. If a value fails the reference range, it will 
automatically be compared to a clinically significant (CS) range. If the value falls within the CS 
range, it will be noted as “N” for not clinical significant. If the value fails the CS range, it will be 
flagged with a “Y” which prompts the PI to determine how the out-of-range value should be 
followed using 4 Investigator flags: "N", not clinically significant, "R", requesting a recheck, "^", 
checking at the next scheduled visit, or "Y", clinically significant. All clinically significant lab 
tests and the corresponding values will be listed by subject. All clinical laboratory data will be 
presented in by-subject data listings.
7.12.3 Vital Signs
For Part 1, single measurements of heart rate and blood pressure will be obtained at screening, 
Day 1 predose and at 4, 12 (Day 1), and 24 hours (Day 2) postdose of Period 1, and Day 1 
predose, Day 5 predose and at 4 hours (Day 5), 12 hours (Day 5), 24 hours (Day 6), and 240 
hours (Day 15) postdose of Period 2 (times relative to TAK-788 dose) or upon early termination. 
For Part 2, single measurements of heart rate and blood pressure will be recorded at screening, 
Day 1 predose and at 4 hours (Day 1), 12 hours (Day 1), and 24 hours (Day 2) postdose of Period 
1, and Day 1 predose, Day 7 predose and at 4 hours (Day 7), 12 hours (Day 7), 24 hours (Day 8), 
and 168 hours (Day 14) postdose of Period 2 (times relative to TAK-788 dose) or upon early 
termination. For Parts 1 and 2, respiration rate and temperature are collected at screening, 240 
hours (Day 15) postdose at Period 2 for Part 1, 168 hours (Day 14) postdose at Period 2 for Part 
2 or upon early termination. Additional unscheduled vital signs measurements may be taken at 
other times, if deemed necessary by the PI.
For each part, summary statistics (n, mean, SD, minimum, median, and maximum) will be 
reported for vital sign results and change from baseline (heart rate and blood pressure only) by 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 23 of 25
Statistical Analysis Plan Final
06 June 2019
treatment and time point of collection. Vital signs will also be displayed in a data listing by 
subject.
7.12.4 12-Lead ECGs
For Part 1, standard 12-lead ECGs will be recorded at screening, Day 1 predose and at 4 hours 
(Day 1) and 24 hours (Day 2) postdose of Period 1, and Day 1 predose, Day 5 predose and at 4 
hours (Day 5), 24 hours (Day 6), and 240 hours (Day 15) postdose of Period 2 (times relative to 
TAK-788 dose) or upon early termination. For Part 2, standard 12-lead ECGs will be recorded at 
screening, Day 1 predose and at 4 (Day 1) and 24 hours (Day 2) postdose of Period 1, and Day 1 
predose, Day 7 predose and at 4 hours (Day 7), 24 hours (Day 8), and 168 hours (Day 14) 
postdose of Period 2 (times relative to TAK-788 dose) or upon early termination. Additional 
unscheduled ECGs may be recorded at other times, if deemed necessary by the PI. 
For each part, summary statistics (n, mean, SD, minimum, median, and maximum) will be 
reported for ECG results and change from baseline by treatment and time point of collection. 
ECG data will also be displayed in a data listing by subject. ECG overall interpretation will 
indicate if the results are normal, abnormal NCS (not clinically significant) or abnormal CS 
(clinically significant).
7.12.5 Pulmonary Function Test (PFT)
For Parts 1 and 2, spirometry measures will be taken at screening (within 7 days prior to first 
dosing) using a standard calibrated spirometer to determine the parameters: FEV1 (forced 
expiratory volume), FVC (forced vital capacity), and FEV1/FVC. Spirometry may be repeated 
during the study in response to pulmonary symptoms at the discretion of the Investigator or 
designee. PFT results will be presented in a data listing by subject. Results will be interpreted by 
the PI and recorded in the comment column.
7.12.6 Physical Exams
For Parts 1 and 2, a full physical exam will be performed at screening. Symptom driven physical 
exams may be performed at other times, if deemed necessary by the PI. Physical exam findings 
will be presented in a data listing by subject. Reproductive system findings will also be listed by 
subject. For “Abnormal” result, a flag “*” will be added as “Abnormal*”.
7.12.7 Overdose 
All cases of overdose will be presented in a data listing by subject. Any AEs associated with 
overdose will be documented as AEs. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 24 of 25
Statistical Analysis Plan Final
06 June 2019
7.13
Interim Analysis
Interim PK analysis will be conducted after completion of Part 1 Cohort 1 to determine the dose 
to be used for Part 1 Cohort 2.
7.14
Preliminary Analysis
QCed plasma concentration data will be plotted using nominal times to aid in the determination 
of samples for repeat bioanalysis. If requested, a preliminary PK analysis will be completed as 
described in the CPAP and Section 7.10.1 of the SAP, with the following changes: 1) QCed data 
will be used (not QAed); 2) nominal times will be used for the calculation of PK parameters (not 
actual sampling times); 3) tables and figures will be created using Phoenix® WinNonlin® 
Version 7.0 or higher.
7.15
Changes in the Statistical Analysis Plan 
Two (2) protocol clarification letters were issued for this study. The first clarification letter 
issued on 24 April 2019 was written to correct an error in the number and strength of rifampin 
capsules. The second clarification letter issued on 25 April 2019 was written to correct an 
inconsistency in the contraceptive wording in Appendix D (Pregnancy and Contraception) of the 
protocol. 
During generation of the SAP, it was determined to include a nonparametric analysis of Tmax in 
the study to address the Tmax primary endpoint. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


TAK-788-1006
Celerion Study Number CA24219
Page 25 of 25
Statistical Analysis Plan Final
06 June 2019
8.0
REFERENCES
Not applicable.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use



䢢
䢢
䢢
䢢
䢢
䢢
䢢
䢢
(/(&7521,&6,*1$785(6
Signed by 
Meaning of Signature 
Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 





ഓജഓഔഓഔେങଛഓ൅ങ୆ചൄച
䣖䣃䣍䢯䢹䢺䢺䢯䢳䢲䢲䢸䣡䢪䣅䣃䢴䢶䢴䢳䢻䢫䣡䣕䣃䣒䣡䣈䣫䣰䣣䣮䣡䢴䢹䣏䣃䣛䢴䢲䢳䢻
ഥൌ൒൞ൟൄൟൌ൞ൟൌ୆൞ഃത൓൓୕൒୙ൄ൏
ഔജഐഭ༲൑ഐകഓഔജഃഔഗഝഔജഃସଷദ
PPD
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
blble T
ate 
ate 
abl
HH:mm ‘U
H:mm 
e T
ab